BACKGROUND I-GENE
: O
Ischemic I-GENE
heart O
disease O
is O
the O
primary O
cause I-GENE
of O
morbidity I-GENE
and O
mortality I-GENE
among I-GENE
diabetics I-GENE
, O
especially I-GENE
those I-GENE
who I-GENE
became I-GENE
ill I-GENE
at O
a O
young I-GENE
age I-GENE
. O

More I-GENE
importantly I-GENE
, O
this I-GENE
fusion I-GENE
converted I-GENE
a O
less I-GENE
effective I-GENE
vaccine I-GENE
into I-GENE
one I-GENE
with I-GENE
significant I-GENE
potency I-GENE
against I-GENE
established I-GENE
E7 O
- I-GENE
expressing I-GENE
metastatic I-GENE
tumors I-GENE
. O

Reverse I-GENE
transcription I-GENE
- I-GENE
PCR I-GENE
analysis I-GENE
of O
mRNA I-GENE
from O
patients I-GENE
shows I-GENE
that I-GENE
each I-GENE
of O
these I-GENE
five I-GENE
mutations I-GENE
results I-GENE
in O
aberrant I-GENE
splicing O
. O

Using I-GENE
the O
postural I-GENE
and O
force I-GENE
data I-GENE
as O
input I-GENE
to O
a O
3 I-GENE
- I-GENE
D I-GENE
biomechanical I-GENE
model I-GENE
, O
the O
lumbosacral O
spinal O
compression I-GENE
was I-GENE
calculated I-GENE
. O

Sequence I-GENE
analysis I-GENE
revealed I-GENE
significant I-GENE
differences I-GENE
between I-GENE
the O
5 O
' O
region O
of O
the O
beta I-GENE
subunit I-GENE
gene I-GENE
and O
the O
corresponding I-GENE
regions O
of O
the O
homologous O
GlyR I-GENE
alpha I-GENE
subunit I-GENE
genes I-GENE
; O
it I-GENE
also I-GENE
identified I-GENE
a O
novel I-GENE
exon O
( O
exon O
0 O
) O
that I-GENE
encodes I-GENE
most I-GENE
of O
the O
5 O
'- O
untranslated O
portion I-GENE
of O
the O
GlyR I-GENE
beta I-GENE
mRNA I-GENE
. O

Therefore I-GENE
, O
we I-GENE
suggested I-GENE
that I-GENE
both I-GENE
proteins I-GENE
might I-GENE
belong I-GENE
to O
the O
PLTP O
family O
. O

Influence I-GENE
of O
compression I-GENE
therapy I-GENE
on I-GENE
symptoms I-GENE
following I-GENE
soft I-GENE
tissue I-GENE
injury I-GENE
from O
maximal I-GENE
eccentric I-GENE
exercise I-GENE
. O

STAT5A O
mutations O
in O
the O
Src O
homology O
2 O
( O
SH2 I-GENE
) O
and O
SH3 O
domains I-GENE
did I-GENE
not I-GENE
alter I-GENE
the O
BTK O
- O
mediated O
tyrosine O
phosphorylation O
. O

In I-GENE
the O
present I-GENE
work I-GENE
, O
the O
complete O
genome I-GENE
sequences O
of O
Pyrococcus O
horikoshii O
and O
Pyrococcus O
abyssi O
, O
two I-GENE
species I-GENE
in O
a O
genus I-GENE
of O
hyperthermophilic I-GENE
archaeon I-GENE
( I-GENE
archaebacterium I-GENE
), O
were I-GENE
compared I-GENE
to O
detect I-GENE
large I-GENE
genome I-GENE
polymorphisms I-GENE
linked I-GENE
with I-GENE
restriction I-GENE
- I-GENE
modification I-GENE
gene I-GENE
homologs I-GENE
. O

In I-GENE
addition I-GENE
, O
these I-GENE
patients I-GENE
show I-GENE
both I-GENE
quantitative I-GENE
and O
qualitative I-GENE
differences I-GENE
in O
their I-GENE
infectious I-GENE
microbiological I-GENE
spectrum I-GENE
, O
mainly I-GENE
in O
clean I-GENE
- I-GENE
contaminated I-GENE
, O
contaminated I-GENE
and O
dirty I-GENE
surgical I-GENE
procedures I-GENE
. O

Here I-GENE
we I-GENE
show I-GENE
that I-GENE
PKC O
and O
p44 O
/ O
p42MAPK I-GENE
signalings I-GENE
are I-GENE
required I-GENE
for O
the O
HBx O
- O
induced O
Sp1 I-GENE
- I-GENE
mediated O
IGF O
- I-GENE
II I-GENE
P4 I-GENE
transcriptional I-GENE
activity I-GENE
since I-GENE
( O
i O
) O
PKC O
activation O
by I-GENE
PMA I-GENE
or O
PKC O
expression O
vector I-GENE
increases I-GENE
Sp1 I-GENE
phosphorylation O
and O
P4 I-GENE
activity I-GENE
in O
HBx I-GENE
- I-GENE
transfected I-GENE
HepG2 I-GENE
cells I-GENE
; O
( I-GENE
ii I-GENE
) I-GENE
PKC O
inhibition I-GENE
by I-GENE
PKC O
inhibitor I-GENE
Go6976 I-GENE
reduces I-GENE
Sp1 I-GENE
phosphorylation O
, O
P4 I-GENE
activity I-GENE
, O
and O
IGF O
- I-GENE
II I-GENE
mRNA I-GENE
in O
HBx I-GENE
- I-GENE
transfected I-GENE
HepG2 I-GENE
cells I-GENE
; O
and O
( O
iii I-GENE
) I-GENE
the O
inhibition I-GENE
of O
MEK O
activation O
by I-GENE
U0126 I-GENE
reduces I-GENE
Sp1 I-GENE
phosphorylation O
, O
P4 I-GENE
activity I-GENE
and O
IGF O
- I-GENE
II I-GENE
mRNA I-GENE
in O
HBx I-GENE
- I-GENE
transfected I-GENE
HepG2 I-GENE
cells I-GENE
. O

We I-GENE
show I-GENE
that I-GENE
p73 I-GENE
can I-GENE
transcriptionally I-GENE
inhibit I-GENE
a O
number I-GENE
of O
cellular O
and O
viral O
promoters O
. O

Similarly I-GENE
, O
curcumin O
( O
diferuloylmethane O
), O
an I-GENE
anti I-GENE
- I-GENE
inflammatory I-GENE
agent I-GENE
, O
suppressed I-GENE
OSM I-GENE
- I-GENE
stimulated O
STAT1 O
phosphorylation O
, O
DNA O
- I-GENE
binding I-GENE
activity I-GENE
of O
STAT1 O
, O
and O
c I-GENE
- I-GENE
Jun O
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
activation I-GENE
without I-GENE
affecting I-GENE
JAK1 I-GENE
, O
JAK2 O
, O
JAK3 O
, O
ERK1 O
/ O
2 O
, O
and O
p38 O
phosphorylation O
. O

The I-GENE
effects I-GENE
of O
the O
transfected I-GENE
receptors I-GENE
were I-GENE
associated I-GENE
with I-GENE
antagonism I-GENE
of O
activator I-GENE
protein I-GENE
1 I-GENE
( I-GENE
AP I-GENE
- I-GENE
1 I-GENE
) I-GENE
activity I-GENE
. O

Furthermore I-GENE
, O
the O
soluble O
forms I-GENE
of O
ATF6 O
and O
the O
G13 I-GENE
gene I-GENE
product I-GENE
are I-GENE
unable I-GENE
to O
bind I-GENE
to O
several I-GENE
point I-GENE
mutants I-GENE
of O
the O
cis O
- I-GENE
acting I-GENE
ER I-GENE
stress I-GENE
response I-GENE
element I-GENE
in O
vitro I-GENE
that I-GENE
hardly I-GENE
respond I-GENE
to O
ER I-GENE
stress I-GENE
in O
vivo I-GENE
. O

PURPOSE I-GENE
: O
The I-GENE
objective I-GENE
of O
this I-GENE
study I-GENE
was I-GENE
to O
assess I-GENE
first O
embryo O
cleavage O
( O
FEC O
) O
25 O
- I-GENE
27 I-GENE
h I-GENE
after I-GENE
intracytoplasmic I-GENE
sperm I-GENE
injection I-GENE
( O
ICSI O
) O
as O
a O
parameter I-GENE
for O
the O
embryo O
selection I-GENE
process I-GENE
. O

RESULTS I-GENE
: O
A I-GENE
significant I-GENE
correlation I-GENE
( I-GENE
p O
< I-GENE
0 O
. O
001 I-GENE
) I-GENE
was I-GENE
observed I-GENE
for O
mean I-GENE
wall O
thickness I-GENE
and O
vessel I-GENE
wall O
area I-GENE
between I-GENE
MRI I-GENE
and O
histopathology O
( O
r O
= I-GENE
0 O
. O
87 I-GENE
and O
r I-GENE
= I-GENE
0 O
. O
85 O
, O
respectively I-GENE
). O

Molecular I-GENE
cloning I-GENE
, O
genomic I-GENE
mapping I-GENE
, O
and O
expression O
of O
two I-GENE
secretor I-GENE
blood O
group I-GENE
alpha I-GENE
( I-GENE
1 I-GENE
, O
2 I-GENE
) I-GENE
fucosyltransferase I-GENE
genes I-GENE
differentially I-GENE
regulated I-GENE
in O
mouse I-GENE
uterine I-GENE
epithelium I-GENE
and O
gastrointestinal O
tract O
. O

We I-GENE
show I-GENE
that I-GENE
several I-GENE
heme I-GENE
- I-GENE
responsive I-GENE
mechanisms I-GENE
combine I-GENE
to O
regulate I-GENE
DAN I-GENE
/ I-GENE
TIR I-GENE
gene I-GENE
expression O
. O

No I-GENE
' I-GENE
TATA I-GENE
' I-GENE
motif I-GENE
was I-GENE
identified I-GENE
near I-GENE
either I-GENE
the O
GABPalpha O
or O
ATPsynCF6 O
transcription O
start O
sites O
. O

These I-GENE
results I-GENE
indicate I-GENE
the O
presence I-GENE
of O
TATA O
- O
unified O
transcription O
systems O
in O
contemporary I-GENE
eukaryotes I-GENE
and O
provide I-GENE
insight I-GENE
into I-GENE
the O
residual I-GENE
need I-GENE
for O
TBP O
by I-GENE
all I-GENE
three I-GENE
Pols I-GENE
in O
other I-GENE
eukaryotes I-GENE
despite I-GENE
a O
lack I-GENE
of O
TATA O
elements O
in O
their I-GENE
promoters I-GENE
. O

Different I-GENE
thermoluminescent I-GENE
detectors I-GENE
( I-GENE
TLD I-GENE
) I-GENE
have I-GENE
been I-GENE
used I-GENE
to O
measure I-GENE
the O
contribution I-GENE
of O
the O
low O
linear O
energy I-GENE
transfer I-GENE
component I-GENE
( I-GENE
LET I-GENE
< I-GENE
10 O
keV O
/ O
micrometer O
) O
and O
plastic O
nuclear O
track O
detectors O
( O
PNTD O
) O
for O
the O
high O
linear O
energy I-GENE
tranfer I-GENE
( O
LET O
) O
component O
. O

However I-GENE
, O
the O
beta5L O
splice O
variant I-GENE
was I-GENE
found I-GENE
only I-GENE
in O
the O
retina I-GENE
. O

This I-GENE
analysis I-GENE
supports I-GENE
the O
use I-GENE
of O
fluticasone I-GENE
propionate I-GENE
88 I-GENE
microg I-GENE
twice I-GENE
daily I-GENE
as O
first O
- I-GENE
line I-GENE
treatment I-GENE
in O
patients I-GENE
with I-GENE
persistent I-GENE
asthma I-GENE
previously I-GENE
treated I-GENE
with I-GENE
short I-GENE
- I-GENE
acting I-GENE
beta2 I-GENE
- I-GENE
agonist I-GENE
alone I-GENE
. O

The I-GENE
mice I-GENE
are I-GENE
phenotypically I-GENE
normal I-GENE
and O
do I-GENE
not I-GENE
develop I-GENE
spontaneous I-GENE
tumors I-GENE
at O
an I-GENE
early I-GENE
age I-GENE
, O
in O
contrast I-GENE
to O
knock I-GENE
- I-GENE
out I-GENE
( I-GENE
p53 O
(-/-)) I-GENE
strains I-GENE
with I-GENE
a O
defective O
p53 O
gene O
. O

Furthermore I-GENE
, O
stable I-GENE
expression O
of O
a O
constitutively I-GENE
active I-GENE
form I-GENE
of O
chicken I-GENE
Notch1 I-GENE
or O
Notch2 O
in O
a O
B I-GENE
cell I-GENE
line I-GENE
results I-GENE
in O
a O
down I-GENE
- I-GENE
regulation O
of O
surface O
IgM O
expression O
, O
which I-GENE
is I-GENE
accompanied I-GENE
by I-GENE
the O
reduction I-GENE
of O
IgH I-GENE
gene I-GENE
transcripts I-GENE
. O

On I-GENE
Cox I-GENE
proportional I-GENE
hazards I-GENE
regression I-GENE
adenocarcinoma I-GENE
( I-GENE
P I-GENE
= I-GENE
0 O
. O
006 O
), O
the O
development I-GENE
of O
BPF I-GENE
( I-GENE
P I-GENE
= I-GENE
0 O
. O
003 O
), O
older I-GENE
age I-GENE
( I-GENE
P I-GENE
= I-GENE
0 O
. O
03 I-GENE
) O
and O
higher O
pathological I-GENE
stage I-GENE
( I-GENE
P I-GENE
= I-GENE
0 O
. O
02 I-GENE
) I-GENE
were I-GENE
independent I-GENE
adverse I-GENE
predictors I-GENE
of O
survival I-GENE
. O

We I-GENE
found I-GENE
that I-GENE
RhoA O
can I-GENE
initiate I-GENE
a O
linear I-GENE
kinase I-GENE
cascade I-GENE
leading I-GENE
to O
the O
activation O
of O
ERK6 O
( O
p38 O
gamma O
), O
a O
recently I-GENE
identified I-GENE
member O
of O
the O
p38 O
family O
of O
MAPKs O
. O

Twenty I-GENE
- I-GENE
six O
( O
55 O
%) I-GENE
( I-GENE
95 I-GENE
% I-GENE
CI O
, O
41 O
- O
69 O
%) I-GENE
patients I-GENE
experienced I-GENE
> I-GENE
or O
= I-GENE
grade I-GENE
3 I-GENE
acute I-GENE
toxicity I-GENE
( I-GENE
RTOG I-GENE
). O

We I-GENE
hypothesize I-GENE
that I-GENE
proprioception I-GENE
may I-GENE
be I-GENE
used I-GENE
to O
calibrate I-GENE
the O
efference I-GENE
copy I-GENE
during O
development I-GENE
and O
in O
response O
to O
perturbations O
by O
signaling O
potential O
mismatches I-GENE
between I-GENE
eye I-GENE
movement I-GENE
information O
derived O
from O
the O
efferent O
command O
and O
the O
actual I-GENE
motion I-GENE
of O
the O
eye I-GENE
transduced I-GENE
by I-GENE
the O
proprioceptive I-GENE
organs I-GENE
. O

Thus I-GENE
, O
BALB I-GENE
/ I-GENE
c I-GENE
mice I-GENE
appear I-GENE
to O
be I-GENE
the O
most I-GENE
appropriate I-GENE
strain O
of O
mice I-GENE
to O
perform I-GENE
studies I-GENE
on I-GENE
the O
possible I-GENE
connection I-GENE
between I-GENE
infection I-GENE
with I-GENE
T I-GENE
. O
canis I-GENE
and O
allergic I-GENE
asthma I-GENE
. O

They I-GENE
correspond I-GENE
to O
nucleotides I-GENE
equivalent I-GENE
to O
base O
- O
pair O
C1 O
- O
G72 O
and O
discriminator O
base O
A73 O
in O
the O
amino O
acid O
- I-GENE
acceptor I-GENE
branch I-GENE
of O
the O
molecule O
. O

Our I-GENE
results I-GENE
suggest I-GENE
that I-GENE
the O
central I-GENE
role I-GENE
of O
the O
Notch O
- O
CBF1 O
/ O
RBP O
- O
Jkappa O
signaling O
pathway O
in O
cell O
fate I-GENE
decisions I-GENE
renders I-GENE
it I-GENE
susceptible I-GENE
to O
pathways I-GENE
of O
viral O
replication O
and O
oncogenic I-GENE
conversion I-GENE
. O

High O
- I-GENE
affinity I-GENE
binding I-GENE
of O
NF I-GENE
- I-GENE
1 I-GENE
to O
PSE I-GENE
- I-GENE
B I-GENE
, O
but I-GENE
not I-GENE
to O
PSE I-GENE
- I-GENE
A I-GENE
, O
was I-GENE
confirmed I-GENE
by I-GENE
competition I-GENE
of O
DNA I-GENE
- I-GENE
protein I-GENE
interactions I-GENE
by I-GENE
using I-GENE
NF I-GENE
- I-GENE
1 I-GENE
DNA I-GENE
elements I-GENE
and O
antibodies I-GENE
. O

The I-GENE
first O
case I-GENE
of O
HCV I-GENE
seroconversion I-GENE
in O
Portugal I-GENE
after I-GENE
the O
introduction I-GENE
of O
HCV I-GENE
NAT I-GENE
screening I-GENE
. O

Substitutions O
in O
the O
YFV I-GENE
Ag I-GENE
- I-GENE
binding I-GENE
region I-GENE
( I-GENE
ABR I-GENE
) I-GENE
occur I-GENE
at O
four I-GENE
of O
the O
eight I-GENE
highly I-GENE
conserved O
residues I-GENE
that I-GENE
are I-GENE
essential I-GENE
for O
binding I-GENE
of O
peptide I-GENE
- I-GENE
Ag I-GENE
in O
the O
class O
Ia O
molecules O
. O

The I-GENE
Novacor I-GENE
Left I-GENE
Ventricular I-GENE
Assist I-GENE
System I-GENE
( O
LVAS O
) O
( O
Novacor O
Corp O
, O
Oakland O
, O
CA I-GENE
) I-GENE
was I-GENE
initially I-GENE
console I-GENE
- I-GENE
based I-GENE
and O
has I-GENE
been I-GENE
available I-GENE
since I-GENE
1993 I-GENE
in O
a O
wearable I-GENE
configuration I-GENE
. O

Ileal O
digestibilities O
of O
DM I-GENE
, O
OM O
, O
CP O
, O
total O
dietary I-GENE
fiber I-GENE
( I-GENE
TDF I-GENE
), O
fat I-GENE
and O
gross I-GENE
energy I-GENE
( I-GENE
GE I-GENE
) I-GENE
were I-GENE
lower I-GENE
( I-GENE
P I-GENE
< I-GENE
0 O
. O
05 I-GENE
) I-GENE
for O
dogs I-GENE
fed I-GENE
diets I-GENE
containing I-GENE
supplemental I-GENE
fiber I-GENE
compared I-GENE
with I-GENE
dogs I-GENE
fed I-GENE
the O
control O
diet I-GENE
. O

In I-GENE
addition I-GENE
, O
the O
consensus O
amino O
acid O
motif O
for O
serine I-GENE
threonine I-GENE
receptor I-GENE
kinases I-GENE
was I-GENE
also I-GENE
present I-GENE
. O

Here I-GENE
, O
we I-GENE
show I-GENE
that I-GENE
the O
phorbol I-GENE
ester I-GENE
PMA I-GENE
decreases I-GENE
both I-GENE
basal I-GENE
and O
dexamethasone I-GENE
/ I-GENE
cAMP I-GENE
- I-GENE
induced O
expression O
of O
a O
luciferase O
gene I-GENE
under I-GENE
the O
control O
of O
the O
G6Pase I-GENE
promoter I-GENE
in O
transiently I-GENE
transfected I-GENE
H4IIE I-GENE
hepatoma I-GENE
cells I-GENE
. O

The I-GENE
difference I-GENE
between I-GENE
the O
patients I-GENE
and O
the O
controls I-GENE
was I-GENE
statistically I-GENE
significant I-GENE
( I-GENE
p O
= I-GENE
0 O
. O
03 I-GENE
). O

Altogether I-GENE
, O
we I-GENE
confirm I-GENE
that I-GENE
all I-GENE
genes I-GENE
of O
the O
Rad52 O
recombinational O
repair O
pathway O
are I-GENE
required I-GENE
for O
the O
survival I-GENE
of O
rad27 I-GENE
Delta I-GENE
strains I-GENE
at O
both I-GENE
permissive I-GENE
( I-GENE
23 I-GENE
degrees I-GENE
C I-GENE
) O
and O
semipermissive O
( O
30 O
degrees I-GENE
C I-GENE
) I-GENE
temperatures I-GENE
for O
growth I-GENE
. O

Neuron O
- O
specific O
Bcl O
- I-GENE
2 I-GENE
homology I-GENE
3 I-GENE
domain I-GENE
- I-GENE
only I-GENE
splice O
variant I-GENE
of O
Bak I-GENE
is I-GENE
anti I-GENE
- I-GENE
apoptotic I-GENE
in O
neurons I-GENE
, O
but I-GENE
pro I-GENE
- I-GENE
apoptotic I-GENE
in O
non I-GENE
- I-GENE
neuronal I-GENE
cells I-GENE
. O

The I-GENE
mechanism I-GENE
of O
the O
induction I-GENE
of O
3beta I-GENE
- I-GENE
HSD I-GENE
type I-GENE
1 I-GENE
gene I-GENE
expression O
was I-GENE
further I-GENE
characterized I-GENE
in O
ZR I-GENE
- I-GENE
75 I-GENE
- I-GENE
1 I-GENE
human I-GENE
breast I-GENE
cancer O
cells I-GENE
. O

Contagious I-GENE
bovine I-GENE
pleuropneumonia I-GENE
is I-GENE
a O
major I-GENE
threat I-GENE
for O
cattle I-GENE
in O
Africa I-GENE
. O

Treatment I-GENE
includes I-GENE
both I-GENE
medical I-GENE
and O
surgical I-GENE
options I-GENE
, O
with I-GENE
medical I-GENE
therapy I-GENE
further I-GENE
subclassified I-GENE
into I-GENE
pharmacologic I-GENE
and O
pneumatic I-GENE
dilation I-GENE
. O

Since I-GENE
the O
latter I-GENE
is I-GENE
very I-GENE
small I-GENE
for O
physiological I-GENE
flows I-GENE
, O
the O
result I-GENE
is I-GENE
that I-GENE
alpha I-GENE
< I-GENE
1 I-GENE
even I-GENE
at O
relatively I-GENE
high I-GENE
values I-GENE
of O
the O
Reynolds I-GENE
number I-GENE
( O
i O
. O
e O
., I-GENE
for O
non I-GENE
- I-GENE
negligible I-GENE
inertia I-GENE
) I-GENE
and O
we I-GENE
validate I-GENE
our I-GENE
perturbation I-GENE
theory I-GENE
results I-GENE
by I-GENE
comparison I-GENE
with I-GENE
a O
numerical O
integration O
of O
the O
full I-GENE
model I-GENE
. O

This I-GENE
plus O
the O
reduced O
phosphorylation O
of O
p27 O
by I-GENE
MAPK I-GENE
enhanced O
the O
stability I-GENE
of O
p27 O
that I-GENE
associated I-GENE
with I-GENE
nuclear I-GENE
Cdk2 O
at O
high O
stoichiometry O
and O
inhibited I-GENE
its I-GENE
kinase I-GENE
activity I-GENE
. O

Similar I-GENE
data I-GENE
were I-GENE
also I-GENE
obtained I-GENE
when I-GENE
either I-GENE
dominant I-GENE
negative O
EGFR O
- O
CD533 O
or O
dominant O
negative O
Ras O
N17 I-GENE
were I-GENE
used I-GENE
to O
block I-GENE
MAPK I-GENE
activation O
. O

The I-GENE
assay I-GENE
herein I-GENE
described I-GENE
allows I-GENE
the O
comparison I-GENE
of O
relative I-GENE
FGFR O
expression O
levels I-GENE
, O
both I-GENE
within I-GENE
a O
single I-GENE
RNA I-GENE
pool I-GENE
and O
among I-GENE
multiple I-GENE
RNA I-GENE
pool I-GENE
samples I-GENE
. O

This I-GENE
was I-GENE
most I-GENE
pronounced I-GENE
during O
the O
initial I-GENE
phase O
of O
Erk O
activation O
. O

DESIGN I-GENE
: O
Prospective I-GENE
cohort I-GENE
study I-GENE
with I-GENE
a O
20 I-GENE
y I-GENE
follow I-GENE
- I-GENE
up O
period I-GENE
, O
the O
First I-GENE
National I-GENE
Health I-GENE
and O
Examination I-GENE
Survey I-GENE
( I-GENE
NHANES I-GENE
1 I-GENE
) I-GENE
Epidemiologic I-GENE
Follow I-GENE
- I-GENE
up O
Study I-GENE
( I-GENE
NHEFS I-GENE
). O

To I-GENE
assess I-GENE
the O
maximum I-GENE
oxygen I-GENE
uptake I-GENE
( O
V O
' O
O2 O
max O
) O
of O
Hong I-GENE
Kong I-GENE
Chinese I-GENE
children I-GENE
and O
to O
explore I-GENE
its I-GENE
association I-GENE
with I-GENE
respiratory I-GENE
illnesses I-GENE
, O
we I-GENE
conducted I-GENE
the O
Multistage I-GENE
Fitness I-GENE
Test I-GENE
( O
MFT O
), O
a O
20 O
- I-GENE
m I-GENE
shuttle I-GENE
run I-GENE
test I-GENE
, O
in O
1 O
, O
427 I-GENE
schoolchildren I-GENE
aged I-GENE
between I-GENE
8 I-GENE
- I-GENE
12 I-GENE
years I-GENE
. O

After I-GENE
all I-GENE
doses I-GENE
of O
d I-GENE
- I-GENE
amphetamine I-GENE
, O
responding I-GENE
occurred I-GENE
largely I-GENE
on I-GENE
the O
saline I-GENE
key I-GENE
under I-GENE
both I-GENE
schedules I-GENE
. O

A I-GENE
novel I-GENE
myeloid I-GENE
- I-GENE
restricted I-GENE
zebrafish I-GENE
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
with I-GENE
a O
potent I-GENE
transcriptional O
activation O
domain O
. O

METHODS I-GENE
: O
Humphrey I-GENE
Field I-GENE
Analyzer I-GENE
model I-GENE
630 I-GENE
( I-GENE
HFA I-GENE
I I-GENE
, O
program I-GENE
30 O
- I-GENE
2 I-GENE
with I-GENE
a O
rectangular I-GENE
6 I-GENE
degrees I-GENE
x I-GENE
6 I-GENE
degrees I-GENE
grid I-GENE
) I-GENE
was I-GENE
used I-GENE
as O
the O
conventional I-GENE
perimetric I-GENE
method I-GENE
. O

These I-GENE
data I-GENE
reveal I-GENE
a O
complex I-GENE
network I-GENE
of O
interactions I-GENE
between I-GENE
GTPases O
in O
the O
ARF O
family O
and O
their I-GENE
effectors I-GENE
and O
reveal I-GENE
a O
potential O
for O
cross I-GENE
- I-GENE
talk I-GENE
not I-GENE
demonstrated I-GENE
previously I-GENE
. O

Net O
lift O
and O
combined I-GENE
drag I-GENE
from O
all I-GENE
8 O
bearings O
of O
the O
4 I-GENE
- I-GENE
bladed I-GENE
impeller I-GENE
are I-GENE
compared I-GENE
with I-GENE
predictions I-GENE
based I-GENE
on I-GENE
2 I-GENE
- I-GENE
D I-GENE
theory I-GENE
. O

In I-GENE
the O
course I-GENE
of O
screening I-GENE
for O
transcription I-GENE
factors I-GENE
which I-GENE
interact I-GENE
with I-GENE
the O
human I-GENE
myeloperoxidase I-GENE
( I-GENE
MPO I-GENE
) I-GENE
promoter I-GENE
we I-GENE
, O
for O
the O
first O
time I-GENE
, O
identified I-GENE
and O
cloned O
the O
cDNA O
and O
genomic O
DNA O
for O
human O
HBP1 O
( O
HMG O
- O
Box O
containing O
protein O
1 O
), O
a O
member O
of O
the O
high O
mobility O
group O
of O
non O
- O
histone O
chromosomal O
proteins O
. O

Therefore I-GENE
, O
vitamin I-GENE
D3 I-GENE
analogues I-GENE
have I-GENE
a O
substantial I-GENE
antipsoriatic I-GENE
effect I-GENE
. O

Methylation O
at O
both I-GENE
cytosine I-GENE
residues O
in O
the O
E2F O
element O
(( O
m O
) O
CG O
( O
m O
) O
CG I-GENE
) I-GENE
generated I-GENE
a O
new I-GENE
methylcytosine I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
complex I-GENE
. O

Hepatitis O
A O
infected O
food I-GENE
handler I-GENE
at O
an I-GENE
Edmonton I-GENE
, O
Alberta I-GENE
retail I-GENE
food I-GENE
facility I-GENE
: O
public I-GENE
health I-GENE
protection I-GENE
strategies I-GENE
. O

The I-GENE
co O
- I-GENE
existence I-GENE
of O
TE I-GENE
domains I-GENE
within I-GENE
modular I-GENE
PKSs I-GENE
along I-GENE
with I-GENE
physically I-GENE
separated I-GENE
, O
monofunctional I-GENE
TEs I-GENE
( I-GENE
TE I-GENE
IIs I-GENE
) I-GENE
has I-GENE
been I-GENE
reported I-GENE
for O
a O
number I-GENE
of O
modular I-GENE
polyketide I-GENE
and O
non I-GENE
- I-GENE
ribosomal I-GENE
peptide I-GENE
synthases I-GENE
( I-GENE
NRPS I-GENE
). O

Two I-GENE
independent I-GENE
transgenic I-GENE
lines I-GENE
were I-GENE
produced I-GENE
, O
and O
both I-GENE
showed I-GENE
expression O
of O
the O
Gus I-GENE
gene I-GENE
specifically I-GENE
in O
the O
endosperm O
during O
mid I-GENE
- I-GENE
development I-GENE
( I-GENE
first O
detected I-GENE
10 I-GENE
- I-GENE
12 I-GENE
d I-GENE
after I-GENE
anthesis I-GENE
). O

Treadmill I-GENE
training I-GENE
at O
least I-GENE
for O
2 I-GENE
weeks I-GENE
can I-GENE
reduce I-GENE
the O
infarction I-GENE
size I-GENE
and O
edema I-GENE
caused I-GENE
by I-GENE
MCA I-GENE
occlusion I-GENE
( I-GENE
P I-GENE
< I-GENE
0 O
. O
01 I-GENE
). O

Mechanism I-GENE
in O
the O
sequential I-GENE
control O
of O
cell O
morphology I-GENE
and O
S I-GENE
phase O
entry I-GENE
by I-GENE
epidermal I-GENE
growth I-GENE
factor I-GENE
involves I-GENE
distinct I-GENE
MEK O
/ O
ERK O
activations O
. O

We I-GENE
randomly I-GENE
assigned I-GENE
1 I-GENE
, O
219 I-GENE
subjects I-GENE
to O
receive I-GENE
either I-GENE
the O
standard I-GENE
three I-GENE
- I-GENE
times I-GENE
- I-GENE
weekly I-GENE
( I-GENE
TIW I-GENE
) I-GENE
interferon I-GENE
alfa I-GENE
- I-GENE
2b I-GENE
dose I-GENE
( O
3 O
MIU O
) O
or O
the O
once I-GENE
- I-GENE
weekly I-GENE
( I-GENE
QW I-GENE
) I-GENE
peginterferon I-GENE
alfa I-GENE
- I-GENE
2b I-GENE
( O
0 O
. O
5 O
, O
1 O
. O
0 O
, O
or O
1 O
. O
5 O
microg I-GENE
/ I-GENE
kg I-GENE
). O

These I-GENE
data I-GENE
suggest I-GENE
that I-GENE
proper I-GENE
direct I-GENE
binding I-GENE
of O
Nhp2p I-GENE
to O
H I-GENE
/ I-GENE
ACA I-GENE
snoRNAs I-GENE
is I-GENE
required I-GENE
for O
the O
assembly I-GENE
of O
H I-GENE
/ I-GENE
ACA I-GENE
snoRNPs I-GENE
and O
hence I-GENE
for O
the O
stability I-GENE
of O
some I-GENE
of O
their I-GENE
components O
. O

The O
decrements O
in O
cerebrovascular O
resistance O
induced O
by O
hexamethonium O
, O
in O
mm I-GENE
Hg I-GENE
ml I-GENE
(- I-GENE
1 I-GENE
). I-GENE
min I-GENE
(- O
1 I-GENE
), O
were I-GENE
: O
under I-GENE
control O
. O

Here I-GENE
we I-GENE
provide I-GENE
the O
first O
evidence I-GENE
for O
the O
involvement I-GENE
of O
GCN1 O
- O
GCN2 O
interaction O
in O
activation O
of O
GCN2 O
per I-GENE
se I-GENE
. O

As I-GENE
a O
reflection O
of O
uncertainties O
in O
the O
estimates I-GENE
for O
individual I-GENE
sources I-GENE
, O
the O
90th O
percentiles O
of O
PCDD O
/ O
F O
releases O
for O
1999 I-GENE
ranged I-GENE
up O
to O
4 O
. O
1 I-GENE
g I-GENE
I I-GENE
- I-GENE
TEQ I-GENE
/ I-GENE
y I-GENE
. O

To I-GENE
test I-GENE
the O
hypothesis I-GENE
that I-GENE
these I-GENE
elements I-GENE
are I-GENE
required I-GENE
for O
promoter I-GENE
activity I-GENE
, O
we I-GENE
compared I-GENE
the O
reporter I-GENE
expression O
activity I-GENE
of O
segments O
containing O
mutations O
of O
these I-GENE
elements I-GENE
with I-GENE
activity I-GENE
of O
the O
parent O
Hlx O
promoter O
sequence O
. O

Using I-GENE
RACE I-GENE
techniques I-GENE
we I-GENE
have I-GENE
cloned O
and O
sequenced I-GENE
one I-GENE
of O
the O
hamster O
liver O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
hexobarbital I-GENE
dehydrogenases I-GENE
which I-GENE
catalyze I-GENE
not I-GENE
only I-GENE
cyclic I-GENE
alcohols I-GENE
but I-GENE
also I-GENE
17beta I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
steroids I-GENE
and O
3alpha I-GENE
- I-GENE
hydroxysteroids I-GENE
. O

Concerted O
transcriptional O
activation O
of O
the O
low O
density I-GENE
lipoprotein I-GENE
receptor I-GENE
gene I-GENE
by I-GENE
insulin O
and O
luteinizing I-GENE
hormone I-GENE
in O
cultured I-GENE
porcine I-GENE
granulosa I-GENE
- I-GENE
luteal I-GENE
cells I-GENE
: O
possible I-GENE
convergence I-GENE
of O
protein I-GENE
kinase I-GENE
a O
, O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
and O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
signaling O
pathways I-GENE
. O

Human I-GENE
T I-GENE
- I-GENE
cell I-GENE
leukemia I-GENE
virus I-GENE
type I-GENE
I I-GENE
( I-GENE
HTLV I-GENE
- I-GENE
I I-GENE
) I-GENE
Tax I-GENE
is I-GENE
a O
potent I-GENE
transcriptional I-GENE
regulator I-GENE
that I-GENE
can I-GENE
activate I-GENE
or O
repress I-GENE
specific I-GENE
cellular I-GENE
genes I-GENE
and O
that I-GENE
has I-GENE
been I-GENE
proposed I-GENE
to O
contribute I-GENE
to O
leukemogenesis I-GENE
in O
adult I-GENE
T I-GENE
- I-GENE
cell I-GENE
leukemia I-GENE
. O

Also I-GENE
, O
small I-GENE
, O
sense I-GENE
and O
antisense O
approximately O
22 O
nt I-GENE
RNAs O
, O
derived O
from O
the O
satRNA O
, O
were I-GENE
associated I-GENE
with I-GENE
the O
replicating O
satellite O
. O

Deletional I-GENE
analyses I-GENE
of O
VDR O
indicated I-GENE
that I-GENE
GRIP1 I-GENE
and O
RAC3 I-GENE
required I-GENE
an I-GENE
intact O
VDR O
activation O
function I-GENE
( I-GENE
AF I-GENE
- I-GENE
2 I-GENE
) I-GENE
domain I-GENE
for O
efficient I-GENE
interaction O
as O
well O
as O
additional I-GENE
but I-GENE
distinct I-GENE
regions O
of O
the O
VDR O
. O

RESULTS I-GENE
: O
During I-GENE
the O
stabilization I-GENE
period I-GENE
, O
PaCO2 I-GENE
( I-GENE
mean I-GENE
+/- I-GENE
SD I-GENE
) I-GENE
was I-GENE
33 I-GENE
+/- I-GENE
5 I-GENE
mm I-GENE
Hg I-GENE
, O
and O
arrhythmias I-GENE
were I-GENE
not I-GENE
detected I-GENE
. O

TT I-GENE
cells I-GENE
, O
a O
human I-GENE
MTC I-GENE
cell I-GENE
line I-GENE
expressing I-GENE
MEN I-GENE
2A I-GENE
type I-GENE
RET O
, O
display I-GENE
transcriptionally I-GENE
active I-GENE
RelA I-GENE
( I-GENE
p65 I-GENE
) O
in O
the O
nucleus I-GENE
. O

The I-GENE
human I-GENE
protein I-GENE
sequence I-GENE
exhibits I-GENE
a O
putative I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
similar I-GENE
to O
that I-GENE
seen I-GENE
in O
rat I-GENE
HBP1 I-GENE
and O
shows I-GENE
homology I-GENE
with I-GENE
the O
activation O
and O
repressor I-GENE
domains I-GENE
previously I-GENE
demonstrated I-GENE
in O
the O
rat I-GENE
protein I-GENE
. O

In I-GENE
contrast I-GENE
the O
human I-GENE
and O
mouse I-GENE
BCNT I-GENE
proteins I-GENE
contain I-GENE
one I-GENE
repeat I-GENE
unit I-GENE
and O
lack I-GENE
the O
RTE I-GENE
- I-GENE
1 I-GENE
- I-GENE
derived I-GENE
portion I-GENE
. O

Direct I-GENE
superoxide I-GENE
scavenging I-GENE
activity I-GENE
of O
nonsteroidal I-GENE
anti I-GENE
- I-GENE
inflammatory I-GENE
drugs I-GENE
: O
determination I-GENE
by I-GENE
electron I-GENE
spin I-GENE
resonance I-GENE
using I-GENE
the O
spin I-GENE
trap I-GENE
method I-GENE
. O

A O
single O
nucleotide O
polymorphism I-GENE
( O
SNP O
) O
in O
exon O
2 O
, O
which I-GENE
is I-GENE
tightly I-GENE
liked I-GENE
to O
another I-GENE
SNP I-GENE
( I-GENE
GTG83 I-GENE
/ I-GENE
ATG83 I-GENE
), O
creates I-GENE
an I-GENE
additional I-GENE
alternative O
in O
- O
frame O
AUG I-GENE
in O
B I-GENE
- I-GENE
type I-GENE
MTH1 I-GENE
mRNAs I-GENE
yielding I-GENE
the O
fourth I-GENE
MTH1 I-GENE
polypeptide I-GENE
, O
p26 I-GENE
that I-GENE
possesses I-GENE
an I-GENE
additional I-GENE
mitochondrial I-GENE
targeting I-GENE
signal I-GENE
. O

Six I-GENE
of O
the O
gstC O
' O
mutants O
, O
primarily I-GENE
in O
the O
C O
- O
terminal O
half O
of O
C I-GENE
', I-GENE
exhibited I-GENE
a O
defect I-GENE
in O
the O
ability I-GENE
to O
bind I-GENE
L I-GENE
protein I-GENE
. O

We I-GENE
developed I-GENE
a O
system O
for O
domain O
shuffling O
to O
establish I-GENE
the O
function I-GENE
of O
C1 I-GENE
domains I-GENE
from O
human I-GENE
Raf O
kinase I-GENE
and O
rat O
PKC O
eta O
in O
yeast O
. O

Expression I-GENE
of O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
2 I-GENE
US3 I-GENE
affects I-GENE
the O
Cdc42 O
/ O
Rac O
pathway O
and O
attenuates I-GENE
c I-GENE
- I-GENE
Jun O
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
activation O
. O

Inhibition I-GENE
of O
constitutive I-GENE
NF I-GENE
- I-GENE
kappaB O
activity I-GENE
results I-GENE
in O
cell O
death O
of O
TT I-GENE
cells I-GENE
and O
blocks I-GENE
focus I-GENE
formation I-GENE
induced O
by I-GENE
oncogenic I-GENE
forms I-GENE
of O
RET O
in O
NIH O
3T3 I-GENE
cells I-GENE
. O

Corneal O
scrapping O
and O
deep I-GENE
stromal I-GENE
biopsy I-GENE
were I-GENE
obtained I-GENE
and O
stained I-GENE
for O
microscopic I-GENE
evaluation I-GENE
with I-GENE
periodic I-GENE
acid I-GENE
- I-GENE
Schiff I-GENE
, O
Giemsa O
, O
and O
Gomori O
' O
s O
methenamine I-GENE
silver I-GENE
stains I-GENE
. O

ICAM I-GENE
- I-GENE
1 I-GENE
has I-GENE
been I-GENE
suggested I-GENE
a O
predictor I-GENE
of O
the O
onset I-GENE
of O
GO I-GENE
. O

Once I-GENE
ICP I-GENE
reaches I-GENE
critical I-GENE
values I-GENE
(> I-GENE
30 O
mm I-GENE
Hg I-GENE
) I-GENE
herniation I-GENE
occurs I-GENE
, O
usually I-GENE
within I-GENE
2 I-GENE
to O
5 I-GENE
days I-GENE
. O

The I-GENE
present I-GENE
data I-GENE
also I-GENE
demonstrate I-GENE
that I-GENE
ectopic I-GENE
expression O
of O
blr1 I-GENE
increased I-GENE
JNK O
/ O
SAPK O
activity I-GENE
, O
but I-GENE
JNK O
/ O
SAPK O
activation O
was I-GENE
not I-GENE
needed I-GENE
for O
accelerated I-GENE
RA I-GENE
- I-GENE
induced O
differentiation I-GENE
and O
growth I-GENE
arrest I-GENE
. O

Here I-GENE
, O
we I-GENE
identify I-GENE
Rsc3 I-GENE
and O
Rsc30 I-GENE
as O
novel I-GENE
components O
of O
the O
essential I-GENE
yeast I-GENE
remodeler I-GENE
RSC I-GENE
complex I-GENE
. O

The I-GENE
pharmacokinetic I-GENE
profiles I-GENE
of O
digoxin I-GENE
and O
warfarin I-GENE
were I-GENE
not I-GENE
altered I-GENE
by I-GENE
the O
simultaneous I-GENE
and O
continued I-GENE
administration I-GENE
of O
sevelamer I-GENE
. O

Forskolin I-GENE
treatment I-GENE
( I-GENE
10 I-GENE
microM I-GENE
) O
of O
the O
transfected I-GENE
cells I-GENE
for O
3 I-GENE
-- I-GENE
6 I-GENE
h I-GENE
maximally I-GENE
induced O
luciferase O
threefold I-GENE
. O

E2F1 O
- O
mediated O
transcriptional O
inhibition I-GENE
of O
the O
plasminogen O
activator I-GENE
inhibitor I-GENE
type I-GENE
1 I-GENE
gene I-GENE
. O

In I-GENE
this I-GENE
report I-GENE
this I-GENE
technique I-GENE
was I-GENE
applied I-GENE
to O
human I-GENE
breast I-GENE
carcinoma I-GENE
MDA I-GENE
- I-GENE
MB231 I-GENE
cells I-GENE
overexpressing I-GENE
human I-GENE
MPG I-GENE
in O
order I-GENE
to O
assess I-GENE
whether I-GENE
up O
- O
regulation O
of O
the O
initial I-GENE
step I-GENE
in O
BER I-GENE
alters I-GENE
the O
activity I-GENE
of O
selected O
other I-GENE
BER I-GENE
( I-GENE
hOGG1 I-GENE
and O
APE I-GENE
/ I-GENE
ref I-GENE
- I-GENE
1 I-GENE
) I-GENE
or O
direct I-GENE
reversal I-GENE
( I-GENE
MGMT I-GENE
) I-GENE
repair I-GENE
activities I-GENE
. O

Chlamydia I-GENE
and O
cervical I-GENE
cancer O
: O
a O
real I-GENE
association I-GENE
? I-GENE

In I-GENE
children I-GENE
unable I-GENE
to O
perform I-GENE
forced I-GENE
expiratory I-GENE
maneuvers I-GENE
( I-GENE
n I-GENE
= I-GENE
25 O
), O
FOT O
, O
contrary O
to O
the O
interrupter I-GENE
technique I-GENE
, O
clearly I-GENE
identified I-GENE
a O
subgroup I-GENE
of O
young I-GENE
children I-GENE
with I-GENE
high I-GENE
resistance I-GENE
values I-GENE
at O
baseline I-GENE
, O
which I-GENE
returned I-GENE
to O
normal I-GENE
after I-GENE
bronchodilation I-GENE
. O

Together I-GENE
, O
these I-GENE
results I-GENE
identify I-GENE
HPK1 I-GENE
as O
a O
new I-GENE
component O
of O
TCR O
signaling O
. O

Pro I-GENE
- I-GENE
inflammatory I-GENE
cytokine I-GENE
, O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( I-GENE
TNF O
- I-GENE
alpha I-GENE
), O
produced I-GENE
from O
adipose I-GENE
tissues I-GENE
in O
obese I-GENE
subjects I-GENE
, O
is I-GENE
known I-GENE
to O
play I-GENE
a O
predominant I-GENE
role I-GENE
in O
inducing I-GENE
insulin O
resistance O
. O

The I-GENE
Schistosoma I-GENE
mansoni I-GENE
homologue I-GENE
( I-GENE
SmSmad2 I-GENE
) I-GENE
was I-GENE
overexpressed I-GENE
in O
bacteria I-GENE
as O
a O
Sj26 O
- O
GST O
fusion O
protein O
and O
used I-GENE
to O
raise I-GENE
specific I-GENE
antibodies I-GENE
. O

To I-GENE
study I-GENE
the O
in O
vivo I-GENE
role I-GENE
of O
p16 I-GENE
. O
7 O
, O
a O
phi29 O
mutant O
containing O
a O
suppressible O
mutation O
in O
gene O
16 O
. O
7 O
was I-GENE
constructed I-GENE
. O

The I-GENE
differences I-GENE
in O
the O
CPIgG O
, O
CRP O
, O
and O
fibrinogen O
levels I-GENE
in O
patients I-GENE
who I-GENE
were I-GENE
diagnosed I-GENE
with I-GENE
ACS I-GENE
versus I-GENE
those I-GENE
who I-GENE
were I-GENE
not I-GENE
( I-GENE
non I-GENE
- I-GENE
ACS I-GENE
) I-GENE
were I-GENE
evaluated I-GENE
. O

There I-GENE
are I-GENE
many I-GENE
different I-GENE
proposals I-GENE
for O
the O
statistical I-GENE
analysis I-GENE
of O
data I-GENE
to O
determine I-GENE
early I-GENE
onset I-GENE
of O
action I-GENE
. O

Coexpression O
of O
the O
p120 O
( O
ctn O
) O
protein I-GENE
with I-GENE
an I-GENE
N I-GENE
- I-GENE
terminal I-GENE
deletion I-GENE
, O
which I-GENE
eliminates I-GENE
some I-GENE
potential O
tyrosine O
phosphorylation O
sites O
, O
or O
the O
protein I-GENE
with I-GENE
a O
single O
amino O
acid O
substitution I-GENE
( I-GENE
tyrosine I-GENE
at O
217 I-GENE
to O
phenylalanine I-GENE
) I-GENE
resulted I-GENE
in O
an I-GENE
increase I-GENE
in O
the O
aggregation O
of O
v I-GENE
- I-GENE
Src O
- I-GENE
transformed I-GENE
EL I-GENE
and O
EalphaCL I-GENE
cells I-GENE
. O

We I-GENE
find I-GENE
that I-GENE
our I-GENE
response I-GENE
function I-GENE
is I-GENE
well O
approximated I-GENE
by I-GENE
the O
GSER I-GENE
only I-GENE
within I-GENE
a O
particular I-GENE
frequency I-GENE
range I-GENE
determined I-GENE
by I-GENE
the O
material I-GENE
parameters I-GENE
of O
both I-GENE
the O
bead O
and O
the O
network I-GENE
. O

The I-GENE
novel I-GENE
approach I-GENE
to O
insulin O
administration I-GENE
known I-GENE
as O
chronic I-GENE
intermittent I-GENE
intravenous I-GENE
insulin O
therapy I-GENE
( O
CIIIT O
) O
delivers O
insulin O
in O
a O
pulsatile I-GENE
fashion I-GENE
and O
achieves I-GENE
physiological I-GENE
insulin O
concentration I-GENE
in O
the O
portal O
vein O
. O

This I-GENE
article I-GENE
comparatively I-GENE
evaluates I-GENE
five I-GENE
Generic I-GENE
Systems I-GENE
that I-GENE
describe I-GENE
the O
basic I-GENE
alternatives I-GENE
to O
composting I-GENE
facility I-GENE
design I-GENE
and O
control O
. O

With I-GENE
a O
GC I-GENE
content I-GENE
of O
45 O
% I-GENE
the O
one I-GENE
segment I-GENE
would I-GENE
correspond I-GENE
to O
" I-GENE
isochore I-GENE
H1 I-GENE
" O
and O
the O
other I-GENE
segment I-GENE
( I-GENE
39 I-GENE
% I-GENE
GC I-GENE
in O
human I-GENE
, O
40 I-GENE
% I-GENE
GC O
in O
mouse O
) O
to O
" O
isochore I-GENE
L1 I-GENE
/ I-GENE
L2 I-GENE
". I-GENE

A I-GENE
review I-GENE
of O
the O
literature I-GENE
identified I-GENE
8 I-GENE
comprehensive I-GENE
clinical I-GENE
studies I-GENE
, O
all I-GENE
of O
which I-GENE
failed I-GENE
to O
document I-GENE
any I-GENE
relationship I-GENE
between I-GENE
NF1 O
and O
intracranial O
aneurysms O
. O

Serial I-GENE
US I-GENE
images I-GENE
were I-GENE
obtained I-GENE
before I-GENE
and O
20 O
, O
30 O
, O
40 O
, O
50 I-GENE
, O
60 O
, O
90 O
, O
120 I-GENE
, O
150 O
, O
180 I-GENE
, O
240 I-GENE
, O
and O
300 O
s O
after I-GENE
intravenous I-GENE
injection I-GENE
of O
2 I-GENE
g I-GENE
of O
contrast I-GENE
agent I-GENE
using I-GENE
conventional I-GENE
and O
harmonic I-GENE
PD I-GENE
US I-GENE
. O

Eight I-GENE
CAD I-GENE
patients I-GENE
who I-GENE
were I-GENE
matched I-GENE
to O
the O
treated I-GENE
patients I-GENE
for O
age I-GENE
(+/- I-GENE
3 I-GENE
years I-GENE
), O
baseline I-GENE
low I-GENE
density I-GENE
lipoprotein I-GENE
(+/- I-GENE
5 I-GENE
mg I-GENE
/ I-GENE
dL I-GENE
), O
and O
triglycerides O
(+/- I-GENE
50 I-GENE
mg I-GENE
/ I-GENE
dL I-GENE
) I-GENE
but I-GENE
who I-GENE
had I-GENE
never I-GENE
been I-GENE
treated I-GENE
with I-GENE
lipid I-GENE
- I-GENE
lowering I-GENE
drugs I-GENE
were I-GENE
selected O
as O
controls I-GENE
. O

Here I-GENE
we I-GENE
present I-GENE
evidence I-GENE
that I-GENE
the O
distal I-GENE
half O
( O
Stem O
2 O
) O
of O
the O
conserved O
base O
- O
paired O
stem O
structure O
found I-GENE
in O
all I-GENE
hY I-GENE
RNAs I-GENE
also I-GENE
plays I-GENE
a O
critical I-GENE
role I-GENE
in O
the O
export I-GENE
process I-GENE
. O

The I-GENE
contrasting I-GENE
effects I-GENE
of O
dopaminergic I-GENE
stimulation O
on I-GENE
the O
motor I-GENE
performance I-GENE
and O
on I-GENE
some I-GENE
aspects I-GENE
of O
cognitive I-GENE
processing O
suggest I-GENE
the O
existence I-GENE
of O
complex I-GENE
interactions I-GENE
within I-GENE
pre I-GENE
- I-GENE
and O
postsynaptic I-GENE
brain I-GENE
dopamine I-GENE
receptors I-GENE
, O
and O
an I-GENE
intervention I-GENE
of O
segregated I-GENE
basal I-GENE
ganglia I-GENE
- I-GENE
prefrontal I-GENE
cortex I-GENE
loops I-GENE
in O
motor I-GENE
and O
cognitive I-GENE
behaviour I-GENE
. O

The I-GENE
size I-GENE
of O
the O
infarct I-GENE
was I-GENE
determined I-GENE
using I-GENE
the O
creatine I-GENE
kinase I-GENE
integral I-GENE
method I-GENE
. O

These I-GENE
corrections I-GENE
do I-GENE
not I-GENE
involve I-GENE
sequences I-GENE
predicted I-GENE
to O
function I-GENE
as O
transcription I-GENE
factor I-GENE
binding I-GENE
sites I-GENE
. O

A I-GENE
comprehensive I-GENE
neuropsychological I-GENE
battery I-GENE
was I-GENE
administered I-GENE
to O
48 I-GENE
veterans I-GENE
with I-GENE
Gulf I-GENE
War I-GENE
Illness I-GENE
( I-GENE
GWI I-GENE
) I-GENE
characterized I-GENE
by I-GENE
severe I-GENE
fatigue I-GENE
( I-GENE
GV I-GENE
- I-GENE
F I-GENE
) O
and O
39 O
healthy I-GENE
veterans I-GENE
( I-GENE
GV I-GENE
- I-GENE
H I-GENE
). O

Quantitative I-GENE
PCR I-GENE
studies I-GENE
indicated I-GENE
that I-GENE
synthesis O
and O
transport O
of O
vector I-GENE
DNA I-GENE
into I-GENE
the O
nucleus I-GENE
were I-GENE
similar I-GENE
for O
macrophages I-GENE
infected O
with I-GENE
the O
clone I-GENE
239 I-GENE
and O
316 I-GENE
pseudotypes I-GENE
, O
suggesting I-GENE
that I-GENE
the O
restriction O
for O
SIVmac239 I-GENE
infection I-GENE
is I-GENE
after I-GENE
reverse I-GENE
transcription I-GENE
and O
nuclear I-GENE
import I-GENE
of O
viral O
DNA O
. O

EXAFS I-GENE
measurements I-GENE
around I-GENE
the O
Ge I-GENE
- I-GENE
K I-GENE
edge I-GENE
have I-GENE
been I-GENE
carried I-GENE
out I-GENE
for O
liquid I-GENE
Ge I-GENE
- I-GENE
Si I-GENE
alloys I-GENE
for O
the O
first O
time I-GENE
to O
investigate I-GENE
the O
local I-GENE
structure O
around I-GENE
a O
Ge I-GENE
atom I-GENE
. O

Hp I-GENE
positive I-GENE
relatives I-GENE
of O
gastric O
cancer O
had I-GENE
a O
markedly I-GENE
higher O
prevalence I-GENE
of O
atrophy I-GENE
than I-GENE
those I-GENE
with I-GENE
Hp I-GENE
negativity I-GENE
without I-GENE
cancer O
relatives I-GENE
( I-GENE
29 I-GENE
vs O
. O

Thus I-GENE
, O
replication O
fork O
movement I-GENE
near I-GENE
HML I-GENE
pauses I-GENE
at O
a O
silent I-GENE
origin I-GENE
which I-GENE
is I-GENE
competent I-GENE
for O
replication I-GENE
initiation I-GENE
but I-GENE
kept I-GENE
silent I-GENE
through I-GENE
Orc2p I-GENE
, O
a O
component O
of O
the O
replication O
initiator O
. O

Cardiac I-GENE
markers I-GENE
troponin I-GENE
T I-GENE
, O
CK I-GENE
- I-GENE
MB I-GENE
mass I-GENE
and O
myoglobin O
were I-GENE
helpful I-GENE
in O
the O
differential I-GENE
diagnosis I-GENE
of O
chest I-GENE
pain I-GENE
, O
even I-GENE
when I-GENE
the O
ECG I-GENE
was I-GENE
unremarkable I-GENE
or O
nonspecific I-GENE
. O

RESULTS I-GENE
: O
A I-GENE
novel I-GENE
gene I-GENE
was I-GENE
cloned O
. O

Both I-GENE
pancreatic I-GENE
and O
intestinal O
cell O
lines I-GENE
were I-GENE
found I-GENE
to O
express I-GENE
a O
number I-GENE
of O
POU O
( O
OCT I-GENE
binding I-GENE
) I-GENE
homeodomain I-GENE
proteins I-GENE
examined I-GENE
by I-GENE
electrophoretic I-GENE
mobility I-GENE
shift I-GENE
assay I-GENE
. O

In I-GENE
conclusion I-GENE
, O
USPIO I-GENE
- I-GENE
enhanced O
MRI I-GENE
data I-GENE
were I-GENE
capable I-GENE
to O
characterize I-GENE
tumor I-GENE
microvessel I-GENE
properties I-GENE
in O
this I-GENE
breast I-GENE
cancer O
model I-GENE
: O
microvascular I-GENE
permeability I-GENE
( I-GENE
determined I-GENE
using I-GENE
USPIO I-GENE
) I-GENE
correlated I-GENE
significantly I-GENE
with I-GENE
tumor I-GENE
grade I-GENE
. O

Radiolabeled I-GENE
biantennary I-GENE
N I-GENE
- I-GENE
glycans I-GENE
synthesized I-GENE
by I-GENE
Pro I-GENE
(-) I-GENE
5Lec20 I-GENE
were I-GENE
proportionately I-GENE
less I-GENE
ricin I-GENE
- I-GENE
bound O
than I-GENE
similar I-GENE
species I-GENE
from O
parental I-GENE
CHO I-GENE
cells I-GENE
, O
and O
Lec20 O
cell O
extracts I-GENE
had I-GENE
a O
markedly I-GENE
reduced O
ability I-GENE
to O
transfer I-GENE
Gal I-GENE
to O
GlcNAc I-GENE
- I-GENE
terminating I-GENE
acceptors I-GENE
. O

CONCLUSION I-GENE
: O
The I-GENE
training I-GENE
of O
novices I-GENE
using I-GENE
MIST I-GENE
- I-GENE
VR I-GENE
yields I-GENE
quantifiable I-GENE
changes I-GENE
in O
skill I-GENE
that I-GENE
are I-GENE
transferable I-GENE
to O
a O
simple I-GENE
real I-GENE
task I-GENE
and O
are I-GENE
similar I-GENE
to O
the O
results I-GENE
achieved I-GENE
with I-GENE
conventional I-GENE
training I-GENE
. O

To I-GENE
investigate I-GENE
the O
convergent I-GENE
role I-GENE
of O
the O
insulin O
/ O
IGF O
- I-GENE
I I-GENE
effector I-GENE
pathway O
mediating I-GENE
bihormonal I-GENE
stimulation O
of O
LDL O
receptor I-GENE
promoter I-GENE
expression O
, O
transfected I-GENE
granulosa I-GENE
- I-GENE
luteal I-GENE
cells I-GENE
were I-GENE
pretreated I-GENE
for O
30 O
min I-GENE
with I-GENE
two I-GENE
specific O
inhibitors O
of O
phophatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
wortmannin I-GENE
( I-GENE
100 O
nM I-GENE
) O
and O
LY O
294002 O
( O
10 O
microM I-GENE
), O
or O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
, O
PD I-GENE
98059 I-GENE
( I-GENE
50 I-GENE
microM I-GENE
), O
U0126 O
( O
10 O
microM I-GENE
), O
or O
the O
latter I-GENE
' I-GENE
s I-GENE
inactive I-GENE
derivative O
, O
U0124 O
( O
10 O
microM I-GENE
). O

Instead I-GENE
, O
affective I-GENE
flattening I-GENE
was I-GENE
associated I-GENE
with I-GENE
both I-GENE
dopamine I-GENE
receptor I-GENE
sensitivity I-GENE
and O
psychomotor I-GENE
slowing I-GENE
. O

Other I-GENE
therapies I-GENE
are I-GENE
also I-GENE
available I-GENE
, O
including I-GENE
hypertonic I-GENE
saline I-GENE
solution I-GENE
, O
THAM I-GENE
( I-GENE
Tris I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
methyl I-GENE
- I-GENE
aminomethane I-GENE
) O
buffer O
, O
and O
high O
- I-GENE
dose I-GENE
barbiturates I-GENE
. O

CONCLUSION I-GENE
: O
There I-GENE
are I-GENE
no O
differences I-GENE
in O
the O
measurement I-GENE
data I-GENE
derived I-GENE
from O
this I-GENE
method I-GENE
and O
actual I-GENE
measurement I-GENE
data I-GENE
from O
an I-GENE
object I-GENE
created I-GENE
by I-GENE
the O
computer I-GENE
- I-GENE
aided I-GENE
dental I-GENE
design I-GENE
program I-GENE
. O

NF I-GENE
- I-GENE
kappaB O
pathway O
activation O
occurs I-GENE
during O
transformation I-GENE
induced O
by I-GENE
a O
number I-GENE
of O
classical I-GENE
oncogenes I-GENE
, O
including I-GENE
Bcr I-GENE
/ O
Abl O
, O
Ras O
and O
Rac O
, O
and O
is I-GENE
necessary I-GENE
for O
full O
transforming O
potential O
. O

Our I-GENE
results I-GENE
indicate I-GENE
that I-GENE
Gab1 I-GENE
is I-GENE
involved I-GENE
in O
the O
control O
of O
egr O
- O
1 O
expression O
regulated O
by O
insulin O
. O

The I-GENE
human I-GENE
cytomegalovirus I-GENE
( I-GENE
HCMV I-GENE
) I-GENE
major I-GENE
immediate I-GENE
- I-GENE
early I-GENE
protein I-GENE
IE2 O
is I-GENE
a O
nuclear I-GENE
phosphoprotein I-GENE
that I-GENE
is I-GENE
believed I-GENE
to O
be I-GENE
a O
key I-GENE
regulator I-GENE
in O
both I-GENE
lytic I-GENE
and O
latent I-GENE
infections I-GENE
. O

Unexpectedly O
, O
Arg1 I-GENE
- I-GENE
expressing I-GENE
COS1 I-GENE
cells I-GENE
showed I-GENE
no O
significant I-GENE
proteinase I-GENE
activity I-GENE
to O
various I-GENE
synthesized I-GENE
substrates I-GENE
under I-GENE
neutral I-GENE
or O
acidic I-GENE
conditions I-GENE
in O
this I-GENE
study I-GENE
. O

METHODS I-GENE
: O
126 I-GENE
patients I-GENE
with I-GENE
histologically I-GENE
confirmed I-GENE
MFH I-GENE
were I-GENE
analyzed I-GENE
. O

Regression I-GENE
analyses I-GENE
showed I-GENE
that I-GENE
SOREMP I-GENE
dream I-GENE
occurrences I-GENE
were I-GENE
significantly I-GENE
related I-GENE
to O
the O
amount I-GENE
of O
REM I-GENE
sleep I-GENE
, O
while I-GENE
NREMP I-GENE
dream I-GENE
occurrences I-GENE
were I-GENE
related I-GENE
to O
arousals I-GENE
from O
NREM I-GENE
sleep I-GENE
. O

[ O
Diabetologia O
( O
2001 O
) O
44 O
[ O
Suppl I-GENE
3 I-GENE
]: I-GENE
B37 I-GENE
- I-GENE
B44 I-GENE
] O

RESULTS I-GENE
: O
In I-GENE
vivo I-GENE
, O
there I-GENE
was I-GENE
a O
wide I-GENE
distribution I-GENE
with I-GENE
the O
coefficient I-GENE
of O
variation I-GENE
( I-GENE
SD I-GENE
/ I-GENE
mean I-GENE
x I-GENE
100 O
%) I-GENE
for O
different I-GENE
valve I-GENE
sizes I-GENE
ranging I-GENE
from O
21 I-GENE
% I-GENE
to O
39 I-GENE
% I-GENE
in O
the O
St I-GENE
Jude I-GENE
Medical I-GENE
valve I-GENE
and O
from O
25 O
% I-GENE
to O
33 I-GENE
% I-GENE
in O
the O
Omnicarbon I-GENE
valve I-GENE
. O

A O
microsporidian O
, O
Nosema O
algerae O
Vavra O
and O
undeen O
, O
was I-GENE
found I-GENE
parasitizing I-GENE
larvae I-GENE
and O
adults I-GENE
of O
a O
laboratory I-GENE
colony I-GENE
of O
Culex O
pipiens O
L O
. O
originated O
from O
Gharbia O
Governorate O
. O

Nearly I-GENE
all I-GENE
isolates I-GENE
of O
S O
. O
intermedius O
and O
most I-GENE
isolates I-GENE
of O
S O
. O
constellatus O
, O
but I-GENE
only I-GENE
19 I-GENE
% I-GENE
of O
those I-GENE
of O
S O
. O
anginosus O
, O
were I-GENE
associated I-GENE
with I-GENE
abscess I-GENE
. O

One I-GENE
of O
the O
conserved O
RNA I-GENE
subdomains I-GENE
, O
designated I-GENE
P3 I-GENE
, O
has I-GENE
previously I-GENE
been I-GENE
shown I-GENE
to O
be I-GENE
required I-GENE
for O
nucleolar O
localization O
. O

A O
total O
of O
25 O
patients I-GENE
with I-GENE
malignant I-GENE
brain I-GENE
tumours I-GENE
were I-GENE
investigated I-GENE
. O

Interventions I-GENE
aimed I-GENE
at O
these I-GENE
specific I-GENE
mediators I-GENE
and O
processes I-GENE
may I-GENE
be I-GENE
successful I-GENE
in O
reducing O
the O
very I-GENE
significant I-GENE
human I-GENE
and O
economic I-GENE
costs I-GENE
of O
vascular I-GENE
access I-GENE
dysfunction I-GENE
. O

We I-GENE
used I-GENE
stored I-GENE
plasma I-GENE
samples I-GENE
from O
409 I-GENE
patients I-GENE
in O
the O
National I-GENE
Institute I-GENE
of O
Neurological O
Diseases O
and O
Stroke O
( O
NINDS O
) O
tissue O
plasminogen O
activator I-GENE
( I-GENE
t I-GENE
- I-GENE
PA I-GENE
) I-GENE
Stroke I-GENE
Trial I-GENE
to O
examine I-GENE
the O
relationship I-GENE
between I-GENE
an I-GENE
apolipoprotein O
( I-GENE
Apo I-GENE
) I-GENE
E2 I-GENE
or O
an I-GENE
Apo I-GENE
E4 I-GENE
phenotype O
and O
a O
favorable I-GENE
outcome I-GENE
3 I-GENE
months I-GENE
after I-GENE
stroke I-GENE
, O
the O
risk I-GENE
of O
intracerebral I-GENE
hemorrhage I-GENE
, O
and O
the O
response O
to O
intravenous I-GENE
t I-GENE
- I-GENE
PA I-GENE
therapy I-GENE
. O

These I-GENE
results I-GENE
were I-GENE
robust I-GENE
to O
changes I-GENE
in O
the O
baseline I-GENE
assumptions I-GENE
of O
the O
model I-GENE
. O

Cis I-GENE
- I-GENE
acting I-GENE
CCAAT I-GENE
elements I-GENE
are I-GENE
frequently I-GENE
found I-GENE
in O
eukaryotic I-GENE
promoter I-GENE
regions I-GENE
. O

The I-GENE
binary I-GENE
and O
tertiary I-GENE
combinations I-GENE
of O
plant I-GENE
- I-GENE
derived I-GENE
molluscicides I-GENE
Azadirachta I-GENE
indica I-GENE
and O
Cedrus I-GENE
deodara I-GENE
oil I-GENE
with I-GENE
synergists I-GENE
MGK I-GENE
- I-GENE
264 I-GENE
, O
piperonyl O
butoxide O
( O
PB O
) O
and O
fruit O
powder O
of O
Embelia I-GENE
ribes I-GENE
were I-GENE
used I-GENE
against I-GENE
the O
Lymnaea I-GENE
acuminata I-GENE
. O

This I-GENE
article I-GENE
reports I-GENE
the O
design I-GENE
and O
development I-GENE
of O
an I-GENE
ECG I-GENE
simulator I-GENE
intended I-GENE
for O
use I-GENE
in O
the O
testing I-GENE
, O
calibration O
and O
maintenance O
of O
electrocardiographic O
equipment O
. O

Exchanging O
the O
human O
propeptide O
in O
this I-GENE
chimera I-GENE
with I-GENE
either I-GENE
the O
murine I-GENE
MIC I-GENE
- I-GENE
1 I-GENE
or O
TGF O
- O
beta1 O
propeptide I-GENE
resulted I-GENE
in O
secretion O
of O
the O
unprocessed O
, O
monomeric O
chimera O
, O
suggesting I-GENE
a O
specific I-GENE
interaction O
between I-GENE
the O
human I-GENE
MIC I-GENE
- I-GENE
1 I-GENE
propeptide I-GENE
and O
mature O
peptide O
. O

RESULTS I-GENE
: O
The I-GENE
analyzed I-GENE
fragment I-GENE
has I-GENE
significant I-GENE
activity I-GENE
in O
EpCAM I-GENE
positive I-GENE
cells I-GENE
, O
and O
it I-GENE
is I-GENE
regulated I-GENE
negatively I-GENE
by I-GENE
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
( I-GENE
TNFalpha I-GENE
). O

The I-GENE
mutant I-GENE
receptors I-GENE
, O
as O
well O
as O
sBMPR I-GENE
- I-GENE
IA I-GENE
, O
were I-GENE
expressed O
as O
fusion I-GENE
proteins I-GENE
with I-GENE
thioredoxin I-GENE
in O
Escherichia I-GENE
coli I-GENE
, O
and O
purified O
using I-GENE
reverse I-GENE
phase O
high I-GENE
performance I-GENE
liquid I-GENE
chromatography I-GENE
( I-GENE
RP I-GENE
- I-GENE
HPLC I-GENE
) I-GENE
after I-GENE
digestion I-GENE
with I-GENE
enterokinase I-GENE
. O

The I-GENE
dual I-GENE
specificity O
kinases I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( I-GENE
MAPK I-GENE
) I-GENE
kinase I-GENE
( O
MKK O
) O
7 O
and O
MKK4 I-GENE
are I-GENE
the O
only I-GENE
molecules I-GENE
known I-GENE
to O
directly I-GENE
activate I-GENE
the O
stress I-GENE
kinases I-GENE
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinases I-GENE
( I-GENE
SAPKs I-GENE
)/ I-GENE
c I-GENE
- I-GENE
Jun O
N I-GENE
- I-GENE
terminal I-GENE
kinases I-GENE
( O
JNKs O
) O
in O
response O
to O
environmental I-GENE
or O
mitogenic I-GENE
stimuli I-GENE
. O

This I-GENE
unique I-GENE
work I-GENE
needs I-GENE
to O
be I-GENE
edited I-GENE
critically I-GENE
and O
afterwards I-GENE
translated I-GENE
into I-GENE
Urdu I-GENE
and O
other I-GENE
languages I-GENE
for O
the O
benefit I-GENE
of O
the O
present I-GENE
day I-GENE
students I-GENE
and O
scholars I-GENE
. O

RANTES O
( O
regulated O
upon I-GENE
activation I-GENE
, O
normally I-GENE
T I-GENE
- I-GENE
cell O
expressed O
and O
presumably I-GENE
secreted I-GENE
) I-GENE
is I-GENE
a O
CC I-GENE
chemokine I-GENE
which I-GENE
recruits I-GENE
and O
activates I-GENE
monocytes I-GENE
, O
lymphocytes I-GENE
, O
and O
eosinophils I-GENE
, O
all I-GENE
cell I-GENE
types O
present I-GENE
in O
the O
lung O
inflammatory I-GENE
infiltrate I-GENE
induced O
by I-GENE
RSV I-GENE
infection I-GENE
. O

Gabapentin O
for O
opiod O
- O
related O
myoclonus O
in O
cancer O
patients I-GENE
. O

Recently I-GENE
, O
it I-GENE
was I-GENE
shown I-GENE
that I-GENE
purified I-GENE
RAG1 I-GENE
/ I-GENE
2 I-GENE
proteins I-GENE
can I-GENE
cleave I-GENE
DNA I-GENE
hairpins I-GENE
in O
vitro I-GENE
, O
but I-GENE
the O
same I-GENE
activity I-GENE
was I-GENE
also I-GENE
described I-GENE
for O
a O
protein O
complex O
of O
the O
DNA O
repair O
proteins O
Nbs1 O
/ O
Mre11 O
/ O
Rad50 O
. O

APC I-GENE
- I-GENE
resistance I-GENE
was I-GENE
determined I-GENE
with I-GENE
a O
functional I-GENE
method I-GENE
with I-GENE
high I-GENE
sensitivity I-GENE
and O
specificity O
for O
the O
factor I-GENE
V I-GENE
Leiden I-GENE
mutation I-GENE
. O

A I-GENE
picture I-GENE
is I-GENE
emerging I-GENE
showing I-GENE
a O
gradient I-GENE
of O
function I-GENE
among I-GENE
p53 O
, O
p73 O
, O
p63 I-GENE
ranging I-GENE
from O
tumor I-GENE
suppression I-GENE
to O
development I-GENE
. O

High O
plasma O
AVP O
levels I-GENE
observed I-GENE
in O
the O
two I-GENE
cases I-GENE
suggest I-GENE
that I-GENE
SSRIs I-GENE
stimulate I-GENE
AVP O
secretion O
, O
thereby I-GENE
causing I-GENE
SIADH I-GENE
. O

Mutation I-GENE
of O
the O
octamer I-GENE
element I-GENE
also I-GENE
significantly I-GENE
reduced O
the O
ability I-GENE
of O
HDAC1 I-GENE
to O
confer I-GENE
repression I-GENE
of O
inducible O
HLA O
- O
DRA O
promoter O
activation O
. O

Requirements O
for O
the O
nuclear I-GENE
- I-GENE
cytoplasmic I-GENE
translocation I-GENE
of O
infected O
- O
cell O
protein O
0 O
of O
herpes I-GENE
simplex I-GENE
virus I-GENE
1 I-GENE
. O

The O
system O
, O
designed I-GENE
to O
exploit I-GENE
the O
relatively I-GENE
constant I-GENE
small I-GENE
intestine I-GENE
transit I-GENE
time I-GENE
, O
consists I-GENE
of O
a O
drug I-GENE
- I-GENE
containing I-GENE
core I-GENE
coated I-GENE
with I-GENE
a O
polymeric I-GENE
matrix I-GENE
formed I-GENE
by I-GENE
a O
channeling I-GENE
agent I-GENE
( I-GENE
NaCl I-GENE
, O
mannitol O
, O
and O
Emdex O
) O
and O
an I-GENE
inert I-GENE
polymer I-GENE
( I-GENE
Eudragit I-GENE
RS100 I-GENE
). O

The I-GENE
activity I-GENE
of O
Rac1 O
leads I-GENE
to O
STAT3 O
translocation I-GENE
to O
the O
nucleus I-GENE
coincident I-GENE
with I-GENE
STAT3 O
- I-GENE
dependent I-GENE
gene I-GENE
expression O
. O

Treatment I-GENE
of O
ischemic I-GENE
heart O
disease O
in O
the O
elderly O

To I-GENE
avoid I-GENE
misinterpretations I-GENE
, O
special I-GENE
reference I-GENE
values I-GENE
should I-GENE
be I-GENE
applied I-GENE
for O
preadolescents O
, O
at O
least I-GENE
with I-GENE
regard I-GENE
to O
FVC I-GENE
and O
FEV1 I-GENE
. O

STUDY I-GENE
OBJECTIVE I-GENE
: O
This I-GENE
study I-GENE
assessed I-GENE
several I-GENE
methodological I-GENE
aspects I-GENE
related I-GENE
to O
the O
quality I-GENE
of O
published I-GENE
controlled O
clinical I-GENE
trials I-GENE
( I-GENE
CCTs I-GENE
) I-GENE
in O
relation I-GENE
to O
the O
participation I-GENE
of O
an I-GENE
epidemiologist I-GENE
/ I-GENE
biostatistician I-GENE
( I-GENE
E I-GENE
/ I-GENE
B I-GENE
). O

To I-GENE
the O
best I-GENE
of O
our I-GENE
knowledge I-GENE
, O
SNTCS I-GENE
is I-GENE
highly I-GENE
malignant I-GENE
. O

Northern I-GENE
blot I-GENE
analysis I-GENE
with I-GENE
one I-GENE
of O
the O
PARNAs I-GENE
revealed I-GENE
a O
highly I-GENE
abundant I-GENE
signal O
of O
approximately O
2 O
. O
0 O
kilobases I-GENE
( I-GENE
kb I-GENE
) I-GENE
present I-GENE
in O
all I-GENE
cell I-GENE
lines I-GENE
tested I-GENE
. O

The I-GENE
effect I-GENE
of O
crude I-GENE
oil I-GENE
spillage I-GENE
on I-GENE
growth I-GENE
, O
productivity I-GENE
and O
nutrient I-GENE
uptake I-GENE
of O
maize I-GENE
( I-GENE
Zea I-GENE
mays I-GENE
L I-GENE
.) I-GENE
was I-GENE
assessed I-GENE
in O
a O
pot I-GENE
experiment I-GENE
using I-GENE
an I-GENE
Evwreni I-GENE
manifold I-GENE
sample I-GENE
of O
a O
petroleum I-GENE
development I-GENE
company I-GENE
, O
which I-GENE
had I-GENE
a O
specific O
gravity O
of O
0 O
. O
8778 O
. O

10 O
. O
0 O
+/- I-GENE
2 I-GENE
. O
0 O
pmol O
/ O
24 O
h I-GENE
, O
P I-GENE
< I-GENE
0 O
. O
01 I-GENE
) I-GENE
and O
remained I-GENE
elevated I-GENE
. O

Pitx2 O
rescues O
the O
GABAergic I-GENE
differentiation I-GENE
defect I-GENE
and O
partially I-GENE
rescues I-GENE
the O
axon I-GENE
guidance I-GENE
and O
behavioral I-GENE
phenotypes O
of O
unc O
- O
30 O
mutants O
, O
indicating I-GENE
a O
high I-GENE
degree I-GENE
of O
functional I-GENE
conservation I-GENE
between I-GENE
these I-GENE
evolutionarily I-GENE
related I-GENE
genes I-GENE
. O

Phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
potentiates I-GENE
, O
but I-GENE
does I-GENE
not I-GENE
trigger I-GENE
, O
T O
cell O
proliferation O
mediated O
by I-GENE
the O
IL I-GENE
- I-GENE
2 I-GENE
receptor I-GENE
. O

In I-GENE
addition I-GENE
, O
stonin I-GENE
2 I-GENE
binds I-GENE
to O
the O
C2B O
domains O
of O
synaptotagmins O
I O
and O
II O
. O

Sequence I-GENE
comparison I-GENE
and O
binding I-GENE
studies I-GENE
of O
the O
18 O
- O
bp O
MOK2 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
present I-GENE
in O
intron O
2 O
of O
human O
, O
bovine O
, O
and O
mouse I-GENE
IRBP I-GENE
genes I-GENE
show I-GENE
that I-GENE
the O
3 O
'- O
half O
sequence O
is I-GENE
the O
essential I-GENE
core I-GENE
element I-GENE
for O
MOK2 I-GENE
binding I-GENE
. O

Measurements I-GENE
were I-GENE
obtained I-GENE
: O
( O
i O
) O
just I-GENE
after I-GENE
the O
traumatic I-GENE
exposure I-GENE
( I-GENE
D0 I-GENE
); I-GENE
( I-GENE
ii I-GENE
) I-GENE
3 I-GENE
days I-GENE
after I-GENE
this I-GENE
first O
measurement I-GENE
( I-GENE
D3 I-GENE
); I-GENE
and O
( I-GENE
iii I-GENE
) I-GENE
30 O
days I-GENE
after I-GENE
( I-GENE
D30 I-GENE
). O

Long I-GENE
- I-GENE
term I-GENE
results I-GENE
with I-GENE
MACOP I-GENE
- I-GENE
B I-GENE
and O
radiation I-GENE
therapy I-GENE
for O
aggressive I-GENE
lymphomas I-GENE
] I-GENE
BACKGROUND I-GENE
: O
Long I-GENE
- I-GENE
term I-GENE
results I-GENE
are I-GENE
needed I-GENE
to O
evaluate I-GENE
chemotherapy I-GENE
regimens I-GENE
and O
prognostic I-GENE
factors I-GENE
in O
non I-GENE
- I-GENE
Hodgkin I-GENE
' I-GENE
s I-GENE
lymphomas I-GENE
( I-GENE
NHL I-GENE
). O

From I-GENE
the O
above I-GENE
results I-GENE
, O
we I-GENE
might I-GENE
infer I-GENE
that I-GENE
the O
seizure I-GENE
type I-GENE
of O
TLE O
and O
a O
high O
frequency I-GENE
of O
seizure I-GENE
are I-GENE
two I-GENE
major I-GENE
independent I-GENE
precipitate I-GENE
factors I-GENE
for O
abnormal I-GENE
latencies I-GENE
of O
P300 O
in O
the O
epileptic I-GENE
patients I-GENE
. O

Rapamycin O
( O
FRAP I-GENE
/ I-GENE
mTOR I-GENE
inhibitor I-GENE
) I-GENE
blocked I-GENE
4E I-GENE
- I-GENE
BP1 I-GENE
phosphorylation O
causing I-GENE
a O
predominance O
of O
the O
alpha I-GENE
( I-GENE
hypophosphorylated I-GENE
) I-GENE
band I-GENE
. O

We I-GENE
investigate I-GENE
the O
reaction I-GENE
kinetics I-GENE
of O
small I-GENE
spherical I-GENE
particles I-GENE
with I-GENE
inertia I-GENE
, O
obeying I-GENE
coalescence I-GENE
type I-GENE
of O
reaction I-GENE
, O
B I-GENE
+ I-GENE
B I-GENE
--> I-GENE
B I-GENE
, O
and O
being I-GENE
advected I-GENE
by I-GENE
hydrodynamical I-GENE
flows I-GENE
with I-GENE
time I-GENE
- I-GENE
periodic I-GENE
forcing I-GENE
. O

Corticosteroid O
- O
mediated O
transcriptional O
inhibition I-GENE
was I-GENE
greater I-GENE
for O
MR I-GENE
/ O
GR O
in O
combination I-GENE
than I-GENE
for O
MR I-GENE
or O
GR O
alone I-GENE
. O

These I-GENE
data I-GENE
define I-GENE
a O
conserved O
pathway O
wherein I-GENE
sequential I-GENE
histone O
modifications I-GENE
establish I-GENE
a O
" O
histone O
code I-GENE
" I-GENE
essential I-GENE
for O
the O
epigenetic O
inheritance O
of O
heterochromatin I-GENE
assembly I-GENE
. O

The I-GENE
bovine I-GENE
PGHS I-GENE
- I-GENE
2 I-GENE
cDNA I-GENE
was I-GENE
cloned O
by I-GENE
a O
combination I-GENE
of O
reverse I-GENE
transcription I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction I-GENE
and O
cDNA I-GENE
library I-GENE
screening I-GENE
. O

Telomerase I-GENE
is I-GENE
a O
ribonucleoprotein I-GENE
complex I-GENE
that I-GENE
synthesizes I-GENE
telomeric I-GENE
DNA I-GENE
onto I-GENE
chromosomes I-GENE
using I-GENE
its I-GENE
RNA I-GENE
component I-GENE
as O
template I-GENE
. O

The I-GENE
iterative I-GENE
method I-GENE
proposed I-GENE
by I-GENE
Bengtsson I-GENE
[ I-GENE
Appl I-GENE
. O

Several I-GENE
distinct I-GENE
apoptotic I-GENE
stimuli I-GENE
induce I-GENE
the O
expression O
and O
caspase O
- O
dependent O
cleavage O
of O
hTAF O
( O
II O
) O
80 O
delta O
. O
hTAF O
( O
II O
) O
80 O
delta O
, O
unlike I-GENE
hTAF I-GENE
( I-GENE
II I-GENE
) O
80 O
, O
forms I-GENE
a O
TFIID O
- O
like O
complex O
lacking O
hTAF O
( O
II O
) O
31 O
. O

With I-GENE
NEU I-GENE
overexpression I-GENE
, O
nodal I-GENE
control O
decreased I-GENE
from O
72 I-GENE
% I-GENE
to O
34 I-GENE
% I-GENE
( I-GENE
p O
= I-GENE
. O
008 I-GENE
). O

The I-GENE
mouse I-GENE
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
( I-GENE
PDGF I-GENE
) I-GENE
beta I-GENE
- I-GENE
receptor I-GENE
promoter I-GENE
contains I-GENE
a O
CCAAT O
motif O
, O
and O
NF I-GENE
- I-GENE
Y I-GENE
plays I-GENE
an I-GENE
essential I-GENE
role I-GENE
in O
its I-GENE
transcription I-GENE
. O

Biol I-GENE
. O

The I-GENE
loop I-GENE
domain I-GENE
of O
heat I-GENE
shock I-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
dictates I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
specificity O
and O
responses I-GENE
to O
heat O
stress O
. O

This I-GENE
activation I-GENE
was I-GENE
then I-GENE
blocked I-GENE
by I-GENE
CGS I-GENE
12066A I-GENE
. O

Among I-GENE
the O
transcription I-GENE
factors I-GENE
known I-GENE
to O
interact I-GENE
with I-GENE
Groucho I-GENE
- I-GENE
related I-GENE
protein I-GENE
, O
only I-GENE
RUNX1 I-GENE
was I-GENE
appreciably I-GENE
downregulated I-GENE
by I-GENE
E2A I-GENE
- I-GENE
HLF I-GENE
. O

A I-GENE
new I-GENE
intron O
of O
476 O
base O
pairs O
was I-GENE
found I-GENE
in O
the O
middle O
of O
the O
5 O
'- O
untranslated O
leader O
sequence O
and O
was I-GENE
shown I-GENE
to O
robustly I-GENE
enhance I-GENE
the O
promoter I-GENE
activity I-GENE
. O

Our I-GENE
findings I-GENE
further I-GENE
our I-GENE
understanding I-GENE
of O
how I-GENE
ZBP I-GENE
- I-GENE
89 I-GENE
modulates I-GENE
cell O
proliferation O
and O
reveals I-GENE
a O
novel I-GENE
mechanism I-GENE
by I-GENE
which I-GENE
the O
p53 O
protein I-GENE
is I-GENE
stabilized I-GENE
. O

In I-GENE
the O
free I-GENE
- I-GENE
swimming I-GENE
rotatory I-GENE
test I-GENE
mice I-GENE
spend I-GENE
most I-GENE
of O
the O
time I-GENE
swimming I-GENE
close I-GENE
to O
the O
wall O
of O
the O
container O
attempting O
to O
escape O
from O
an I-GENE
aversive I-GENE
test I-GENE
situation I-GENE
. O

As I-GENE
well O
, O
mixtures O
of O
( O
LA I-GENE
)( I-GENE
12 I-GENE
) I-GENE
with I-GENE
the O
longer I-GENE
chain I-GENE
PEs I-GENE
exhibit I-GENE
unusual I-GENE
biomodal I-GENE
enthalpy I-GENE
variations I-GENE
, O
suggesting I-GENE
peptide I-GENE
immiscibility I-GENE
in O
thicker I-GENE
gel I-GENE
state I-GENE
bilayers I-GENE
. O

At I-GENE
the O
time I-GENE
of O
the O
blind I-GENE
therapeutic I-GENE
doses I-GENE
, O
Tg I-GENE
- I-GENE
off I-GENE
values I-GENE
ranged I-GENE
from O
8 O
to O
608 I-GENE
microg I-GENE
/ O
l O
. O

Nephrotoxicity I-GENE
after I-GENE
orthotopic I-GENE
liver I-GENE
transplantation I-GENE
in O
cyclosporin I-GENE
A I-GENE
and O
FK I-GENE
506 I-GENE
- I-GENE
treated I-GENE
patients I-GENE
. O

In I-GENE
contrast I-GENE
to O
MPc3 I-GENE
, O
data I-GENE
indicate I-GENE
that I-GENE
the O
Pc I-GENE
protein I-GENE
M33 I-GENE
does I-GENE
not I-GENE
interact I-GENE
with I-GENE
AF9 I-GENE
. O

Hydrocoele I-GENE
is I-GENE
common I-GENE
in O
men I-GENE
in O
Wuchereria I-GENE
bancrofti I-GENE
- I-GENE
endemic I-GENE
areas I-GENE
, O
the O
treatment I-GENE
for O
which I-GENE
is I-GENE
currently I-GENE
surgical I-GENE
intervention I-GENE
. O

Of I-GENE
the O
patients I-GENE
in O
each I-GENE
regimen I-GENE
who I-GENE
reached I-GENE
study I-GENE
end I-GENE
points I-GENE
, O
17 O
of O
29 I-GENE
( I-GENE
59 I-GENE
%) I-GENE
were I-GENE
in O
regimen I-GENE
A O
, O
11 O
of O
20 O
( O
55 O
%) I-GENE
were I-GENE
in O
regimen I-GENE
B I-GENE
, O
and O
28 O
of O
43 O
( O
65 I-GENE
%) I-GENE
were I-GENE
in O
regimen I-GENE
C I-GENE
met I-GENE
the O
treatment I-GENE
success I-GENE
criterion I-GENE
. O

One I-GENE
maternal O
death O
, O
reduced O
body I-GENE
weight O
, O
and O
reduced O
weight O
gain I-GENE
were I-GENE
noted I-GENE
at O
the O
high O
dose I-GENE
; O
confirmed I-GENE
pregnancy O
rates I-GENE
were I-GENE
84 O
to O
100 O
% I-GENE
for O
each I-GENE
group I-GENE
. O

Karger O
AG O
, O
Basel O

In I-GENE
regards I-GENE
to O
the O
latter I-GENE
activity I-GENE
, O
it I-GENE
has I-GENE
been I-GENE
shown I-GENE
that I-GENE
S3 I-GENE
contains I-GENE
vigorous I-GENE
N I-GENE
- I-GENE
glycosylase O
activity I-GENE
for O
the O
removal I-GENE
of O
8 O
- O
oxoguanine O
residues O
in O
DNA O
that I-GENE
leaves I-GENE
baseless I-GENE
sites I-GENE
in O
their I-GENE
places I-GENE
. O

We I-GENE
describe I-GENE
a O
total O
of O
39 O
DEAH O
helicases O
in O
these I-GENE
four I-GENE
species I-GENE
. O

A I-GENE
prospective I-GENE
trial I-GENE
was I-GENE
undertaken I-GENE
to O
determine I-GENE
( I-GENE
1 I-GENE
) I-GENE
clinical I-GENE
characteristics I-GENE
of O
patients I-GENE
with I-GENE
chest I-GENE
pain I-GENE
; O
( I-GENE
2 I-GENE
) I-GENE
value I-GENE
of O
cardiac I-GENE
markers I-GENE
troponin I-GENE
T I-GENE
, O
myoglobin O
and O
CK I-GENE
- I-GENE
MB I-GENE
mass I-GENE
in O
differentiating I-GENE
cardiac I-GENE
and O
noncardiac I-GENE
chest I-GENE
pain I-GENE
; O
( O
3 O
) O
the O
proportion I-GENE
of O
patients I-GENE
with I-GENE
ACS I-GENE
in O
whom I-GENE
these I-GENE
markers I-GENE
provided I-GENE
helpful I-GENE
additional I-GENE
information I-GENE
on I-GENE
admission I-GENE
and O
afterwards I-GENE
. O

Inactivity O
of O
the O
human O
cytomegalovirus O
( O
HCMV O
) O
major O
immediate O
- O
early O
regulatory O
region O
( O
MIERR O
), O
which I-GENE
is I-GENE
composed I-GENE
of O
promoter I-GENE
, O
enhancer I-GENE
, O
unique I-GENE
region O
, O
and O
modulator O
, O
is O
linked O
to O
lack I-GENE
of O
HCMV O
replication O
in O
latently O
infected O
cells I-GENE
and O
in O
other I-GENE
nonpermissive I-GENE
cell O
types O
, O
including I-GENE
human I-GENE
embryonal I-GENE
NTera2 I-GENE
carcinoma I-GENE
( I-GENE
NT2 I-GENE
) I-GENE
cells I-GENE
. O

The I-GENE
observed I-GENE
triplexes I-GENE
depend I-GENE
on I-GENE
the O
length O
of O
the O
repeat O
. O

Statistical I-GENE
Analysis I-GENE
included I-GENE
ANOVA I-GENE
, O
the O
Pearson I-GENE
Product I-GENE
Moment I-GENE
Correlation I-GENE
Coefficient I-GENE
, O
Principal I-GENE
Components I-GENE
Analysis I-GENE
and O
Discriminant I-GENE
Function I-GENE
Analysis I-GENE
and O
the O
calculation O
of O
Cronbach O
' O
s O
alpha I-GENE
( I-GENE
alpha I-GENE
) I-GENE
RESULTS I-GENE
: O
Both I-GENE
Sensitivity I-GENE
and O
specificity O
exceed O
90 O
. O
00 I-GENE
at O
23 O
/ O
24 O
, O
Chronbach O
' O
s O
alpha O
for O
the O
total O
scale I-GENE
was I-GENE
equal I-GENE
to O
0 O
. O
95 O
. O

BACKGROUND I-GENE
: O
Previous I-GENE
studies I-GENE
have I-GENE
indicated I-GENE
that I-GENE
the O
60 O
-, O
30 O
-, O
28 O
- O
and O
12 O
- O
item O
versions O
of O
the O
General I-GENE
Health I-GENE
Questionnaire I-GENE
( I-GENE
GHQ I-GENE
) I-GENE
are I-GENE
liable I-GENE
to O
retest I-GENE
effects I-GENE
, O
especially I-GENE
when I-GENE
administered I-GENE
multiple I-GENE
times I-GENE
with I-GENE
short I-GENE
intervals I-GENE
. O

Cross I-GENE
- I-GENE
linking I-GENE
FcalphaR I-GENE
on I-GENE
wt I-GENE
- I-GENE
ITAM I-GENE
or O
IIA I-GENE
- I-GENE
ITAM I-GENE
cells I-GENE
triggered I-GENE
equivalent I-GENE
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
- I-GENE
dependent I-GENE
activation O
of O
PKBalpha O
. O

An I-GENE
F222W I-GENE
: O
W21F I-GENE
rGST I-GENE
A1 I-GENE
- I-GENE
1 I-GENE
double I-GENE
mutant I-GENE
provides I-GENE
a O
direct I-GENE
fluorescence I-GENE
probe I-GENE
of O
changes I-GENE
in O
the O
environment I-GENE
of O
the O
C O
- O
terminal O
residue O
. O

Binding I-GENE
of O
serum I-GENE
response I-GENE
factor I-GENE
to O
CArG I-GENE
box I-GENE
sequences I-GENE
is I-GENE
necessary I-GENE
but I-GENE
not I-GENE
sufficient I-GENE
to O
restrict I-GENE
gene I-GENE
expression O
to O
arterial I-GENE
smooth I-GENE
muscle I-GENE
cells I-GENE
. O

They I-GENE
consist I-GENE
of O
at O
least I-GENE
two I-GENE
separable I-GENE
components O
, O
one I-GENE
heat I-GENE
stable I-GENE
and O
the O
other I-GENE
heat I-GENE
labile I-GENE
. O

No I-GENE
preferential I-GENE
VH I-GENE
/ I-GENE
VL I-GENE
- I-GENE
chains I-GENE
correlated I-GENE
with I-GENE
any I-GENE
of O
the O
12 O
different I-GENE
antigen I-GENE
reactivities I-GENE
, O
even I-GENE
for O
mAbs I-GENE
with I-GENE
nearly I-GENE
identical I-GENE
cross I-GENE
- I-GENE
reactivities I-GENE
. O

These I-GENE
results I-GENE
were I-GENE
compared I-GENE
with I-GENE
the O
estimates I-GENE
of O
penetration I-GENE
from O
steady I-GENE
- I-GENE
state I-GENE
calculations I-GENE
, O
square I-GENE
root I-GENE
of O
time I-GENE
calculations I-GENE
, O
and O
a O
biologically I-GENE
based I-GENE
mathematical I-GENE
model I-GENE
. O

Based I-GENE
on I-GENE
this I-GENE
analysis I-GENE
, O
we I-GENE
propose I-GENE
that I-GENE
the O
interactions I-GENE
of O
Sos O
with I-GENE
the O
switch I-GENE
1 I-GENE
and O
switch I-GENE
2 I-GENE
regions O
of O
Ras O
have I-GENE
distinct I-GENE
functional I-GENE
consequences I-GENE
: O
the O
interaction O
with I-GENE
switch I-GENE
2 I-GENE
mediates I-GENE
the O
anchoring O
of O
Ras O
to O
Sos O
, O
whereas I-GENE
the O
interaction I-GENE
with I-GENE
switch I-GENE
1 I-GENE
leads I-GENE
to O
disruption I-GENE
of O
the O
nucleotide O
- I-GENE
binding I-GENE
site I-GENE
and O
GDP I-GENE
dissociation I-GENE
. O

Thus I-GENE
, O
the O
interaction O
of O
Tat O
with O
the O
components O
of O
this I-GENE
rel I-GENE
/ I-GENE
AP1 O
cooperative I-GENE
complex I-GENE
seems I-GENE
to O
induce I-GENE
quantitative I-GENE
and O
qualitative I-GENE
alterations I-GENE
of O
this I-GENE
complex I-GENE
as O
activation O
progresses O
, O
resulting I-GENE
in O
a O
decrease I-GENE
of O
IL I-GENE
- I-GENE
2 I-GENE
gene I-GENE
transcription I-GENE
. O

SIT O
( O
SHP2 I-GENE
- I-GENE
interacting I-GENE
transmembrane I-GENE
adaptor I-GENE
protein I-GENE
) I-GENE
is I-GENE
a O
recently I-GENE
identified I-GENE
transmembrane I-GENE
adaptor I-GENE
protein I-GENE
, O
which I-GENE
is I-GENE
expressed O
in O
lymphocytes I-GENE
. O

In I-GENE
this I-GENE
manuscript I-GENE
we I-GENE
demonstrate I-GENE
that I-GENE
two I-GENE
tandem O
Ets O
sites O
in O
the O
mouse I-GENE
GL I-GENE
alpha I-GENE
promoter I-GENE
bind I-GENE
the O
transcription I-GENE
factors I-GENE
Elf I-GENE
- I-GENE
1 I-GENE
and O
PU I-GENE
. O
1 O
, O
and O
that I-GENE
the O
3 I-GENE
' I-GENE
site I-GENE
is I-GENE
essential I-GENE
for O
expression O
of O
a O
luciferase O
reporter I-GENE
gene I-GENE
driven I-GENE
by I-GENE
the O
GL I-GENE
alpha I-GENE
promoter I-GENE
. O

ICA O
in O
the O
reference I-GENE
solution I-GENE
was I-GENE
characterised I-GENE
by I-GENE
LC I-GENE
and O
time I-GENE
- I-GENE
of O
- I-GENE
flight I-GENE
( I-GENE
TOF I-GENE
) I-GENE
MS I-GENE
and O
quantified I-GENE
by I-GENE
LC I-GENE
chemiluminescent I-GENE
nitrogen I-GENE
detection I-GENE
( I-GENE
LC I-GENE
- I-GENE
CLND I-GENE
). O

These I-GENE
disorders I-GENE
include I-GENE
low I-GENE
- I-GENE
back I-GENE
pain I-GENE
, O
saddle I-GENE
anesthesia I-GENE
, O
bilateral I-GENE
sciatica I-GENE
, O
then I-GENE
motor I-GENE
weakness I-GENE
of O
the O
lower I-GENE
extremities I-GENE
or O
chronic I-GENE
paraplegia I-GENE
and O
, O
bladder I-GENE
dysfunction I-GENE
. O

C O
. O
elegans I-GENE
embryogenesis I-GENE
begins I-GENE
with I-GENE
a O
stereotyped I-GENE
sequence I-GENE
of O
asymmetric I-GENE
cell I-GENE
divisions I-GENE
that I-GENE
are I-GENE
largely I-GENE
responsible I-GENE
for O
establishing I-GENE
the O
nematode I-GENE
body I-GENE
plan I-GENE
. O

Additionally I-GENE
, O
a O
CaCO3 I-GENE
- I-GENE
CO2 I-GENE
/ I-GENE
N2 I-GENE
buffered I-GENE
solution I-GENE
was I-GENE
necessary I-GENE
to O
maintain I-GENE
a O
pH I-GENE
of O
8 O
. O

Mss4 I-GENE
also I-GENE
acts I-GENE
as O
a O
relatively I-GENE
inefficient I-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( I-GENE
GEF I-GENE
). O

Effects I-GENE
of O
3 I-GENE
' I-GENE
terminus I-GENE
modifications I-GENE
on I-GENE
mRNA I-GENE
functional O
decay O
during O
in O
vitro I-GENE
protein I-GENE
synthesis O
. O

Disciplinary I-GENE
action I-GENE
for O
DNA O
violation O
. O

This I-GENE
is I-GENE
necessary I-GENE
if I-GENE
psychiatric I-GENE
diagnoses I-GENE
are I-GENE
ultimately I-GENE
going I-GENE
to O
be I-GENE
refined I-GENE
and O
validated I-GENE
against I-GENE
biological I-GENE
criteria I-GENE
. O

We I-GENE
also I-GENE
demonstrate I-GENE
that I-GENE
the O
spo20 I-GENE
(+) I-GENE
gene I-GENE
product I-GENE
is I-GENE
structurally I-GENE
homologous O
to O
Saccharomyces O
cerevisiae O
Sec14 O
, O
the O
major O
phosphatidylinositol I-GENE
transfer I-GENE
protein I-GENE
of O
budding I-GENE
yeast I-GENE
. O

In I-GENE
addition I-GENE
, O
another I-GENE
derivative O
of O
pCMVJS21 O
( O
pCMVJS21DeltaGP O
) O
in O
which I-GENE
the O
gag O
, O
pol O
( O
and O
orf O
- O
x O
) O
coding O
sequences O
were I-GENE
deleted I-GENE
also I-GENE
gave I-GENE
transformed I-GENE
foci I-GENE
. O

It I-GENE
is I-GENE
shown I-GENE
that I-GENE
, O
for O
any I-GENE
periodic I-GENE
input I-GENE
, O
the O
map I-GENE
representing I-GENE
the O
relation I-GENE
between I-GENE
input I-GENE
phases I-GENE
at O
consecutive I-GENE
discharge I-GENE
times I-GENE
can I-GENE
be I-GENE
restricted I-GENE
to O
a O
piecewise I-GENE
continuous I-GENE
, O
orientation I-GENE
preserving I-GENE
circle I-GENE
map I-GENE
. O

Decreased I-GENE
serum I-GENE
ceruloplasmin I-GENE
and O
copper I-GENE
levels I-GENE
in O
cervical I-GENE
dystonia I-GENE
. O

Northern I-GENE
blot I-GENE
analysis I-GENE
of O
RNAs O
from O
a O
number I-GENE
of O
mouse I-GENE
tissues I-GENE
reveals I-GENE
that I-GENE
Atp6i I-GENE
is I-GENE
expressed O
predominantly I-GENE
in O
osteoclasts O
, O
and O
this I-GENE
predominant I-GENE
expression O
was I-GENE
confirmed I-GENE
by I-GENE
reverse I-GENE
- I-GENE
transcription I-GENE
polymerase I-GENE
chain I-GENE
reaction I-GENE
( I-GENE
RT I-GENE
- I-GENE
PCR I-GENE
) I-GENE
assay I-GENE
and O
immunohistochemical I-GENE
analysis I-GENE
. O

Behavioural I-GENE
tests I-GENE
with I-GENE
192 I-GENE
specimen I-GENE
of O
the O
roman I-GENE
garden I-GENE
snail I-GENE
Helix I-GENE
pomatia I-GENE
L I-GENE
. O
were I-GENE
performed I-GENE
in O
order I-GENE
to O
clarify I-GENE
whether I-GENE
the O
thermopreferendum I-GENE
of O
this I-GENE
pulmonate I-GENE
is I-GENE
influenced I-GENE
not I-GENE
only I-GENE
by I-GENE
the O
temperature O
of O
the O
substratum I-GENE
but I-GENE
also I-GENE
by I-GENE
air I-GENE
temperature I-GENE
. O

As I-GENE
well O
, O
IFN O
- I-GENE
gamma I-GENE
- I-GENE
induced O
expression O
of O
IRF O
- I-GENE
1 I-GENE
and O
its I-GENE
binding I-GENE
to O
the O
IRF O
element I-GENE
is I-GENE
inhibited I-GENE
. O

Baseline I-GENE
BMD I-GENE
values I-GENE
were I-GENE
significantly I-GENE
lower I-GENE
in O
the O
oligo I-GENE
- I-GENE
amenorrheic I-GENE
group I-GENE
than I-GENE
in O
the O
two I-GENE
others I-GENE
at O
the O
level I-GENE
of O
lumbar I-GENE
spine I-GENE
( I-GENE
anteroposterior I-GENE
view I-GENE
: O
0 O
. O
941 I-GENE
+/- I-GENE
0 O
. O
039 O
in O
oligo O
- O
amenorrheic O
vs O
1 O
. O
077 I-GENE
+/- I-GENE
0 O
. O
029 O
or O
1 O
. O
051 I-GENE
+/- I-GENE
0 O
. O
017 I-GENE
g I-GENE
x I-GENE
cm I-GENE
(- O
2 I-GENE
), O
P I-GENE
< I-GENE
0 O
. O
005 I-GENE
, O
in O
the O
eumenorrheic O
and O
contraceptive I-GENE
user I-GENE
groups I-GENE
, O
respectively I-GENE
) I-GENE
but I-GENE
not I-GENE
in O
weight O
- O
bearing O
bone O
such I-GENE
as O
proximal O
and O
midshaft I-GENE
femur I-GENE
. O

The O
glucose O
/ O
insulin O
stimulation O
was I-GENE
inhibited I-GENE
by I-GENE
the O
addition I-GENE
of O
polyunsaturated O
fatty O
acids O
. O

We I-GENE
report I-GENE
the O
results I-GENE
of O
a O
detailed I-GENE
policy I-GENE
analysis I-GENE
comparing I-GENE
2 I-GENE
CJD I-GENE
- I-GENE
related I-GENE
decisions I-GENE
: O
a O
1995 I-GENE
recall I-GENE
of O
blood O
from O
a O
donor I-GENE
with I-GENE
classic I-GENE
CJD I-GENE
and O
the O
1999 O
decision O
to O
defer O
donations O
from O
individuals I-GENE
with I-GENE
a O
6 I-GENE
- I-GENE
month I-GENE
travel I-GENE
history I-GENE
to O
the O
UK I-GENE
between I-GENE
1980 I-GENE
and O
1996 I-GENE
due I-GENE
to O
concerns O
related O
to O
variant O
CJD O
. O

The O
5 O
' O
flanking O
sequence O
of O
the O
3B I-GENE
gene I-GENE
is I-GENE
extremely I-GENE
A I-GENE
+ I-GENE
T I-GENE
rich I-GENE
but I-GENE
contains I-GENE
five I-GENE
G I-GENE
/ I-GENE
C I-GENE
rich I-GENE
stretches I-GENE
, O
each I-GENE
approximately O
7bp O
long O
, O
which I-GENE
have I-GENE
strong I-GENE
sequence O
similarity O
to O
the O
G I-GENE
boxes I-GENE
found I-GENE
upstream I-GENE
of O
other I-GENE
developmentally I-GENE
regulated I-GENE
Dictyostelium I-GENE
genes I-GENE
. O

PACAP I-GENE
mRNA I-GENE
was I-GENE
widely I-GENE
expressed O
in O
most I-GENE
human I-GENE
tissues I-GENE
; O
in O
transfected I-GENE
cells I-GENE
, O
PACAP I-GENE
was I-GENE
diffusely I-GENE
expressed O
in O
the O
cytoplasm I-GENE
. O

The I-GENE
proportion I-GENE
of O
the O
biopsies I-GENE
found I-GENE
to O
be I-GENE
seropositive I-GENE
for O
HBs O
antigen I-GENE
was I-GENE
27 O
. O
9 O
%, I-GENE
and O
these I-GENE
showed I-GENE
either I-GENE
MGN I-GENE
or O
MPGN I-GENE
pattern I-GENE
. O

In I-GENE
the O
present I-GENE
study I-GENE
, O
we I-GENE
have I-GENE
determined I-GENE
the O
ICBP90 I-GENE
gene I-GENE
structure O
by I-GENE
screening I-GENE
of O
a O
human I-GENE
placenta I-GENE
genomic I-GENE
library I-GENE
and O
PCR I-GENE
analysis I-GENE
. O

In I-GENE
the O
stable I-GENE
transfectants I-GENE
( I-GENE
BM3 I-GENE
cells I-GENE
) I-GENE
expressing I-GENE
a O
mutant I-GENE
bacterial I-GENE
P450 O
AA I-GENE
epoxygenase I-GENE
, O
F87V I-GENE
BM3 I-GENE
, O
which I-GENE
was I-GENE
genetically I-GENE
engineered I-GENE
to O
metabolize I-GENE
arachidonic I-GENE
acid I-GENE
only I-GENE
to O
14 O
, O
15 O
- O
EET O
, O
AA I-GENE
did I-GENE
not I-GENE
induce I-GENE
apoptosis I-GENE
and O
protected I-GENE
against I-GENE
agonist I-GENE
- I-GENE
induced O
apoptosis I-GENE
. O

The I-GENE
revitalization I-GENE
of O
surgery I-GENE
for O
Parkinson I-GENE
' O
s O
disease O
( O
PD I-GENE
) I-GENE
has I-GENE
fueled I-GENE
discussion I-GENE
about I-GENE
the O
best I-GENE
methodology I-GENE
to O
define I-GENE
the O
target O
. O

Foreigners I-GENE
return I-GENE
. O

She O
drank O
alcohol O
once I-GENE
or O
twice I-GENE
a O
week I-GENE
and O
regularly I-GENE
took I-GENE
an I-GENE
analgesic I-GENE
preparation I-GENE
, O
containing O
aspirin O
and O
acetaminophen O
, O
for O
alleviation O
of O
headaches O
. O

The I-GENE
authors I-GENE
did I-GENE
not I-GENE
detect I-GENE
any I-GENE
significant I-GENE
correlations I-GENE
between I-GENE
parameters I-GENE
of O
the O
lipids I-GENE
of O
bone I-GENE
marrow I-GENE
and O
leptin O
levels I-GENE
in O
serum I-GENE
and O
bone I-GENE
marrow I-GENE
. O

When I-GENE
the O
blood O
clot I-GENE
is I-GENE
formed I-GENE
in O
the O
vitreous I-GENE
cavity I-GENE
, O
intravitreal I-GENE
injection I-GENE
of O
t I-GENE
- I-GENE
PA I-GENE
can I-GENE
convert I-GENE
plasminogen O
to O
plasmin O
and O
remove O
the O
clot O
. O

When I-GENE
this I-GENE
CCAAT I-GENE
box I-GENE
was I-GENE
inserted I-GENE
into I-GENE
a O
heterologous I-GENE
promoter I-GENE
construct I-GENE
, O
OA I-GENE
induction I-GENE
was I-GENE
dependent I-GENE
on I-GENE
an I-GENE
intact O
CCAAT I-GENE
box I-GENE
. O

Encouraged I-GENE
by I-GENE
a O
Dutch I-GENE
study I-GENE
using I-GENE
etidronate I-GENE
/ I-GENE
fluoride I-GENE
in O
corticoid I-GENE
- I-GENE
induced O
osteoporosis I-GENE
, O
we I-GENE
performed I-GENE
a O
pilot I-GENE
study I-GENE
in O
33 I-GENE
men I-GENE
with I-GENE
severe I-GENE
established I-GENE
primary O
osteoporosis I-GENE
giving I-GENE
cyclically I-GENE
etidronate I-GENE
for O
14 I-GENE
days I-GENE
followed I-GENE
by I-GENE
fluoride I-GENE
plus O
calcium O
/ O
vitamin O
D O
for O
76 O
days I-GENE
. O

Far I-GENE
Western I-GENE
blot I-GENE
analysis I-GENE
suggested I-GENE
that I-GENE
the O
tandem I-GENE
SH2 I-GENE
domains I-GENE
of O
SHP2 I-GENE
bind I-GENE
to O
Gab1 O
in O
a O
specific O
orientation I-GENE
, O
in O
which I-GENE
the O
N I-GENE
- I-GENE
SH2 I-GENE
domain I-GENE
binds I-GENE
to O
phosphotyrosine O
( O
Tyr O
( O
P O
))- O
627 O
and O
the O
C I-GENE
- I-GENE
SH2 I-GENE
domain I-GENE
binds I-GENE
to O
Tyr O
( O
P O
)- O
659 O
. O

Electrophoretic I-GENE
mobility I-GENE
shift I-GENE
assays I-GENE
and O
coimmunoprecipitation I-GENE
studies I-GENE
suggest I-GENE
that I-GENE
homo I-GENE
- I-GENE
and O
heterodimerization I-GENE
occurs I-GENE
between I-GENE
cKrox I-GENE
family I-GENE
members I-GENE
. O

Expression I-GENE
of O
human I-GENE
RACK1 I-GENE
efficiently I-GENE
relieves I-GENE
E1A O
- I-GENE
mediated O
growth I-GENE
inhibition I-GENE
in O
HF7c I-GENE
and O
protects I-GENE
human I-GENE
tumor I-GENE
cells I-GENE
from O
E1A O
- O
induced O
apoptosis I-GENE
. O

By I-GENE
using I-GENE
space I-GENE
- I-GENE
discrete I-GENE
/ I-GENE
continuous I-GENE
metapopulation I-GENE
dynamic I-GENE
models I-GENE
and O
computer I-GENE
simulations I-GENE
, O
we I-GENE
show I-GENE
that I-GENE
there I-GENE
can I-GENE
be I-GENE
two I-GENE
principally I-GENE
different I-GENE
regimes I-GENE
of O
metapopulation I-GENE
dynamics I-GENE
. O

Arterial O
blood O
gas I-GENE
tensions I-GENE
were I-GENE
similar I-GENE
across I-GENE
all I-GENE
ventilation I-GENE
modes I-GENE
. O

Four I-GENE
casein O
kinase I-GENE
I I-GENE
isoforms I-GENE
are I-GENE
differentially I-GENE
partitioned I-GENE
between I-GENE
nucleus I-GENE
and O
cytoplasm I-GENE
. O

CONCLUSION I-GENE
: O
Extrusion I-GENE
cooking I-GENE
is I-GENE
effective I-GENE
for O
the O
inactivation I-GENE
of O
DON I-GENE
but I-GENE
is I-GENE
of O
limited I-GENE
value I-GENE
for O
AFB1 I-GENE
, O
even I-GENE
if I-GENE
metabisulphite I-GENE
is I-GENE
added I-GENE
. O

Also I-GENE
, O
the O
EWS O
protein I-GENE
stimulates I-GENE
transcription I-GENE
mediated O
by I-GENE
the O
COOH O
- O
terminal O
transactivation O
domain O
of O
the O
cofactor O
CREB O
- O
binding O
protein O
( O
CBP O
). O

HSF O
binds I-GENE
DNA O
as O
a O
trimer O
, O
and O
additional I-GENE
trimers I-GENE
can I-GENE
bind I-GENE
DNA I-GENE
co O
- I-GENE
operatively I-GENE
. O

Two I-GENE
cases I-GENE
with I-GENE
marked I-GENE
chronic I-GENE
arm I-GENE
lymphoedema I-GENE
reported I-GENE
major I-GENE
and O
persistent I-GENE
improvements I-GENE
in O
arm I-GENE
volume I-GENE
for O
at O
least I-GENE
12 I-GENE
months I-GENE
after I-GENE
treatment I-GENE
with I-GENE
HBO2 I-GENE
. O

Growth O
hormone O
and O
insulin O
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
receptors I-GENE
in O
the O
temporomandibular I-GENE
joint I-GENE
of O
the O
rat O
. O

Folate I-GENE
metabolism I-GENE
in O
the O
human I-GENE
malaria I-GENE
parasite I-GENE
Plasmodium I-GENE
falciparum I-GENE
is I-GENE
an I-GENE
essential I-GENE
activity I-GENE
for O
cell O
growth O
and O
replication O
, O
and O
the O
target O
of O
an I-GENE
important I-GENE
class I-GENE
of O
therapeutic I-GENE
agents I-GENE
in O
widespread I-GENE
use I-GENE
. O

These I-GENE
results I-GENE
indicate I-GENE
that I-GENE
BACM I-GENE
has I-GENE
antiplaque I-GENE
and O
stronger I-GENE
antidegradation I-GENE
effects I-GENE
than I-GENE
GLCM I-GENE
. O

A O
mutation O
in O
the O
C I-GENE
domain I-GENE
of O
Rb I-GENE
, O
L901Q I-GENE
, O
has I-GENE
been I-GENE
identified I-GENE
that I-GENE
completely I-GENE
abolishes I-GENE
cdk4 I-GENE
/ I-GENE
D1 I-GENE
phosphorylation O
of O
the O
isolated I-GENE
C I-GENE
domain I-GENE
. O

Homo O
- O
oligomerisation O
and O
nuclear O
localisation O
of O
mouse O
histone O
deacetylase O
1 O
. O

Energy I-GENE
expenditure I-GENE
was I-GENE
obtained I-GENE
using I-GENE
a O
primed I-GENE
, O
3 I-GENE
- I-GENE
hour I-GENE
infusion I-GENE
of O
NaH O
( O
13 O
) O
CO O
( O
3 O
'), O
breath O
( O
13 O
) O
CO O
( O
2 O
) O
enrichment I-GENE
determination I-GENE
by I-GENE
isotope I-GENE
ratio I-GENE
mass I-GENE
spectroscopy I-GENE
, O
and O
the O
application I-GENE
of O
a O
standard I-GENE
regression I-GENE
equation I-GENE
. O

Fasting O
gastrin O
levels I-GENE
( I-GENE
normal I-GENE
range I-GENE
: O
25 I-GENE
- I-GENE
110 I-GENE
mU I-GENE
/ I-GENE
L I-GENE
) I-GENE
varied I-GENE
from O
48 O
. O
78 O
mU O
/ O
L O
- O
168 O
. O
20 O
( O
mean I-GENE
: O
85 O
. O
23 O
mU O
/ O
L O
). O

Identification I-GENE
of O
pulmonary I-GENE
vein I-GENE
stenosis I-GENE
after I-GENE
radiofrequency I-GENE
ablation I-GENE
for O
atrial I-GENE
fibrillation I-GENE
using I-GENE
MRI I-GENE
. O

The I-GENE
continuing I-GENE
development I-GENE
of O
ligands I-GENE
that I-GENE
function I-GENE
as O
selective I-GENE
estrogens I-GENE
or O
antiestrogens O
for O
ERalpha O
or O
ERbeta I-GENE
should I-GENE
allow I-GENE
optimized I-GENE
tissue I-GENE
selectivity I-GENE
of O
these I-GENE
agents I-GENE
for O
menopausal I-GENE
hormone I-GENE
replacement I-GENE
therapy I-GENE
and O
the O
treatment I-GENE
and O
prevention I-GENE
of O
breast I-GENE
cancer O
. O

Baseline I-GENE
variables I-GENE
associated I-GENE
with I-GENE
CD I-GENE
included I-GENE
a O
less I-GENE
frequent I-GENE
use I-GENE
of O
prestroke O
aspirin O
and O
a O
higher O
incidence I-GENE
of O
early I-GENE
CT I-GENE
changes I-GENE
of O
edema I-GENE
or O
mass I-GENE
effect I-GENE
or O
dense I-GENE
middle I-GENE
cerebral I-GENE
artery I-GENE
sign I-GENE
. O

A I-GENE
peculiar I-GENE
people I-GENE
: O
" O
the O
physiological I-GENE
aspects I-GENE
of O
Mormonism I-GENE
1850 I-GENE
- I-GENE
1975 I-GENE
." O

SH2D1A I-GENE
protein I-GENE
levels I-GENE
are I-GENE
up O
- I-GENE
regulated I-GENE
by I-GENE
CD40 O
cross I-GENE
- I-GENE
linking I-GENE
and O
down I-GENE
- I-GENE
regulated I-GENE
by I-GENE
B I-GENE
cell I-GENE
receptor I-GENE
ligation I-GENE
. O

The I-GENE
Genescan I-GENE
program I-GENE
predicted I-GENE
an I-GENE
open O
reading O
frame O
of O
a O
novel I-GENE
, O
intron I-GENE
- I-GENE
less I-GENE
gene I-GENE
adjacent I-GENE
to O
the O
B236 I-GENE
spot I-GENE
that I-GENE
encodes I-GENE
a O
putative I-GENE
493 I-GENE
- I-GENE
amino I-GENE
acid I-GENE
protein I-GENE
containing O
the O
SNAG O
repressor O
motif O
in O
the O
NH2 O
- O
terminal O
region O
and O
five I-GENE
C2H2 I-GENE
- I-GENE
type I-GENE
zinc I-GENE
finger I-GENE
motifs O
in O
the O
COOH O
- O
terminal O
half O
. O

Under I-GENE
our I-GENE
conditions I-GENE
, O
the O
combination I-GENE
O3 I-GENE
/ I-GENE
UV I-GENE
did I-GENE
not I-GENE
improve I-GENE
the O
degradation I-GENE
rate I-GENE
obtained I-GENE
by I-GENE
ozonation I-GENE
. O

The I-GENE
metabolic I-GENE
events I-GENE
occurring I-GENE
at O
or O
near I-GENE
that I-GENE
structure O
and O
involving I-GENE
cyclin I-GENE
D3 I-GENE
cause I-GENE
the O
translocation I-GENE
of O
ICP0 O
to O
the O
cytoplasm I-GENE
. O

In I-GENE
the O
single I-GENE
case I-GENE
the O
restoration O
of O
a O
structured I-GENE
daily I-GENE
routine I-GENE
represents I-GENE
the O
presupposition O
for O
a O
cognitive I-GENE
therapy I-GENE
. O

Immunofluorescence I-GENE
studies I-GENE
in O
C2C12 I-GENE
myotubes I-GENE
show I-GENE
that I-GENE
Smad2 I-GENE
and O
MEF2A O
co O
- O
localise O
in O
the O
nucleus I-GENE
of O
multinuclear I-GENE
myotubes I-GENE
during O
differentiation I-GENE
. O

In I-GENE
35 I-GENE
of O
those I-GENE
patients I-GENE
DD I-GENE
was I-GENE
measured I-GENE
also I-GENE
with I-GENE
microlatex I-GENE
tests I-GENE
-- O
Tinaquant O
and O
BC O
d O
- O
dimer O
. O

Simulating O
the O
impact I-GENE
during O
human I-GENE
jumping I-GENE
by I-GENE
means I-GENE
of O
a O
4 I-GENE
- I-GENE
degrees I-GENE
- I-GENE
of O
- I-GENE
freedom I-GENE
model I-GENE
with I-GENE
time I-GENE
- I-GENE
dependent I-GENE
properties I-GENE
. O

A I-GENE
novel I-GENE
approach I-GENE
was I-GENE
developed I-GENE
for O
identifying I-GENE
transcription I-GENE
factor I-GENE
activities I-GENE
associated I-GENE
with I-GENE
NGF I-GENE
- I-GENE
activated I-GENE
, O
but I-GENE
not I-GENE
EGF I-GENE
- I-GENE
activated I-GENE
, O
signaling O
, O
using I-GENE
random I-GENE
oligonucleotide O
clones O
from O
a O
DNA O
recognition I-GENE
library I-GENE
to O
isolate I-GENE
specific I-GENE
DNA I-GENE
binding I-GENE
proteins I-GENE
from O
PC12 I-GENE
nuclear I-GENE
extracts I-GENE
. O

Atheroma I-GENE
appears I-GENE
as O
a O
very I-GENE
low I-GENE
signal I-GENE
intensity I-GENE
area I-GENE
on I-GENE
2 I-GENE
- I-GENE
dimensional I-GENE
time I-GENE
- I-GENE
of O
- I-GENE
flight I-GENE
( I-GENE
TOF I-GENE
) I-GENE
magnetic I-GENE
resonance I-GENE
( I-GENE
MR I-GENE
) I-GENE
images I-GENE
, O
and O
its I-GENE
components O
have I-GENE
various I-GENE
signal I-GENE
intensities I-GENE
on I-GENE
spin I-GENE
- I-GENE
echo I-GENE
( I-GENE
SE I-GENE
) I-GENE
images I-GENE
. O

Finally I-GENE
a O
10 O
- O
nucleotide O
region O
flanking O
the O
exon O
4 I-GENE
protein I-GENE
- I-GENE
binding I-GENE
site I-GENE
is I-GENE
homologous I-GENE
to O
instability I-GENE
elements I-GENE
within I-GENE
five I-GENE
other I-GENE
transcripts I-GENE
, O
suggesting I-GENE
that I-GENE
a O
common I-GENE
coding I-GENE
region I-GENE
determinant I-GENE
may I-GENE
exist I-GENE
. O

Chronic I-GENE
nutritional I-GENE
diseases I-GENE
of O
infectious I-GENE
origin I-GENE
: O
an I-GENE
assessment I-GENE
of O
a O
nascent I-GENE
field I-GENE
. O

The I-GENE
cut I-GENE
- I-GENE
off I-GENE
percentage I-GENE
positivity I-GENE
value I-GENE
was I-GENE
established I-GENE
using I-GENE
500 I-GENE
brucellosis I-GENE
- I-GENE
positive I-GENE
and O
500 I-GENE
brucellosis I-GENE
- I-GENE
negative I-GENE
serum I-GENE
samples I-GENE
, O
confirmed I-GENE
with I-GENE
reference I-GENE
to O
the O
sample I-GENE
data I-GENE
using I-GENE
the O
indirect I-GENE
ELISA I-GENE
kit I-GENE
. O

PROCEDURE O
: O
Cannulas I-GENE
were I-GENE
surgically I-GENE
positioned I-GENE
in O
the O
abomasal I-GENE
body I-GENE
and O
pyloric I-GENE
antrum I-GENE
of O
each I-GENE
calf I-GENE
. O

The I-GENE
utilities I-GENE
measured I-GENE
in O
our I-GENE
study I-GENE
can I-GENE
be I-GENE
applied I-GENE
directly I-GENE
to O
quality I-GENE
- I-GENE
of O
- I-GENE
life I-GENE
determinations I-GENE
in O
clinical I-GENE
trials I-GENE
of O
adjuvant I-GENE
IFN O
alpha I-GENE
- I-GENE
2b I-GENE
to O
measure I-GENE
the O
net I-GENE
benefit I-GENE
of O
therapy I-GENE
. O

Cells O
lacking O
p116 I-GENE
exhibit I-GENE
a O
striking I-GENE
defect I-GENE
in O
the O
formation I-GENE
of O
these I-GENE
macropinocytic I-GENE
structures O
, O
a O
concomitant I-GENE
reduction I-GENE
in O
the O
rate I-GENE
of O
fluid O
phase O
pinocytosis O
, O
a O
significant I-GENE
decrease I-GENE
in O
the O
efficiency I-GENE
of O
chemotactic I-GENE
aggregation O
, O
and O
a O
decrease I-GENE
in O
cellular I-GENE
F I-GENE
- I-GENE
actin O
content I-GENE
. O

Ectopic O
expression O
of O
the O
dominant I-GENE
mutant I-GENE
Lg3 I-GENE
allele I-GENE
is I-GENE
believed I-GENE
to O
cause I-GENE
the O
phenotype O
. O

Specimen I-GENE
mass I-GENE
reduction I-GENE
increased I-GENE
with I-GENE
irradiance I-GENE
from O
19 O
to O
72 I-GENE
% I-GENE
of O
the O
initial I-GENE
mass I-GENE
for O
9 O
-- O
31 O
W O
/ O
cm I-GENE
( I-GENE
2 I-GENE
), O
respectively I-GENE
. O

Analysis I-GENE
of O
the O
genome I-GENE
sequence I-GENE
revealed I-GENE
26 O
, O
588 I-GENE
protein I-GENE
- I-GENE
encoding I-GENE
transcripts I-GENE
for O
which I-GENE
there I-GENE
was I-GENE
strong I-GENE
corroborating I-GENE
evidence I-GENE
and O
an I-GENE
additional I-GENE
approximately O
12 O
, O
000 O
computationally I-GENE
derived I-GENE
genes I-GENE
with I-GENE
mouse I-GENE
matches I-GENE
or O
other I-GENE
weak I-GENE
supporting I-GENE
evidence I-GENE
. O

The I-GENE
other I-GENE
inhibitor I-GENE
was I-GENE
a O
single O
TAR O
decoy O
, O
driven O
by O
the O
U6 O
small I-GENE
nuclear I-GENE
RNA I-GENE
promoter I-GENE
( O
U6 O
- O
P O
). O

By I-GENE
comparison I-GENE
, O
in O
nontumorigenic I-GENE
Ad5 I-GENE
cells I-GENE
, O
class I-GENE
I I-GENE
expression O
is I-GENE
high I-GENE
due I-GENE
to O
negligible O
binding O
of O
COUP O
- I-GENE
TF I-GENE
and O
strong I-GENE
binding I-GENE
of O
NF I-GENE
- I-GENE
kappaB O
. O

Moreover I-GENE
, O
a O
complex O
containing O
PTP O
phi O
, O
paxillin O
, O
and O
a O
paxillin O
- I-GENE
associated I-GENE
tyrosine I-GENE
kinase I-GENE
, O
Pyk2 I-GENE
, O
can I-GENE
be I-GENE
immunoprecipitated I-GENE
from O
macrophage I-GENE
lysates I-GENE
, O
and O
the O
catalytic O
domain O
of O
PTP O
phi I-GENE
selectively I-GENE
binds I-GENE
paxillin O
and O
Pyk2 O
in O
vitro I-GENE
. O

Our I-GENE
previous I-GENE
studies I-GENE
have I-GENE
shown I-GENE
that I-GENE
SHP O
- I-GENE
1 I-GENE
, O
a O
SH2 I-GENE
domain I-GENE
- I-GENE
containing I-GENE
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
, O
is I-GENE
expressed O
not I-GENE
only I-GENE
in O
cells I-GENE
of O
hematopoietic I-GENE
lineages I-GENE
, O
but I-GENE
also I-GENE
in O
many I-GENE
non I-GENE
- I-GENE
hematopoietic I-GENE
cells I-GENE
under I-GENE
the O
control O
of O
an I-GENE
alternative O
tissue I-GENE
- I-GENE
specific I-GENE
promoter I-GENE
, O
P1 I-GENE
. O

Whereas I-GENE
Smad2 I-GENE
was I-GENE
rapidly I-GENE
phosphorylated O
by I-GENE
TGF O
- I-GENE
beta I-GENE
and O
involved I-GENE
in O
the O
initial I-GENE
activation O
of O
Agc O
expression O
in O
confluent I-GENE
cells I-GENE
, O
Smad2 I-GENE
activation I-GENE
was I-GENE
not I-GENE
required I-GENE
for O
maintaining I-GENE
the O
high I-GENE
level I-GENE
of O
Agc O
expression O
. O

The I-GENE
astronaut I-GENE
crew I-GENE
operates I-GENE
the O
payload I-GENE
and O
documents I-GENE
its I-GENE
operation I-GENE
. O

This I-GENE
molecule I-GENE
, O
wH22xeGFP I-GENE
, O
consists I-GENE
of O
the O
entire O
humanized I-GENE
anti I-GENE
- I-GENE
FcgammaRI I-GENE
mAb I-GENE
H22 I-GENE
with I-GENE
eGFP I-GENE
genetically I-GENE
fused I-GENE
to O
the O
C I-GENE
- I-GENE
terminal I-GENE
end I-GENE
of O
each I-GENE
CH3 I-GENE
domain I-GENE
. O
wH22xeGFP I-GENE
binds I-GENE
within I-GENE
the O
ligand I-GENE
- I-GENE
binding I-GENE
region I-GENE
by I-GENE
its I-GENE
Fc O
end I-GENE
, O
as O
well O
as O
outside I-GENE
the O
ligand I-GENE
- I-GENE
binding I-GENE
region I-GENE
by I-GENE
its I-GENE
Fab I-GENE
ends I-GENE
, O
thereby I-GENE
cross I-GENE
- I-GENE
linking I-GENE
FcgammaRI I-GENE
. O

On I-GENE
the O
other I-GENE
hand I-GENE
, O
hepatic I-GENE
arterial I-GENE
infusion I-GENE
therapy I-GENE
prolongs I-GENE
the O
survival I-GENE
of O
H3 I-GENE
patients I-GENE
only I-GENE
. O

Hepatitis I-GENE
B I-GENE
and O
C I-GENE
seroprevalence I-GENE
rates I-GENE
among I-GENE
high I-GENE
- I-GENE
risk I-GENE
adolescents I-GENE
are I-GENE
lower I-GENE
in O
El I-GENE
Paso I-GENE
than I-GENE
in O
other I-GENE
similar I-GENE
US I-GENE
populations I-GENE
, O
presenting I-GENE
an I-GENE
ideal I-GENE
climate I-GENE
for O
prevention I-GENE
programs I-GENE
. O

We I-GENE
found I-GENE
that I-GENE
the O
SOCS I-GENE
box I-GENE
interacted I-GENE
with I-GENE
Cullin I-GENE
- I-GENE
2 I-GENE
and O
promoted I-GENE
ubiquitination I-GENE
of O
TEL I-GENE
- I-GENE
JAK2 I-GENE
. O

A I-GENE
patient I-GENE
is I-GENE
described I-GENE
with I-GENE
skin I-GENE
lesions I-GENE
resembling I-GENE
Kaposi I-GENE
' I-GENE
s I-GENE
sarcoma I-GENE
( I-GENE
KS I-GENE
). O

Special I-GENE
issues I-GENE
devoted I-GENE
to O
the O
biosynthesis I-GENE
of O
woody I-GENE
plant I-GENE
biopolymers I-GENE
and O
related I-GENE
substances I-GENE
. O

These I-GENE
data I-GENE
suggest I-GENE
that I-GENE
ADAM I-GENE
- I-GENE
TS12 I-GENE
may I-GENE
play I-GENE
roles I-GENE
in O
pulmonary I-GENE
cells I-GENE
during O
fetal I-GENE
development I-GENE
or O
in O
tumor I-GENE
processes I-GENE
through I-GENE
its I-GENE
proteolytic I-GENE
activity I-GENE
or O
as O
a O
molecule I-GENE
potentially I-GENE
involved I-GENE
in O
regulation O
of O
cell O
adhesion O
. O

Progressive I-GENE
study I-GENE
and O
robustness I-GENE
test I-GENE
of O
QSAR I-GENE
model I-GENE
based I-GENE
on I-GENE
quantum I-GENE
chemical I-GENE
parameters I-GENE
for O
predicting I-GENE
BCF I-GENE
of O
selected O
polychlorinated I-GENE
organic I-GENE
compounds I-GENE
( I-GENE
PCOCs I-GENE
). O

Additional O
deletion O
mutations O
revealed I-GENE
a O
new I-GENE
, O
67 I-GENE
- I-GENE
amino I-GENE
- I-GENE
acid I-GENE
functional I-GENE
domain I-GENE
within I-GENE
the O
proline I-GENE
- I-GENE
rich I-GENE
region I-GENE
of O
SLP I-GENE
- I-GENE
76 I-GENE
, O
which I-GENE
we I-GENE
have I-GENE
termed I-GENE
the O
P I-GENE
- I-GENE
1 I-GENE
domain I-GENE
. O

Patients I-GENE
with I-GENE
type I-GENE
III I-GENE
SOD O
may I-GENE
have I-GENE
visceral I-GENE
hyperalgesia I-GENE
; O
a O
trial I-GENE
of O
antidepressants O
or O
a O
therapeutic I-GENE
trial I-GENE
with I-GENE
botulinum O
toxin I-GENE
injection I-GENE
into I-GENE
the O
ampulla I-GENE
should I-GENE
be I-GENE
considered I-GENE
prior I-GENE
to O
more I-GENE
invasive I-GENE
endoscopic I-GENE
therapy I-GENE
. O

We I-GENE
have I-GENE
now I-GENE
tested I-GENE
all I-GENE
known I-GENE
mammalian I-GENE
Groucho I-GENE
family I-GENE
members I-GENE
for O
their I-GENE
ability I-GENE
to O
interact I-GENE
specifically I-GENE
with I-GENE
individual I-GENE
Tcf I-GENE
/ I-GENE
Lef I-GENE
family I-GENE
members I-GENE
. O

Body O
weight O
reduction I-GENE
increases I-GENE
insulin O
sensitivity I-GENE
and O
improves I-GENE
both I-GENE
blood O
glucose O
and O
blood O
pressure I-GENE
control O
. O

Sequence I-GENE
analysis I-GENE
indicates I-GENE
that I-GENE
RBP21 I-GENE
shares I-GENE
homology I-GENE
with I-GENE
other I-GENE
retinoblastoma I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
in O
the O
pRb O
- O
binding O
motif O
LxCxE O
at O
the O
C O
- O
terminal O
region O
. O

Tolerance O
in O
renal O
transplantation I-GENE
after I-GENE
allogeneic I-GENE
bone I-GENE
marrow I-GENE
transplantation I-GENE
- I-GENE
6 I-GENE
- I-GENE
year I-GENE
follow I-GENE
- I-GENE
up O
. O

By I-GENE
analyzing I-GENE
5 I-GENE
'- I-GENE
deletion I-GENE
insulin O
promoter I-GENE
- I-GENE
reporter I-GENE
constructs I-GENE
in O
transient I-GENE
transfections I-GENE
of O
clonal I-GENE
INS I-GENE
- I-GENE
1 I-GENE
beta I-GENE
- I-GENE
cells I-GENE
, O
we I-GENE
located O
activating I-GENE
Hh I-GENE
- I-GENE
responsive I-GENE
regions I-GENE
within I-GENE
the O
rat I-GENE
insulin O
I I-GENE
promoter I-GENE
that I-GENE
include I-GENE
the O
glucose O
- O
response O
elements O
Far O
( O
E2 O
) O
and O
Flat O
( O
A2 I-GENE
/ I-GENE
A3 I-GENE
). O

However I-GENE
, O
when I-GENE
directed I-GENE
to O
the O
nucleosome O
by O
fusion O
to O
core O
histone O
H2A O
or O
H2B O
, O
the O
non O
- O
histone O
tail O
forms I-GENE
an I-GENE
MCB I-GENE
that I-GENE
appears I-GENE
identical I-GENE
to O
that I-GENE
of O
the O
endogenous O
protein O
. O

Data I-GENE
were I-GENE
obtained I-GENE
from O
2 I-GENE
undergraduate I-GENE
student I-GENE
samples I-GENE
, O
a O
self I-GENE
- I-GENE
report I-GENE
group I-GENE
( I-GENE
n I-GENE
= I-GENE
132 I-GENE
) I-GENE
who I-GENE
provided I-GENE
NEO I-GENE
- I-GENE
PI I-GENE
- I-GENE
R I-GENE
self I-GENE
- I-GENE
ratings I-GENE
on I-GENE
2 I-GENE
occasions I-GENE
separated I-GENE
by I-GENE
a O
7 O
- O
to O
14 O
- I-GENE
day I-GENE
interval I-GENE
and O
an I-GENE
informant I-GENE
group I-GENE
( I-GENE
n I-GENE
= I-GENE
109 I-GENE
) I-GENE
who I-GENE
provided I-GENE
ratings I-GENE
of O
well O
- I-GENE
known I-GENE
friends I-GENE
or O
relatives I-GENE
on I-GENE
2 I-GENE
occasions I-GENE
separated I-GENE
by I-GENE
a O
6 I-GENE
month I-GENE
interval I-GENE
. O

Pulmonary O
embolectomy O
and O
lung O
transplantation I-GENE
are I-GENE
the O
main I-GENE
indications I-GENE
for O
the O
use I-GENE
of O
heart O
- O
lung O
- I-GENE
machine I-GENE
. O

Comparison I-GENE
of O
German I-GENE
language I-GENE
versions I-GENE
of O
the O
QWB I-GENE
- I-GENE
SA I-GENE
and O
SF I-GENE
- I-GENE
36 I-GENE
evaluating I-GENE
outcomes I-GENE
for O
patients I-GENE
with I-GENE
prostate O
disease O
. O

The I-GENE
median I-GENE
preoperative I-GENE
best I-GENE
- I-GENE
corrected I-GENE
visual I-GENE
acuity I-GENE
of O
0 O
. O
08 O
( O
range I-GENE
hand O
motions O
/ O
0 O
. O
003 O
to O
0 O
. O
4 O
), O
improved I-GENE
by I-GENE
5 I-GENE
lines I-GENE
to O
a O
median I-GENE
final I-GENE
postoperative I-GENE
best I-GENE
- I-GENE
corrected I-GENE
visual I-GENE
acuity I-GENE
of O
0 O
. O
25 O
( O
range I-GENE
0 O
. O
025 O
- O
0 O
. O
5 O
) O
( O
P O
= I-GENE
0 O
. O
001 I-GENE
). O

Angina O
( O
Q O
) O
persistence I-GENE
showed I-GENE
marked I-GENE
associations I-GENE
with I-GENE
previous I-GENE
myocardial I-GENE
infarction I-GENE
, O
diagnosed I-GENE
angina I-GENE
, O
electrocardiogram I-GENE
ischemia I-GENE
, O
and O
subsequent I-GENE
major I-GENE
ischemic I-GENE
heart O
disease O
events I-GENE
from O
Q5 I-GENE
onward I-GENE
. O

Site I-GENE
- I-GENE
directed I-GENE
mutagenesis I-GENE
of O
CAR I-GENE
revealed I-GENE
that I-GENE
CAR I-GENE
residues O
Leu73 O
and O
Lys121 O
and O
/ O
or O
Lys123 I-GENE
are I-GENE
critical I-GENE
contact O
residues O
, O
with I-GENE
Tyr80 I-GENE
and O
Tyr83 I-GENE
being I-GENE
peripherally I-GENE
involved I-GENE
in O
the O
binding O
interaction O
with O
the O
Ad5 O
, O
Ad9 O
, O
Ad12 O
, O
and O
Ad41L I-GENE
fiber I-GENE
knobs I-GENE
. O

Transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
( I-GENE
TGF O
- I-GENE
beta I-GENE
) I-GENE
induced O
growth I-GENE
arrest I-GENE
of O
cells I-GENE
involves I-GENE
regulation O
of O
the O
activities I-GENE
of O
both I-GENE
D I-GENE
- I-GENE
and O
E I-GENE
- I-GENE
type I-GENE
cyclin I-GENE
kinase I-GENE
complexes I-GENE
thought I-GENE
to O
be I-GENE
mediated O
primarily I-GENE
by I-GENE
the O
regulation O
of O
p15 O
( O
Ink4b O
) O
and O
p27 O
( O
Kip1 O
) O
cyclin I-GENE
kinase I-GENE
inhibitors O
. O

These I-GENE
data I-GENE
indicate I-GENE
that I-GENE
the O
SmSmad2 O
responds O
to O
the O
TGF O
- I-GENE
beta I-GENE
signals I-GENE
by I-GENE
interaction I-GENE
with I-GENE
receptor I-GENE
I I-GENE
, O
which I-GENE
phosphorylates I-GENE
it I-GENE
, O
whereupon I-GENE
it I-GENE
translocates I-GENE
into I-GENE
the O
nucleus I-GENE
presumably I-GENE
to O
regulate I-GENE
target I-GENE
gene I-GENE
transcription I-GENE
and O
consequently I-GENE
elicit I-GENE
a O
specific I-GENE
TGF O
- I-GENE
beta I-GENE
effect I-GENE
. O

We I-GENE
propose I-GENE
that I-GENE
TFOs I-GENE
represent I-GENE
a O
therapeutic I-GENE
potential O
to O
specifically I-GENE
diminish I-GENE
the O
expression O
of O
c I-GENE
- I-GENE
sis I-GENE
/ I-GENE
PDGF I-GENE
- I-GENE
B I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
in O
various I-GENE
pathologic I-GENE
settings I-GENE
where I-GENE
constitutive O
expression O
of O
this I-GENE
gene I-GENE
has I-GENE
been I-GENE
observed I-GENE
. O

The I-GENE
increased I-GENE
clearance I-GENE
observed I-GENE
in O
young I-GENE
infants I-GENE
is I-GENE
in O
contrast I-GENE
to O
other I-GENE
opioids I-GENE
. O

Peripheral I-GENE
metabolism I-GENE
of O
androgens I-GENE
takes I-GENE
place I-GENE
in O
various I-GENE
areas I-GENE
within I-GENE
the O
pilosebaceous O
unit O
, O
as O
indicated I-GENE
by I-GENE
local I-GENE
differences I-GENE
in O
the O
activities I-GENE
of O
aromatase O
, O
5alpha O
- O
reductase O
as O
well O
as O
of O
the O
presence I-GENE
of O
the O
androgen O
receptors O
. O

This I-GENE
unique I-GENE
location I-GENE
of O
cavernous I-GENE
malformation I-GENE
is I-GENE
associated I-GENE
with I-GENE
a O
risk I-GENE
of O
permanent I-GENE
loss O
of O
the O
vision I-GENE
. O

The I-GENE
JHRLSS I-GENE
has I-GENE
been I-GENE
used I-GENE
in O
prior I-GENE
studies I-GENE
to O
assess I-GENE
RLS I-GENE
severity I-GENE
, O
but I-GENE
has I-GENE
not I-GENE
previously I-GENE
been I-GENE
validated I-GENE
in O
relation I-GENE
to O
direct I-GENE
measures I-GENE
of O
the O
morbidity I-GENE
associated I-GENE
with I-GENE
RLS I-GENE
. O

Consistent I-GENE
effects I-GENE
on I-GENE
pVHL I-GENE
function I-GENE
were I-GENE
observed I-GENE
for O
all I-GENE
mutations I-GENE
within I-GENE
each I-GENE
subclass I-GENE
. O

Interestingly I-GENE
, O
the O
CYP71D20 I-GENE
- I-GENE
encoded I-GENE
enzyme I-GENE
activity I-GENE
was I-GENE
capable I-GENE
of O
converting I-GENE
both I-GENE
5 I-GENE
- I-GENE
epi I-GENE
- I-GENE
aristolochene I-GENE
and O
1 I-GENE
- I-GENE
deoxycapsidiol I-GENE
to O
capsidiol I-GENE
in O
vitro I-GENE
, O
consistent I-GENE
with I-GENE
the O
notion I-GENE
that I-GENE
this I-GENE
P450 O
enzyme I-GENE
catalyzes I-GENE
both I-GENE
hydroxylations I-GENE
of O
its I-GENE
hydrocarbon O
substrate O
. O

A I-GENE
new I-GENE
species I-GENE
of O
Euspondylus I-GENE
is I-GENE
described I-GENE
based I-GENE
on I-GENE
a O
female I-GENE
( I-GENE
taken I-GENE
within I-GENE
a O
bromeliad O
) O
from O
Cerro O
El O
Humo O
, O
Sucre O
, O
northeastern O
Venezuela O
. O

The I-GENE
most I-GENE
important I-GENE
finding I-GENE
, O
however I-GENE
, O
was I-GENE
that I-GENE
IMT I-GENE
values I-GENE
were I-GENE
related I-GENE
with I-GENE
24 I-GENE
h I-GENE
SBP I-GENE
or O
PP I-GENE
standard I-GENE
deviation I-GENE
( I-GENE
P I-GENE
< I-GENE
0 O
. O
001 I-GENE
), O
a O
measure I-GENE
of O
overall I-GENE
SBP I-GENE
or O
PP I-GENE
variability I-GENE
. O

In I-GENE
addition I-GENE
, O
severe I-GENE
vision I-GENE
loss O
can I-GENE
be I-GENE
seen I-GENE
with I-GENE
interferon I-GENE
alfa I-GENE
- I-GENE
2b I-GENE
- I-GENE
associated I-GENE
retinopathy I-GENE
. O

FLP O
and O
Cre I-GENE
recombinase I-GENE
function I-GENE
in O
Xenopus O
embryos O
. O

Keratoconjunctivitis I-GENE
sicca I-GENE
appears I-GENE
to O
be I-GENE
a O
common I-GENE
ocular I-GENE
complication I-GENE
and O
all I-GENE
children I-GENE
with I-GENE
JRA I-GENE
should I-GENE
be I-GENE
screened I-GENE
for O
it I-GENE
with I-GENE
a O
comprehensive I-GENE
battery I-GENE
of O
tests I-GENE
. O

Moreover I-GENE
, O
PTax O
expressed O
higher O
background I-GENE
activities I-GENE
than I-GENE
PTF I-GENE
, O
indicating I-GENE
that I-GENE
the O
sequence O
of O
the O
synthetic O
regulatory O
region O
can I-GENE
influence I-GENE
background I-GENE
levels I-GENE
. O

After I-GENE
allowing I-GENE
time I-GENE
for O
absorption I-GENE
, O
participants I-GENE
completed I-GENE
a O
bridge I-GENE
simulator I-GENE
task I-GENE
. O

The I-GENE
cleavage I-GENE
site I-GENE
between I-GENE
VPg I-GENE
and O
RNA I-GENE
dependent I-GENE
RNA I-GENE
polymerase I-GENE
was I-GENE
predicted I-GENE
to O
be I-GENE
E445 I-GENE
- I-GENE
T446 I-GENE
based I-GENE
on I-GENE
the O
amino I-GENE
acid I-GENE
sequence I-GENE
analysis I-GENE
of O
the O
polyprotein O
from O
different I-GENE
sobemoviruses I-GENE
. O

Conformational I-GENE
changes I-GENE
of O
the O
ferric I-GENE
uptake I-GENE
regulation O
protein I-GENE
upon I-GENE
metal I-GENE
activation O
and O
DNA O
binding O
; O
first O
evidence I-GENE
of O
structural I-GENE
homologies I-GENE
with I-GENE
the O
diphtheria I-GENE
toxin I-GENE
repressor I-GENE
. O

At I-GENE
visit I-GENE
5 O
, O
the O
isokinetic I-GENE
test I-GENE
showed I-GENE
impaired I-GENE
muscle I-GENE
function I-GENE
recovery I-GENE
from O
23 I-GENE
% I-GENE
to O
32 I-GENE
%, I-GENE
while I-GENE
the O
manual I-GENE
test I-GENE
showed I-GENE
almost I-GENE
full I-GENE
recovery I-GENE
. O

Constitutive O
phosphorylation O
and O
nuclear O
localization O
of O
Smad3 I-GENE
are I-GENE
correlated I-GENE
with I-GENE
increased I-GENE
collagen I-GENE
gene I-GENE
transcription I-GENE
in O
activated I-GENE
hepatic I-GENE
stellate I-GENE
cells I-GENE
. O

Cholesteryl I-GENE
ester I-GENE
transfer I-GENE
protein I-GENE
and O
atherosclerosis I-GENE
in O
Japanese I-GENE
subjects I-GENE
: O
a O
study I-GENE
based I-GENE
on I-GENE
coronary I-GENE
angiography I-GENE
. O

And O
, O
most I-GENE
importantly I-GENE
, O
reconstitution O
of O
a O
consensus O
CRE O
, O
within I-GENE
the O
21 I-GENE
- I-GENE
bp O
enhancers I-GENE
increases I-GENE
binding I-GENE
of O
CREB O
/ O
ATF O
proteins I-GENE
but I-GENE
abrogates I-GENE
basal I-GENE
repression I-GENE
of O
LTR I-GENE
- I-GENE
directed I-GENE
transcription I-GENE
in O
vitro I-GENE
. O

Stable I-GENE
transfection I-GENE
of O
human I-GENE
CHOP I-GENE
cDNA I-GENE
into I-GENE
mammary I-GENE
carcinoma I-GENE
cells I-GENE
demonstrated I-GENE
that I-GENE
CHOP I-GENE
functioned I-GENE
not I-GENE
as O
a O
mediator O
of O
hGH O
- O
stimulated O
mitogenesis I-GENE
but I-GENE
rather I-GENE
enhanced O
the O
protection I-GENE
from O
apoptosis I-GENE
afforded I-GENE
by I-GENE
hGH O
in O
a O
p38 O
MAPK I-GENE
- I-GENE
dependent I-GENE
manner I-GENE
. O

The I-GENE
combination I-GENE
of O
ifosfamide O
, O
epirubicin O
and O
etoposide O
( O
IEV O
) O
is I-GENE
an I-GENE
effective I-GENE
salvage I-GENE
regimen I-GENE
for O
lymphoproliferative O
disease O
. O

Interestingly I-GENE
, O
the O
activity I-GENE
of O
IkappaB I-GENE
kinase I-GENE
( I-GENE
IKK I-GENE
- I-GENE
beta I-GENE
), O
which I-GENE
plays I-GENE
an I-GENE
essential I-GENE
role I-GENE
in O
NF I-GENE
- I-GENE
kappaB O
activation I-GENE
through I-GENE
IkappaB I-GENE
phosphorylation O
, O
was I-GENE
largely I-GENE
enhanced O
in O
paclitaxel I-GENE
- I-GENE
treated I-GENE
cells I-GENE
, O
detected I-GENE
as O
IkappaBalpha O
phosphorylation O
. O

The I-GENE
recessive I-GENE
hos1 I-GENE
mutation I-GENE
causes I-GENE
enhanced O
induction I-GENE
of O
the O
CBF I-GENE
transcription I-GENE
factors I-GENE
by I-GENE
low O
temperature O
as O
well O
as O
of O
their I-GENE
downstream O
cold I-GENE
- I-GENE
responsive I-GENE
genes I-GENE
. O

Apart O
from O
antimicrobial I-GENE
properties I-GENE
, O
recent I-GENE
data I-GENE
indicate I-GENE
that I-GENE
PMN I-GENE
also I-GENE
exert I-GENE
anti I-GENE
- I-GENE
inflammatory I-GENE
effects I-GENE
by I-GENE
stimulation O
and O
release I-GENE
of O
cytokine I-GENE
antagonists I-GENE
such I-GENE
as O
interleukin O
- I-GENE
1 I-GENE
receptor I-GENE
antagonist I-GENE
( I-GENE
IL I-GENE
- I-GENE
1ra I-GENE
). O

Early I-GENE
indicators I-GENE
of O
the O
effect I-GENE
of O
a O
breast I-GENE
cancer O
screening I-GENE
program I-GENE
for O
low I-GENE
- I-GENE
income I-GENE
women I-GENE
. O

An I-GENE
association I-GENE
was I-GENE
demonstrated I-GENE
between I-GENE
the O
expression O
of O
aberrantly O
and O
/ O
or O
alternatively O
spliced O
mdm2 O
mRNAs O
and O
a O
lack I-GENE
of O
progesterone I-GENE
receptor I-GENE
. O

BACKGROUND I-GENE
: O
Dermoscopy I-GENE
is I-GENE
a O
noninvasive I-GENE
technique I-GENE
that I-GENE
increases I-GENE
the O
diagnostic I-GENE
accuracy I-GENE
of O
pigmented I-GENE
skin I-GENE
lesions I-GENE
, O
particularly I-GENE
improving I-GENE
the O
diagnosis I-GENE
of O
patients I-GENE
with I-GENE
cutaneous I-GENE
melanoma I-GENE
in O
situ I-GENE
( I-GENE
CMIS I-GENE
) I-GENE
and O
early I-GENE
invasive I-GENE
melanoma I-GENE
. O

Increased I-GENE
erythropoietin O
synthesis O
in O
patients I-GENE
with I-GENE
COLD I-GENE
or O
left O
heart O
failure I-GENE
is I-GENE
related I-GENE
to O
alterations I-GENE
in O
renal O
haemodynamics O
. O

The I-GENE
( I-GENE
two I-GENE
- I-GENE
motif I-GENE
) I-GENE
domain I-GENE
fold O
contains I-GENE
a O
pair O
of O
calcium O
binding I-GENE
sites I-GENE
very I-GENE
similar I-GENE
to O
those I-GENE
found I-GENE
in O
a O
two I-GENE
- I-GENE
domain I-GENE
prokaryotic I-GENE
betagamma I-GENE
- I-GENE
crystallin I-GENE
fold O
family I-GENE
member I-GENE
, O
Protein I-GENE
S I-GENE
. O

Twenty I-GENE
- I-GENE
five I-GENE
patients I-GENE
also I-GENE
received I-GENE
PET I-GENE
examinations I-GENE
during O
the O
staging I-GENE
procedures I-GENE
. O

In I-GENE
the O
last I-GENE
case I-GENE
, O
both I-GENE
hydroxychloroquine I-GENE
, O
carbamazepine I-GENE
and O
fluvoxamine I-GENE
had I-GENE
a O
common I-GENE
imputability I-GENE
which I-GENE
was I-GENE
plausible I-GENE
. O

In I-GENE
all I-GENE
of O
these I-GENE
cases I-GENE
, O
expression O
of O
the O
implicated I-GENE
genes I-GENE
was I-GENE
absent I-GENE
. O

A I-GENE
subset I-GENE
of O
patients I-GENE
( I-GENE
n I-GENE
= I-GENE
30 O
) I-GENE
underwent I-GENE
multichannel I-GENE
pressure I-GENE
flow I-GENE
studies I-GENE
, O
which I-GENE
demonstrated I-GENE
that I-GENE
transrectal I-GENE
HIFU I-GENE
reduces I-GENE
bladder I-GENE
outflow I-GENE
obstruction I-GENE
. O

Biochemical I-GENE
experiments I-GENE
have I-GENE
shown I-GENE
that I-GENE
CopG I-GENE
co O
- I-GENE
operatively I-GENE
associates I-GENE
to O
its I-GENE
target O
DNA O
at O
low O
protein O
: O
DNA O
ratios I-GENE
, O
completely I-GENE
protecting I-GENE
four I-GENE
helical I-GENE
turns I-GENE
on I-GENE
the O
same I-GENE
face I-GENE
of O
the O
double O
helix O
in O
both I-GENE
directions I-GENE
from O
the O
inverted I-GENE
repeat I-GENE
that I-GENE
constitutes I-GENE
the O
CopG O
primary O
target O
. O

The I-GENE
mechanism I-GENE
of O
ligand I-GENE
- I-GENE
activated I-GENE
estrogen I-GENE
receptor I-GENE
alpha I-GENE
( I-GENE
ERalpha I-GENE
)- I-GENE
dependent I-GENE
activation I-GENE
of O
gene I-GENE
expression O
through I-GENE
the O
SRE I-GENE
was I-GENE
determined I-GENE
by I-GENE
mutational I-GENE
analysis I-GENE
of O
the O
promoter O
, O
analysis I-GENE
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( I-GENE
MAPK I-GENE
) O
pathway O
activation O
by I-GENE
E2 I-GENE
, O
and O
transforming I-GENE
growth I-GENE
factor I-GENE
alpha I-GENE
( I-GENE
TGF O
- I-GENE
alpha I-GENE
) O
as O
a O
positive I-GENE
control O
. O

This I-GENE
study I-GENE
investigated I-GENE
whether I-GENE
boron I-GENE
would I-GENE
enhance I-GENE
the O
ability I-GENE
of O
17beta I-GENE
- I-GENE
estradiol I-GENE
( I-GENE
E2 I-GENE
) I-GENE
or O
parathyroid I-GENE
hormone I-GENE
( I-GENE
PTH I-GENE
) I-GENE
to O
improve I-GENE
bone I-GENE
quality I-GENE
in O
ovariectomized I-GENE
OVX I-GENE
rats I-GENE
. O

2001 O
. O

The I-GENE
Gap69C I-GENE
is I-GENE
a O
single I-GENE
- I-GENE
copy I-GENE
gene I-GENE
producing I-GENE
a O
major I-GENE
2 I-GENE
. O
1 I-GENE
- I-GENE
kb I-GENE
mRNA I-GENE
throughout I-GENE
development I-GENE
, O
but I-GENE
its I-GENE
amount I-GENE
is I-GENE
decreased I-GENE
in O
larvae I-GENE
. O

In I-GENE
the O
long I-GENE
term I-GENE
, O
questions I-GENE
still I-GENE
remain I-GENE
about I-GENE
whether I-GENE
pre I-GENE
- I-GENE
dialysis I-GENE
rHu I-GENE
EPO O
either I-GENE
speeds I-GENE
up O
or O
delays O
the O
onset I-GENE
of O
dialysis I-GENE
. O

The I-GENE
validity I-GENE
of O
the O
FPS I-GENE
- I-GENE
R I-GENE
was I-GENE
further I-GENE
supported I-GENE
by I-GENE
strong I-GENE
positive I-GENE
correlations I-GENE
with I-GENE
the O
VAS O
( O
r O
= I-GENE
0 O
. O
92 I-GENE
, O
N I-GENE
= I-GENE
45 O
) O
and O
the O
CAS O
( O
r O
= I-GENE
0 O
. O
84 O
, O
N I-GENE
= I-GENE
45 O
) O
in O
this I-GENE
clinical I-GENE
sample I-GENE
. O

The I-GENE
BFA I-GENE
System I-GENE
reads I-GENE
a O
text I-GENE
file I-GENE
with I-GENE
flows I-GENE
, O
measured I-GENE
with I-GENE
fluorescent I-GENE
microsphere I-GENE
technique I-GENE
, O
and O
constructs O
the O
lung O
anatomy I-GENE
with I-GENE
volumetric I-GENE
pixels I-GENE
showing I-GENE
the O
flows I-GENE
with I-GENE
a O
color I-GENE
schema I-GENE
. O

Therefore I-GENE
, O
to O
understand I-GENE
how I-GENE
ErbB1 I-GENE
/ I-GENE
ErbB2 I-GENE
signaling O
contributes I-GENE
to O
this I-GENE
process I-GENE
, O
we I-GENE
used I-GENE
the O
ErbB O
kinase I-GENE
inhibitor I-GENE
AG1478in I-GENE
ErbB2 I-GENE
- I-GENE
dependent I-GENE
BT I-GENE
- I-GENE
474 I-GENE
and O
SKBR I-GENE
- I-GENE
3 I-GENE
human I-GENE
breast I-GENE
cancer O
cells I-GENE
. O

Deletion I-GENE
analyses I-GENE
implicate I-GENE
the O
N O
- O
terminal O
110 O
amino O
acids O
of O
Grb14 O
and O
ankyrin O
repeats O
10 O
- O
19 O
of O
tankyrase O
2 O
in O
mediating I-GENE
this I-GENE
interaction O
. O

Hormonal O
regulation O
of O
multiple I-GENE
promoters I-GENE
of O
the O
rat I-GENE
mitochondrial I-GENE
glycerol I-GENE
- I-GENE
3 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase O
gene I-GENE
: O
identification I-GENE
of O
a O
complex O
hormone O
- O
response O
element O
in O
the O
ubiquitous I-GENE
promoter I-GENE
B I-GENE
. O

SAMPLE O
POPULATION O
: O
MCB O
from O
7 O
racing O
Greyhounds O
euthanatized O
for O
reasons I-GENE
unrelated I-GENE
to O
MCB I-GENE
abnormalities I-GENE
. O

Structural I-GENE
studies I-GENE
have I-GENE
shown I-GENE
that I-GENE
class I-GENE
I I-GENE
major O
histocompatibility O
complex O
( O
MHC O
)- I-GENE
restricted I-GENE
peptide I-GENE
- I-GENE
specific I-GENE
T I-GENE
cell I-GENE
receptor I-GENE
( I-GENE
TCR O
)- I-GENE
alpha I-GENE
/ I-GENE
betas I-GENE
make I-GENE
multiple I-GENE
contacts I-GENE
with I-GENE
the O
alpha1 I-GENE
and O
alpha2 I-GENE
helices I-GENE
of O
the O
MHC O
, O
but I-GENE
it I-GENE
is I-GENE
unclear I-GENE
which I-GENE
or O
how I-GENE
many I-GENE
of O
these I-GENE
interactions I-GENE
contribute I-GENE
to O
functional O
binding O
. O

Fans O
in O
tunnels O
and O
open O
windows O
at O
aboveground I-GENE
locations I-GENE
appeared I-GENE
to O
greatly I-GENE
reduce I-GENE
the O
likelihood I-GENE
of O
high I-GENE
PH3 I-GENE
concentrations I-GENE
in O
enclosed I-GENE
areas I-GENE
. O

In I-GENE
DNA I-GENE
strand I-GENE
exchange I-GENE
reactions I-GENE
using I-GENE
oligonucleotides I-GENE
, O
we I-GENE
found I-GENE
that I-GENE
Rec2 I-GENE
exhibited I-GENE
a O
pairing I-GENE
bias I-GENE
that I-GENE
is I-GENE
opposite I-GENE
that I-GENE
of O
RecA I-GENE
. O

A O
major O
mechanism I-GENE
by I-GENE
which I-GENE
estrogens I-GENE
prevent I-GENE
osteoporosis I-GENE
seems I-GENE
to O
be I-GENE
repression I-GENE
of O
transcription I-GENE
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
target I-GENE
genes I-GENE
, O
such I-GENE
as O
the O
osteoclast O
- O
activating O
cytokines O
interleukin O
- O
6 O
and O
interleukin O
- O
1 O
. O

Linear I-GENE
eight I-GENE
- I-GENE
or O
nine I-GENE
- I-GENE
residue I-GENE
D I-GENE
- I-GENE
peptides I-GENE
derived O
from O
the O
pocket I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
the O
cyclic I-GENE
molecules I-GENE
also I-GENE
bind I-GENE
specifically I-GENE
. O

As I-GENE
expected I-GENE
, O
homologous I-GENE
loxP I-GENE
sequences I-GENE
efficiently I-GENE
underwent I-GENE
Cre I-GENE
- I-GENE
mediated O
recombination O
. O

Multistage I-GENE
models I-GENE
and O
the O
A I-GENE
- I-GENE
bomb I-GENE
survivor I-GENE
data I-GENE
: O
implications I-GENE
for O
carcinogenic I-GENE
mechanisms I-GENE
? I-GENE

The I-GENE
results I-GENE
indicate I-GENE
that I-GENE
a O
more I-GENE
differentiated I-GENE
diagnosis I-GENE
of O
the O
molar I-GENE
relationship I-GENE
will I-GENE
allow I-GENE
for O
a O
more I-GENE
causally I-GENE
directed I-GENE
correction I-GENE
of O
Class I-GENE
II I-GENE
molar I-GENE
relationship I-GENE
. O

It I-GENE
is I-GENE
surprising I-GENE
that I-GENE
dnaE173 I-GENE
, O
a O
potent I-GENE
mutator I-GENE
mutation I-GENE
specific I-GENE
for O
sequence I-GENE
substitution I-GENE
as O
well O
as O
single O
- O
base O
frameshift I-GENE
, O
did I-GENE
not I-GENE
enhance I-GENE
the O
frequency I-GENE
of O
the O
hot I-GENE
- I-GENE
spot I-GENE
frameshift I-GENE
mutation I-GENE
. O

Hypercalcemia I-GENE
associated I-GENE
with I-GENE
elevated I-GENE
serum I-GENE
PTH I-GENE
concentration I-GENE
indicating I-GENE
primary O
hyperparathyroidism I-GENE
was I-GENE
found I-GENE
in O
7 I-GENE
BC I-GENE
patients I-GENE
( I-GENE
7 I-GENE
%) I-GENE
and O
in O
none I-GENE
of O
healthy I-GENE
women I-GENE
or O
patients I-GENE
with I-GENE
thyroid I-GENE
cancer O
. O

[ O
figure O
: O
see O
text O
] O
The I-GENE
Stille I-GENE
coupling I-GENE
reaction I-GENE
has I-GENE
been I-GENE
performed I-GENE
in O
1 I-GENE
- I-GENE
butyl I-GENE
- I-GENE
3 I-GENE
- I-GENE
methylimidazolium I-GENE
tetrafluoroborate I-GENE
( O
BMIM O
BF4 O
), O
a O
room I-GENE
- I-GENE
temperature I-GENE
ionic I-GENE
liquid I-GENE
( I-GENE
RTIL I-GENE
). O

Examination I-GENE
of O
various I-GENE
promoter I-GENE
deletion I-GENE
mutants I-GENE
indicated I-GENE
that I-GENE
SF I-GENE
- I-GENE
1 I-GENE
acts I-GENE
through I-GENE
the O
proximal O
promoter O
region O
and O
upstream O
promoter O
sequences O
. O

ORF1 I-GENE
( O
1029 O
bp O
; O
EMBL O
databank O
, O
Accession I-GENE
No I-GENE
. O

Vector I-GENE
stocks I-GENE
containing I-GENE
envelope I-GENE
proteins I-GENE
from O
three I-GENE
different I-GENE
SIVmac I-GENE
clones O
, O
namely I-GENE
, O
SIVmac239 I-GENE
( I-GENE
T I-GENE
- I-GENE
lymphocyte I-GENE
tropic I-GENE
[ I-GENE
T I-GENE
- I-GENE
tropic I-GENE
]), I-GENE
SIVmac316 I-GENE
( I-GENE
macrophage I-GENE
tropic I-GENE
[ I-GENE
M I-GENE
- I-GENE
tropic I-GENE
]), I-GENE
and O
SIVmac1A11 O
( O
dualtropic O
), O
were I-GENE
tested I-GENE
. O

ISS O
and O
the O
acute I-GENE
physiology I-GENE
and O
chronic I-GENE
health I-GENE
evaluation I-GENE
( I-GENE
APACHE I-GENE
II I-GENE
) I-GENE
calculated I-GENE
on I-GENE
admission I-GENE
. O

Ga I-GENE
- I-GENE
67 I-GENE
and O
Tl I-GENE
- I-GENE
201 I-GENE
scintigraphy I-GENE
in O
extramedullary O
plasmacytoma O
: O
a O
case I-GENE
report I-GENE
. O

Finally I-GENE
, O
there I-GENE
are I-GENE
a O
growing I-GENE
number I-GENE
of O
arguments I-GENE
favouring I-GENE
the O
use I-GENE
of O
ACE O
inhibitors O
very I-GENE
early I-GENE
in O
patients I-GENE
with I-GENE
diabetes I-GENE
mellitus I-GENE
. O

This I-GENE
paper I-GENE
describes I-GENE
the O
results I-GENE
of O
an I-GENE
initial I-GENE
study I-GENE
on I-GENE
the O
application I-GENE
of O
linear I-GENE
solvation I-GENE
energy I-GENE
relationships I-GENE
( O
LSERs O
) O
to O
the O
prediction I-GENE
of O
internal I-GENE
standard I-GENE
compounds I-GENE
in O
reversed I-GENE
- I-GENE
phase O
liquid I-GENE
chromatographic I-GENE
( I-GENE
RPLC I-GENE
) I-GENE
method I-GENE
development I-GENE
. O

A I-GENE
38 I-GENE
- I-GENE
year I-GENE
- I-GENE
old I-GENE
woman I-GENE
with I-GENE
ulcerative I-GENE
colitis I-GENE
subsequently I-GENE
developed I-GENE
sarcoidosis I-GENE
. O

Blood O
from O
dams I-GENE
was I-GENE
collected I-GENE
prior I-GENE
to O
inoculation O
and O
at O
time I-GENE
of O
necropsy I-GENE
for O
measurement I-GENE
of O
IgM O
and O
IgG O
antibodies O
to O
M O
. O
pulmonis O
. O

She I-GENE
has I-GENE
since I-GENE
developed I-GENE
a O
positive I-GENE
anti I-GENE
- I-GENE
cardiolipin I-GENE
antibody I-GENE
but I-GENE
does I-GENE
not I-GENE
meet I-GENE
diagnostic I-GENE
criteria I-GENE
for O
systemic I-GENE
lupus I-GENE
erythematosis I-GENE
. O
CONCLUSION I-GENE
: O
The I-GENE
presence I-GENE
of O
known I-GENE
autoimmune I-GENE
disease O
in O
a O
woman I-GENE
with I-GENE
POF I-GENE
should I-GENE
not I-GENE
dissuade I-GENE
the O
clinician I-GENE
from O
evaluating I-GENE
for O
a O
potential O
genetic I-GENE
cause I-GENE
. O

The I-GENE
mutation I-GENE
experiments I-GENE
showed I-GENE
that I-GENE
the O
most I-GENE
critical I-GENE
sequence O
for O
the O
repression I-GENE
of O
PTH I-GENE
was I-GENE
5 I-GENE
'- I-GENE
GGGGGAGGGGAG I-GENE
- I-GENE
3 I-GENE
' I-GENE
(+ I-GENE
1 I-GENE
to O
+ O
12 O
) O
of O
PTHSR O
. O

Thus I-GENE
, O
while I-GENE
the O
folds I-GENE
of O
all I-GENE
Myb O
domains I-GENE
resemble I-GENE
each I-GENE
other I-GENE
closely I-GENE
, O
the O
function I-GENE
of O
each I-GENE
Myb O
domain I-GENE
depends I-GENE
on I-GENE
the O
amino O
acid O
residues O
that I-GENE
are I-GENE
located O
on I-GENE
the O
surface O
of O
each I-GENE
protein I-GENE
. O

A O
cDNA O
clone O
encoding O
C2H2 I-GENE
- I-GENE
type I-GENE
zinc I-GENE
finger I-GENE
protein I-GENE
, O
SCOF I-GENE
- I-GENE
1 I-GENE
, O
was I-GENE
isolated I-GENE
from O
soybean I-GENE
. O

The I-GENE
purpose I-GENE
of O
this I-GENE
study I-GENE
was I-GENE
to O
evaluate I-GENE
simplified I-GENE
methods I-GENE
for O
estimation I-GENE
of O
Technetium I-GENE
Tc I-GENE
99m I-GENE
( I-GENE
99mTc I-GENE
)- I-GENE
pentetate I-GENE
and O
orthoiodohippurate I-GENE
I I-GENE
131 I-GENE
( I-GENE
131I I-GENE
- I-GENE
OIH I-GENE
) I-GENE
plasma I-GENE
clearance I-GENE
in O
dogs I-GENE
and O
cats I-GENE
with I-GENE
1 I-GENE
and O
2 I-GENE
blood O
samples I-GENE
. O

Sevelamer O
hydrochloride O
( O
Renagel O
) O
is I-GENE
a O
nonabsorbed I-GENE
phosphate I-GENE
- I-GENE
binding I-GENE
polymer I-GENE
marketed I-GENE
for O
the O
treatment I-GENE
of O
hyperphosphatemia I-GENE
in O
adult I-GENE
patients I-GENE
receiving I-GENE
hemodialysis I-GENE
. O

Using I-GENE
a O
novel I-GENE
method I-GENE
combining I-GENE
chromatin I-GENE
immunoprecipitation I-GENE
and O
genomic I-GENE
array I-GENE
hybridization I-GENE
, O
we I-GENE
have I-GENE
identified I-GENE
a O
460 I-GENE
- I-GENE
kb I-GENE
CENP I-GENE
- I-GENE
A I-GENE
- I-GENE
binding I-GENE
DNA I-GENE
domain I-GENE
of O
a O
neocentromere O
derived O
from O
the O
20p12 O
region O
of O
an I-GENE
invdup I-GENE
( I-GENE
20p I-GENE
) I-GENE
human I-GENE
marker I-GENE
chromosome O
. O

Cases O
of O
lung O
cancer O
with I-GENE
intramedullary I-GENE
metastasis I-GENE
are I-GENE
rare I-GENE
, O
especially I-GENE
those I-GENE
diagnosed I-GENE
before I-GENE
death I-GENE
. O

Direct I-GENE
current I-GENE
polarography I-GENE
and O
differential I-GENE
pulse I-GENE
polarographic I-GENE
methods I-GENE
have I-GENE
been I-GENE
developed I-GENE
for O
the O
qualitative I-GENE
as O
well O
as O
quantitative I-GENE
analysis I-GENE
of O
vitamin O
B1 O
, O
B2 O
and O
B6 O
. O

Fluorimetric I-GENE
determination I-GENE
of O
methylmercury I-GENE
as O
an I-GENE
ion I-GENE
- I-GENE
association I-GENE
complex I-GENE
with I-GENE
rhodamine I-GENE
B I-GENE
in O
the O
presence I-GENE
of O
iodide I-GENE
. O

The I-GENE
corresponding I-GENE
genotype I-GENE
was I-GENE
determined I-GENE
with I-GENE
a O
restriction I-GENE
enzyme I-GENE
- I-GENE
based I-GENE
assay I-GENE
. O

Patients I-GENE
were I-GENE
divided I-GENE
into I-GENE
two I-GENE
group I-GENE
; O
Control I-GENE
group I-GENE
A I-GENE
in O
which I-GENE
a O
hot I-GENE
- I-GENE
water I-GENE
circulating I-GENE
system O
was I-GENE
used I-GENE
and O
group I-GENE
B I-GENE
in O
which I-GENE
a O
transtracheal O
heating O
and O
humidification O
system O
by I-GENE
ANAMED I-GENE
HUMITUBE I-GENE
was I-GENE
used I-GENE
, O
during O
gastric O
cancer O
operation I-GENE
. O

Mental O
rotation O
of O
paired O
figures O
engendered O
activation O
in O
the O
left O
superior I-GENE
parietal I-GENE
lobule I-GENE
and O
the O
right I-GENE
frontal I-GENE
medial I-GENE
gyrus I-GENE
. O

Here I-GENE
we I-GENE
demonstrate I-GENE
that I-GENE
the O
Ras O
- O
activated O
Raf O
- O
MEK O
- I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
( O
ERK O
) O
signaling O
pathway O
can I-GENE
specifically I-GENE
control O
the O
expression O
of O
individual I-GENE
integrin O
subunits O
in O
a O
variety I-GENE
of O
human I-GENE
and O
mouse I-GENE
cell I-GENE
lines I-GENE
. O

These I-GENE
TxRE I-GENE
contain I-GENE
cyclic I-GENE
AMP I-GENE
- I-GENE
responsive I-GENE
elements O
( O
CRE O
), O
but I-GENE
, O
remarkably I-GENE
, O
the O
" O
TGACGTCA O
" O
consensus O
is I-GENE
never I-GENE
strictly I-GENE
conserved O
in O
any I-GENE
viral I-GENE
strain O
( O
e O
. O
g I-GENE
., I-GENE
AGACGTCA I-GENE
, O
TGACGGCA O
, O
TGACCTCA O
). O

The I-GENE
hatcher I-GENE
incubators I-GENE
of O
both I-GENE
companies I-GENE
were I-GENE
also I-GENE
persistently I-GENE
contaminated I-GENE
with I-GENE
Salmonella I-GENE
livingstone I-GENE
and O
Salmonella I-GENE
thomasville I-GENE
in O
company I-GENE
A I-GENE
and O
with I-GENE
Salmonella I-GENE
senftenberg I-GENE
in O
company I-GENE
B I-GENE
. O

Binding I-GENE
of O
cell I-GENE
type I-GENE
- I-GENE
specific I-GENE
nuclear I-GENE
proteins I-GENE
to O
the O
5 O
'- O
flanking O
region O
of O
maize I-GENE
C4 I-GENE
phosphoenolpyruvate O
carboxylase I-GENE
gene I-GENE
confers I-GENE
its I-GENE
differential I-GENE
transcription I-GENE
in O
mesophyll I-GENE
cells I-GENE
. O

Susceptibility O
to O
ischemia I-GENE
- I-GENE
induced O
arrhythmias I-GENE
was I-GENE
lower I-GENE
in O
1 I-GENE
- I-GENE
week I-GENE
diabetics I-GENE
: O
only I-GENE
42 O
% I-GENE
of O
diabetic I-GENE
hearts I-GENE
exhibited I-GENE
ventricular I-GENE
tachycardia I-GENE
( I-GENE
VT I-GENE
) I-GENE
and O
16 I-GENE
% I-GENE
had I-GENE
short I-GENE
episodes I-GENE
of O
ventricular I-GENE
fibrillation I-GENE
( I-GENE
VF I-GENE
) I-GENE
as O
compared I-GENE
to O
VT I-GENE
100 O
% I-GENE
and O
VF I-GENE
70 I-GENE
% I-GENE
( I-GENE
including I-GENE
sustained I-GENE
VF I-GENE
36 I-GENE
%) I-GENE
in O
the O
non O
- I-GENE
diabetics I-GENE
( I-GENE
P I-GENE
< I-GENE
0 O
. O
05 I-GENE
). O

CONCLUSIONS I-GENE
: O
The I-GENE
methodology I-GENE
of O
LHR O
measurement I-GENE
significantly I-GENE
influences I-GENE
the O
clinical I-GENE
contribution I-GENE
of O
Tl I-GENE
- I-GENE
201 I-GENE
lung O
uptake I-GENE
evaluation I-GENE
. O

The I-GENE
authors I-GENE
made I-GENE
an I-GENE
analysis I-GENE
of O
social I-GENE
- I-GENE
economical I-GENE
conditions I-GENE
limiting I-GENE
the O
possibilities I-GENE
of O
rendering I-GENE
cardiosurgical I-GENE
care I-GENE
to O
children I-GENE
. O

METHODS I-GENE
: O
Experiments I-GENE
testing I-GENE
the O
new I-GENE
catheter I-GENE
and O
comparing I-GENE
it I-GENE
to O
the O
existing I-GENE
catheter I-GENE
included I-GENE
: O
( I-GENE
1 I-GENE
) I-GENE
measurement I-GENE
of O
the O
laser I-GENE
output I-GENE
beam I-GENE
sizes I-GENE
and O
divergences O
; O
( O
2 O
) O
evaluation I-GENE
of O
particulate I-GENE
matter I-GENE
generation I-GENE
during O
ablation I-GENE
of O
atherosclerotic O
tissue O
; O
( O
3 O
) O
measurement I-GENE
of O
ablation I-GENE
hole I-GENE
sizes I-GENE
and O
tissue I-GENE
penetration I-GENE
rates I-GENE
; O
( O
4 O
) O
histopathologic I-GENE
examination I-GENE
of O
laser I-GENE
- I-GENE
induced O
in O
vivo I-GENE
vessel I-GENE
wall O
injury I-GENE
. O

The I-GENE
reproductive I-GENE
effects I-GENE
of O
the O
administration I-GENE
of O
4 I-GENE
- I-GENE
chloro I-GENE
- I-GENE
2 I-GENE
- I-GENE
methylphenoxyacetic I-GENE
acid I-GENE
( I-GENE
MCPA I-GENE
) I-GENE
to O
rats I-GENE
were I-GENE
evaluated I-GENE
through I-GENE
two I-GENE
generations I-GENE
, O
from O
prior I-GENE
to O
mating I-GENE
, O
throughout I-GENE
mating I-GENE
, O
to O
gestation I-GENE
and O
lactation I-GENE
. O

Here I-GENE
we I-GENE
suggest I-GENE
that I-GENE
uvrA I-GENE
and O
the O
nucleotide O
excision O
repair O
pathway O
are I-GENE
involved I-GENE
in O
the O
repair O
of O
acid O
- O
induced O
DNA O
damage I-GENE
and O
are I-GENE
associated I-GENE
with I-GENE
successful I-GENE
adaptation I-GENE
of O
S O
. O
mutans O
to O
low O
pH I-GENE
. O

The I-GENE
improved I-GENE
CSF I-GENE
outflow I-GENE
conductance I-GENE
may I-GENE
increase I-GENE
the O
intracranial I-GENE
compliance I-GENE
and O
thereby I-GENE
dampen I-GENE
a O
pathological I-GENE
ICP I-GENE
waveform I-GENE
. O

These I-GENE
studies I-GENE
demonstrate I-GENE
that I-GENE
site I-GENE
- I-GENE
specific I-GENE
recognition I-GENE
of O
the O
bxd I-GENE
PRE I-GENE
by I-GENE
d I-GENE
( I-GENE
GA I-GENE
)( I-GENE
n I-GENE
) I-GENE
repeat I-GENE
binding I-GENE
activities I-GENE
mediates I-GENE
PcG I-GENE
- I-GENE
dependent I-GENE
silencing I-GENE
. O

The I-GENE
gonadotrope I-GENE
- I-GENE
specific O
and O
regulated O
expression O
of O
the O
GnRH O
receptor O
( O
GnRH O
- I-GENE
R I-GENE
) I-GENE
gene I-GENE
is I-GENE
dependent I-GENE
on I-GENE
multiple I-GENE
transcription I-GENE
factors I-GENE
that I-GENE
interact I-GENE
with I-GENE
the O
noncanonical I-GENE
GnRH O
- I-GENE
R I-GENE
activating I-GENE
sequence O
( O
GRAS O
), O
the O
activator I-GENE
protein I-GENE
- I-GENE
1 I-GENE
( I-GENE
AP I-GENE
- I-GENE
1 I-GENE
) O
element O
, O
and O
the O
steroidogenic I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( I-GENE
SF I-GENE
- I-GENE
1 I-GENE
) I-GENE
binding I-GENE
site I-GENE
. O

Before I-GENE
PO3 I-GENE
administration I-GENE
, O
more I-GENE
than I-GENE
half O
( I-GENE
57 I-GENE
. O
4 I-GENE
%) I-GENE
of O
the O
patients I-GENE
received I-GENE
only I-GENE
1 I-GENE
or O
2 I-GENE
antituberculous I-GENE
drugs I-GENE
( O
ethambutole O
and O
ethionamide O
or O
ethambutole O
and O
oprofloxacin O
). O

Using I-GENE
the O
presented I-GENE
categorical I-GENE
structure O
as O
domain I-GENE
model I-GENE
a O
prototype I-GENE
DSS I-GENE
for O
dipslide I-GENE
urine I-GENE
cultures I-GENE
has I-GENE
been I-GENE
developed I-GENE
. O

Conclusion O
: O
The O
Lp O
( O
a O
) O
levels I-GENE
in O
these I-GENE
children I-GENE
were I-GENE
the O
lower I-GENE
ever I-GENE
reported I-GENE
. O

Foxp1 O
and O
Foxp2 I-GENE
are I-GENE
expressed O
at O
high O
levels I-GENE
in O
the O
lung O
as O
early O
as O
E12 O
. O
5 O
of O
mouse I-GENE
development I-GENE
with I-GENE
Foxp2 I-GENE
expression O
restricted I-GENE
to O
the O
airway I-GENE
epithelium I-GENE
. O

Audiological I-GENE
findings I-GENE
in O
pregnancy O
. O

Children I-GENE
who I-GENE
developed I-GENE
lower I-GENE
respiratory I-GENE
tract I-GENE
infections I-GENE
or O
PCP I-GENE
had I-GENE
increased I-GENE
rates I-GENE
of O
decline I-GENE
of O
CD4 I-GENE
cell I-GENE
counts I-GENE
during O
the O
first O
6 I-GENE
months I-GENE
of O
life I-GENE
. O

A I-GENE
randomized I-GENE
mix I-GENE
of O
180 I-GENE
sections I-GENE
( I-GENE
10 I-GENE
samples I-GENE
x I-GENE
3 I-GENE
tissues I-GENE
x I-GENE
3 I-GENE
stains I-GENE
x I-GENE
2 I-GENE
) I-GENE
gave I-GENE
90 O
matched I-GENE
pairs O
. O

Sural I-GENE
nerve I-GENE
biopsy I-GENE
showed I-GENE
mild I-GENE
thickening I-GENE
of O
the O
perineurium O
, O
vascular I-GENE
alterations I-GENE
with I-GENE
inflammatory I-GENE
cell O
infiltration O
in O
the O
perineurium O
, O
and O
remarkable I-GENE
loss O
of O
large O
and O
small I-GENE
myelinated I-GENE
fibers I-GENE
. O

OBJECTIVES I-GENE
: O
The I-GENE
objective I-GENE
of O
this I-GENE
review I-GENE
was I-GENE
to O
assess I-GENE
the O
effects I-GENE
of O
prophylactic I-GENE
prostaglandin I-GENE
use I-GENE
in O
the O
third I-GENE
stage I-GENE
of O
labour I-GENE
. O

Testing I-GENE
was I-GENE
associated I-GENE
with I-GENE
a O
history I-GENE
of O
nonsexual I-GENE
risk I-GENE
behavior I-GENE
, O
increased I-GENE
knowledge I-GENE
of O
the O
hepatitis O
C O
virus O
, O
and O
healthcare O
provider O
communication O
. O

Cytomegalovirus O
, O
Chlamydia I-GENE
pneumoniae I-GENE
, O
and O
Helicobacter O
pylori O
IgG O
antibodies O
and O
restenosis I-GENE
after I-GENE
stent I-GENE
implantation I-GENE
: O
an I-GENE
angiographic I-GENE
and O
intravascular I-GENE
ultrasound I-GENE
study I-GENE
. O

A I-GENE
5 I-GENE
- I-GENE
month I-GENE
- I-GENE
old I-GENE
infant I-GENE
with I-GENE
persistent I-GENE
congenital I-GENE
stridor I-GENE
and O
acute I-GENE
respiratory I-GENE
distress I-GENE
is I-GENE
presented I-GENE
. O

OBJECTIVE I-GENE
: O
To I-GENE
determine I-GENE
whether I-GENE
RSTD I-GENE
predicts I-GENE
coronary I-GENE
anatomy I-GENE
during O
acute I-GENE
coronary I-GENE
occlusion I-GENE
. O

Even I-GENE
if I-GENE
the O
electrocardiographic I-GENE
signs I-GENE
are I-GENE
subdued I-GENE
, O
the O
underlying I-GENE
blockade I-GENE
of O
I I-GENE
( I-GENE
Kr I-GENE
) I-GENE
current I-GENE
may I-GENE
precipitate I-GENE
the O
occurrence I-GENE
of O
arrhythmia I-GENE
. O

Acetoin I-GENE
can I-GENE
be I-GENE
reused I-GENE
by I-GENE
the O
bacteria I-GENE
during O
stationary I-GENE
phase O
when I-GENE
other I-GENE
carbon I-GENE
sources I-GENE
have I-GENE
been I-GENE
depleted I-GENE
. O

Analysis I-GENE
of O
the O
promoter I-GENE
sequence I-GENE
revealed I-GENE
the O
presence I-GENE
of O
a O
major O
transcriptional O
start O
site O
, O
a O
canonical I-GENE
TATA I-GENE
box I-GENE
and O
putative I-GENE
cis O
regulatory O
elements O
for O
pituitary O
specific O
expression O
as O
well O
as O
an I-GENE
E I-GENE
- I-GENE
responsive I-GENE
element I-GENE
. O

IL I-GENE
- I-GENE
1beta O
was I-GENE
significantly I-GENE
higher O
in O
endometrioma I-GENE
than I-GENE
in O
lesions I-GENE
of O
other I-GENE
localizations I-GENE
. O

An I-GENE
economic I-GENE
analysis I-GENE
using I-GENE
West I-GENE
of O
Scotland I-GENE
Coronary I-GENE
Prevention I-GENE
Study I-GENE
( I-GENE
WOSCOPS I-GENE
) I-GENE
findings I-GENE
indicates I-GENE
that I-GENE
statin I-GENE
treatment I-GENE
would I-GENE
have I-GENE
prevented I-GENE
318 I-GENE
events I-GENE
per I-GENE
10 O
, O
000 O
patients I-GENE
in O
a O
population I-GENE
similar I-GENE
to O
that I-GENE
in O
WOSCOPS I-GENE
( I-GENE
average I-GENE
1 I-GENE
. O
5 I-GENE
% I-GENE
annual I-GENE
risk I-GENE
of O
a O
cardiovascular I-GENE
event I-GENE
) O
at O
a O
discounted I-GENE
cost I-GENE
per I-GENE
life I-GENE
- I-GENE
year I-GENE
gained I-GENE
of O
20 O
, O
375 O
pounds O
($ O
31 O
, O
818 O
). O

Hydrogels O
for O
tissue O
engineering O
. O

No I-GENE
mutation I-GENE
of O
the O
NRL I-GENE
gene I-GENE
was I-GENE
found I-GENE
in O
any I-GENE
of O
the O
two I-GENE
families I-GENE
. O

However I-GENE
, O
most I-GENE
produced I-GENE
significant I-GENE
alteration I-GENE
of O
small O
intestinal O
permeability O
. O

Our I-GENE
results I-GENE
show I-GENE
that I-GENE
CVN I-GENE
specifically I-GENE
recognizes I-GENE
with I-GENE
nanomolar I-GENE
affinity I-GENE
Man I-GENE
( O
9 O
) O
GlcNAc O
( O
2 O
) O
and O
the O
D1D3 O
isomer O
of O
Man O
( O
8 O
) O
GlcNAc O
( O
2 O
). O

Saccharomyces I-GENE
cerevisiae I-GENE
activates I-GENE
a O
regulatory I-GENE
network I-GENE
called I-GENE
" O
general O
control O
" O
that I-GENE
provides I-GENE
the O
cell I-GENE
with I-GENE
sufficient I-GENE
amounts I-GENE
of O
protein I-GENE
precursors I-GENE
during O
amino I-GENE
acid I-GENE
starvation I-GENE
. O

In I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
, O
entry I-GENE
into I-GENE
mitosis I-GENE
requires I-GENE
activation O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
Cdc28 O
in O
its I-GENE
cyclin I-GENE
B I-GENE
( I-GENE
Clb I-GENE
)- I-GENE
associated I-GENE
form I-GENE
. O

Data I-GENE
from O
in O
vitro I-GENE
splicing I-GENE
assays I-GENE
, O
UV O
crosslinking O
and O
RNA I-GENE
- I-GENE
binding I-GENE
competition I-GENE
experiments I-GENE
indicates I-GENE
a O
strong I-GENE
correlation I-GENE
between I-GENE
the O
binding I-GENE
affinities I-GENE
of O
PSI O
for O
the O
SELEX O
sequences O
and O
their I-GENE
ability I-GENE
to O
modulate I-GENE
splicing O
of O
P O
element O
IVS3 O
in O
vitro I-GENE
. O

The I-GENE
sensitivity I-GENE
of O
human I-GENE
neuroblastoma I-GENE
cells I-GENE
SK I-GENE
- I-GENE
N I-GENE
- I-GENE
SH I-GENE
to O
undergo I-GENE
apoptosis I-GENE
induced O
by I-GENE
thapsigargin I-GENE
was I-GENE
examined I-GENE
. O

A I-GENE
., I-GENE
Slatkin I-GENE
, O
D I-GENE
. O

Multiparous I-GENE
women I-GENE
presented I-GENE
higher O
BMI I-GENE
( I-GENE
P I-GENE
= I-GENE
0 O
. O
01 I-GENE
) I-GENE
and O
PBF I-GENE
( I-GENE
P I-GENE
= I-GENE
0 O
. O
03 I-GENE
) I-GENE
compared I-GENE
with I-GENE
primi I-GENE
- I-GENE
and O
nulliparous I-GENE
groups I-GENE
. O

CONCLUSIONS I-GENE
AND I-GENE
CLINICAL I-GENE
RELEVANCE I-GENE
: O
Increased I-GENE
cortical I-GENE
thickness I-GENE
and O
geometric I-GENE
properties I-GENE
of O
left O
MCB O
- O
IV O
and O
- O
V O
of O
Greyhounds O
, O
together I-GENE
with I-GENE
altered I-GENE
turnover I-GENE
and O
orientation I-GENE
of O
osteons O
in O
the O
dorsal I-GENE
quadrants I-GENE
of O
left O
MCB O
, O
are I-GENE
site I-GENE
- I-GENE
specific I-GENE
adaptive I-GENE
responses I-GENE
associated I-GENE
with I-GENE
asymmetric I-GENE
cyclic I-GENE
loading I-GENE
as O
a O
result I-GENE
of O
racing I-GENE
on I-GENE
circular I-GENE
tracks I-GENE
. O

To I-GENE
examine I-GENE
transcriptional O
regulation O
of O
the O
rat O
eIF4E O
gene O
, O
2 O
. O
1 O
kB O
of O
the O
rat I-GENE
eIF4E I-GENE
promoter I-GENE
region I-GENE
was I-GENE
cloned O
and O
the O
contribution I-GENE
of O
specific O
elements O
in O
regulating O
transcription I-GENE
was I-GENE
determined I-GENE
in O
primary O
cultures I-GENE
of O
rat O
cardiocytes O
and O
in O
a O
murine O
C O
( O
2 O
) O
C O
( O
12 O
) O
myoblast O
cell O
line I-GENE
. O

The I-GENE
prevalence I-GENE
of O
tobacco I-GENE
dependence I-GENE
diagnosed I-GENE
according I-GENE
to O
the O
ICD O
- O
10 O
criteria I-GENE
was I-GENE
higher O
in O
alcohol O
- I-GENE
dependent I-GENE
individuals I-GENE
( I-GENE
58 I-GENE
. O
1 I-GENE
%) I-GENE
than I-GENE
in O
nondrinkers I-GENE
or O
social I-GENE
drinkers I-GENE
( O
12 O
. O
8 O
%). O

Management O
of O
postvitrectomy I-GENE
diabetic I-GENE
vitreous I-GENE
hemorrhage I-GENE
with I-GENE
tissue I-GENE
plasminogen O
activator I-GENE
( I-GENE
t I-GENE
- I-GENE
PA I-GENE
) I-GENE
and O
volume I-GENE
homeostatic I-GENE
fluid O
- O
fluid O
exchanger O
. O

Transactivation O
of O
oIFNtau I-GENE
enhancer I-GENE
- I-GENE
reporter I-GENE
constructs I-GENE
was I-GENE
primarily I-GENE
regulated I-GENE
by I-GENE
three I-GENE
regions I-GENE
containing I-GENE
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
, O
GATA I-GENE
like I-GENE
sequence O
and O
site O
( O
s O
) O
unidentified I-GENE
. O

SELECTION O
CRITERIA O
: O
Randomised O
controlled O
trials I-GENE
of O
cabergoline I-GENE
versus I-GENE
placebo I-GENE
in O
patients I-GENE
with I-GENE
a O
clinical I-GENE
diagnosis I-GENE
of O
idiopathic I-GENE
Parkinson I-GENE
' O
s O
disease O
and O
long O
- I-GENE
term I-GENE
complications I-GENE
of O
levodopa I-GENE
therapy I-GENE
. O

0 O
%) I-GENE
and O
IL I-GENE
- I-GENE
12 O
( O
42 O
. O
6 I-GENE
% I-GENE
vs O
. O

Copyright I-GENE
2000 I-GENE
John I-GENE
Wiley I-GENE
& I-GENE
Sons I-GENE
, O
Ltd I-GENE
. O

Here I-GENE
we I-GENE
demonstrate I-GENE
that I-GENE
native I-GENE
MRCK I-GENE
exists I-GENE
in O
high O
- O
molecular O
- O
weight O
complexes O
. O

METHODS I-GENE
: O
This I-GENE
retrospective I-GENE
review I-GENE
comprised I-GENE
2711 I-GENE
eyes I-GENE
that I-GENE
had I-GENE
LASIK I-GENE
between I-GENE
September I-GENE
1996 I-GENE
and O
September I-GENE
1999 I-GENE
. O

Sixty I-GENE
- I-GENE
one I-GENE
cases I-GENE
of O
cholera I-GENE
, O
all I-GENE
caused I-GENE
by I-GENE
V I-GENE
. O
cholerae I-GENE
O1 I-GENE
, O
were I-GENE
reported I-GENE
. O

This I-GENE
could I-GENE
lead I-GENE
to O
subsequent I-GENE
outbreaks I-GENE
if I-GENE
Babesia I-GENE
carrier I-GENE
animals I-GENE
were I-GENE
to O
be I-GENE
introduced I-GENE
into I-GENE
the O
herd I-GENE
. O

Instead I-GENE
, O
TRPS1 I-GENE
potently I-GENE
and O
specifically I-GENE
represses I-GENE
transcriptional O
activation O
mediated O
by I-GENE
other I-GENE
GATA I-GENE
factors I-GENE
. O

Eliminating I-GENE
any I-GENE
subset I-GENE
of O
ASCUS I-GENE
reduces I-GENE
the O
ASCUS I-GENE
/ I-GENE
SIL I-GENE
ratio I-GENE
but I-GENE
also I-GENE
significantly I-GENE
diminishes I-GENE
the O
sensitivity I-GENE
of O
the O
Papanicolaou I-GENE
test I-GENE
. O

In I-GENE
order I-GENE
to O
overcome I-GENE
the O
false I-GENE
positive I-GENE
readings I-GENE
that I-GENE
are I-GENE
possible I-GENE
in O
sphincter I-GENE
manometry I-GENE
, O
we I-GENE
proposed I-GENE
to O
use I-GENE
secretin I-GENE
stimulated I-GENE
endoscopic I-GENE
ultrasound I-GENE
( I-GENE
SSEUS I-GENE
) I-GENE
to O
measure I-GENE
pancreatic I-GENE
ductal I-GENE
response I-GENE
as O
an I-GENE
adjunctive I-GENE
method I-GENE
to O
aid I-GENE
and O
supplement I-GENE
the O
diagnosis I-GENE
. O

Endovascular I-GENE
aneurysm I-GENE
repair I-GENE
with I-GENE
the O
AneuRx I-GENE
stent I-GENE
- I-GENE
graft I-GENE
is I-GENE
safe I-GENE
, O
but I-GENE
is I-GENE
it I-GENE
effective I-GENE
? I-GENE

The I-GENE
difference I-GENE
of O
hardness I-GENE
over I-GENE
time I-GENE
of O
composite I-GENE
specimens I-GENE
was I-GENE
measured I-GENE
using I-GENE
Knoop I-GENE
hardness I-GENE
measurements I-GENE
taken I-GENE
at O
the O
top I-GENE
and O
bottom I-GENE
surfaces I-GENE
of O
resin I-GENE
specimens I-GENE
made I-GENE
in O
a O
Teflon O
mold O
the O
same I-GENE
dimensions I-GENE
as O
the O
cavity I-GENE
prepared I-GENE
in O
dentin I-GENE
. O

Implications O
in O
biomonitoring O
of O
the O
observed I-GENE
accumulation I-GENE
patterns I-GENE
, O
especially I-GENE
in O
the O
different I-GENE
tissues I-GENE
of O
Posidonia I-GENE
oceanica I-GENE
, O
are I-GENE
discussed I-GENE
. O

Based I-GENE
on I-GENE
mutational I-GENE
data I-GENE
and O
possible I-GENE
mRNA I-GENE
structure O
, O
we I-GENE
hypothesized I-GENE
about I-GENE
the O
effect I-GENE
of O
mRNA I-GENE
structure O
on I-GENE
translation O
of O
the O
two I-GENE
major I-GENE
C I-GENE
/ I-GENE
EBPepsilon I-GENE
isoforms I-GENE
: O
p32 O
and O
p30 O
. O

Retinoids I-GENE
participate I-GENE
in O
the O
onset I-GENE
of O
differentiation I-GENE
, O
apoptosis I-GENE
and O
the O
inhibition I-GENE
of O
growth O
in O
a O
wide I-GENE
variety I-GENE
of O
normal I-GENE
and O
cancerous I-GENE
cells I-GENE
. O

We I-GENE
conclude I-GENE
that I-GENE
RPMS I-GENE
acts I-GENE
as O
a O
negative O
regulator O
of O
EBNA2 O
and O
Notch O
activity I-GENE
through I-GENE
its I-GENE
interactions I-GENE
with I-GENE
the O
CBF1 O
- O
associated O
corepressor O
complex O
. O

Isolated O
Systolic O
Hypertension O
: O
An I-GENE
Update I-GENE
. O

Transfection I-GENE
of O
EGFP I-GENE
- I-GENE
tagged I-GENE
DENTT I-GENE
NLS I-GENE
deletion O
constructs O
lacking O
the O
bipartite I-GENE
NLS I-GENE
- I-GENE
1 I-GENE
were I-GENE
excluded I-GENE
from O
the O
nucleolus O
. O

VE I-GENE
- I-GENE
DEF I-GENE
animals I-GENE
had I-GENE
significantly I-GENE
higher O
( O
p O
< I-GENE
0 O
. O
05 I-GENE
) I-GENE
levels I-GENE
of O
myocardial O
lipid O
peroxidation I-GENE
and O
lower I-GENE
( I-GENE
p O
< I-GENE
0 O
. O
05 I-GENE
) I-GENE
protein I-GENE
thiols I-GENE
following I-GENE
I I-GENE
- I-GENE
R I-GENE
compared I-GENE
to O
the O
CON I-GENE
animals I-GENE
. O

The I-GENE
position I-GENE
of O
the O
analyst O
as O
expert O
: O
yesterday O
and O
today O
. O

Furthermore I-GENE
, O
we I-GENE
showed I-GENE
that I-GENE
ERSF I-GENE
including I-GENE
NF I-GENE
- I-GENE
Y I-GENE
and O
ATF6alpha O
and O
/ O
or O
beta I-GENE
and O
capable I-GENE
of O
binding I-GENE
to O
ERSE I-GENE
is I-GENE
indeed I-GENE
formed I-GENE
when I-GENE
the O
cellular I-GENE
UPR I-GENE
is I-GENE
activated I-GENE
. O

We I-GENE
performed I-GENE
the O
present I-GENE
study I-GENE
to O
clarify I-GENE
the O
relationship I-GENE
between I-GENE
the O
DOX I-GENE
binding I-GENE
ability I-GENE
(% I-GENE
DB I-GENE
) O
and O
the O
histologic I-GENE
response I-GENE
, O
rate I-GENE
of O
decrease I-GENE
in O
tumor I-GENE
volume I-GENE
of O
malignant I-GENE
soft I-GENE
tissue I-GENE
tumors I-GENE
after I-GENE
preoperative I-GENE
chemotherapy I-GENE
and O
prognosis I-GENE
. O

We I-GENE
have I-GENE
also I-GENE
isolated I-GENE
and O
analyzed I-GENE
the O
5 O
' O
flanking O
region O
of O
the O
pea I-GENE
33RNP I-GENE
gene I-GENE
. O

We I-GENE
have I-GENE
previously I-GENE
shown I-GENE
that I-GENE
the O
adenoviral O
12S O
E1A O
protein O
modulates O
the O
phosphorylation O
status I-GENE
of O
p130 O
and O
p107 O
without I-GENE
apparent I-GENE
changes I-GENE
in O
the O
cell O
cycle O
dependent O
phosphorylation O
of O
the O
retinoblastoma I-GENE
protein I-GENE
. O

Baseline O
MBF O
in O
females I-GENE
was I-GENE
significantly I-GENE
( I-GENE
P I-GENE
< I-GENE
0 O
. O
001 I-GENE
) I-GENE
higher O
than I-GENE
in O
males I-GENE
. O

Only I-GENE
nine I-GENE
patients I-GENE
were I-GENE
offered I-GENE
surgery I-GENE
( I-GENE
six O
were I-GENE
resected I-GENE
and O
three I-GENE
were I-GENE
found I-GENE
inoperable I-GENE
). O

The I-GENE
deubiquitinating I-GENE
enzyme I-GENE
DUB I-GENE
- I-GENE
2 I-GENE
is I-GENE
induced O
in O
response O
to O
IL I-GENE
- I-GENE
2 I-GENE
but I-GENE
as O
yet I-GENE
its I-GENE
function I-GENE
has I-GENE
not I-GENE
been I-GENE
determined I-GENE
. O

A I-GENE
split I-GENE
motor I-GENE
domain I-GENE
in O
a O
cytoplasmic O
dynein O
. O

Immunological O
and O
biochemical I-GENE
characterization I-GENE
of O
streptococcal I-GENE
pyrogenic I-GENE
exotoxins I-GENE
I I-GENE
and O
J O
( O
SPE O
- O
I O
and O
SPE O
- O
J O
) O
from O
Streptococcus O
pyogenes O
. O

Five I-GENE
modalities I-GENE
of O
nonpharmacologic I-GENE
approaches I-GENE
are I-GENE
recommended I-GENE
at O
present I-GENE
for O
lifestyle I-GENE
modification I-GENE
and O
control O
of O
arterial I-GENE
blood O
pressure I-GENE
elevation I-GENE
: O
1 I-GENE
) I-GENE
weight O
reduction I-GENE
to O
ideal I-GENE
body I-GENE
weight I-GENE
, O
since I-GENE
it I-GENE
reduces I-GENE
risk I-GENE
of O
hypertension I-GENE
as O
well O
as O
overall I-GENE
cardiovascular I-GENE
morbidity I-GENE
and O
mortality I-GENE
; O
2 I-GENE
) I-GENE
dietary I-GENE
sodium I-GENE
restriction I-GENE
to O
less I-GENE
than I-GENE
2 I-GENE
g I-GENE
a O
day I-GENE
, O
without I-GENE
assurance I-GENE
that I-GENE
it I-GENE
will I-GENE
normalize I-GENE
arterial I-GENE
pressure I-GENE
although I-GENE
it I-GENE
may I-GENE
help I-GENE
reduce I-GENE
dosage I-GENE
and O
numbers I-GENE
of O
prescribed I-GENE
antihypertensive I-GENE
drugs I-GENE
; O
3 O
) O
moderation O
of O
alcohol O
consumption I-GENE
to O
less I-GENE
than I-GENE
1 I-GENE
ounce I-GENE
a O
day I-GENE
; O
4 O
) O
a O
regular I-GENE
isotonic I-GENE
exercise I-GENE
program I-GENE
; O
and O
5 O
) O
cessation I-GENE
of O
tobacco I-GENE
consumption I-GENE
. O

Descriptions O
of O
this I-GENE
locus I-GENE
would I-GENE
allow I-GENE
comparison I-GENE
with I-GENE
functionally I-GENE
relevant I-GENE
molecular O
genetic I-GENE
features I-GENE
of O
other I-GENE
species I-GENE
' I-GENE
homologous I-GENE
loci I-GENE
including I-GENE
the O
single I-GENE
- I-GENE
copy I-GENE
equid I-GENE
LH I-GENE
/ I-GENE
CGbeta I-GENE
gene I-GENE
and O
the O
primate I-GENE
LHbeta I-GENE
- I-GENE
CGbeta I-GENE
gene I-GENE
cluster I-GENE
locus I-GENE
. O

METHODS I-GENE
: O
One I-GENE
hundred I-GENE
fourteen I-GENE
consecutive I-GENE
patients I-GENE
( I-GENE
mean I-GENE
age I-GENE
61 I-GENE
years I-GENE
) I-GENE
with I-GENE
focal I-GENE
pancreatic I-GENE
masses I-GENE
, O
detected I-GENE
on I-GENE
CT I-GENE
, O
underwent I-GENE
EUS I-GENE
- I-GENE
FNA I-GENE
by I-GENE
using I-GENE
a O
linear O
- O
array O
echoendoscope O
and O
22 O
- O
gauge O
needles O
. O

The I-GENE
effects I-GENE
of O
chlordiazepoxide O
( O
2 O
. O
5 O
- O
15 O
. O
0mg I-GENE
/ I-GENE
kg I-GENE
), O
a O
full I-GENE
benzodiazepine I-GENE
receptor I-GENE
agonist I-GENE
, O
and O
bretazenil O
( O
5 O
. O
0 O
- O
30 O
. O
0mg I-GENE
/ I-GENE
kg I-GENE
), O
a O
partial I-GENE
benzodiazepine I-GENE
receptor I-GENE
agonist I-GENE
, O
were I-GENE
examined I-GENE
in O
the O
murine I-GENE
elevated I-GENE
plus O
- I-GENE
maze I-GENE
paradigm I-GENE
. O

Acute I-GENE
effects I-GENE
of O
LI O
160 O
( O
extract O
of O
Hypericum O
perforatum O
, O
St O
John O
' O
s O
wort O
) O
and O
two I-GENE
of O
its I-GENE
constituents I-GENE
on I-GENE
neuroendocrine I-GENE
responses I-GENE
in O
the O
rat O
. O

Guidelines O
for O
performing O
a O
routine I-GENE
spiral I-GENE
assay I-GENE
are I-GENE
presented I-GENE
, O
and O
alternative O
test I-GENE
methods I-GENE
intended I-GENE
to O
overcome I-GENE
a O
variety I-GENE
of O
technical I-GENE
difficulties I-GENE
( I-GENE
such I-GENE
as O
restricted I-GENE
sample I-GENE
availability I-GENE
, O
sample I-GENE
viscosity I-GENE
or O
volatility I-GENE
, O
etc I-GENE
.) I-GENE
are I-GENE
recommended I-GENE
. O

An I-GENE
additional I-GENE
9 I-GENE
patients I-GENE
achieved I-GENE
normal I-GENE
levels I-GENE
with I-GENE
adjunctive I-GENE
drug I-GENE
therapy I-GENE
. O

Anti I-GENE
- I-GENE
nucleolin I-GENE
mAb I-GENE
was I-GENE
used I-GENE
to O
confirm I-GENE
the O
antigenic I-GENE
properties I-GENE
of O
this I-GENE
p95 I-GENE
component I-GENE
. O

Eliminating I-GENE
any I-GENE
subset I-GENE
of O
ASCUS I-GENE
reduces I-GENE
the O
ASCUS I-GENE
/ I-GENE
SIL I-GENE
ratio I-GENE
but I-GENE
also I-GENE
significantly I-GENE
diminishes I-GENE
the O
sensitivity I-GENE
of O
the O
Papanicolaou I-GENE
test I-GENE
. O

Prrp I-GENE
can I-GENE
also I-GENE
associate I-GENE
with I-GENE
the O
EVH1 I-GENE
domain I-GENE
of O
Mena I-GENE
, O
another I-GENE
microfilament I-GENE
- I-GENE
associated I-GENE
protein I-GENE
. O

Experience I-GENE
with I-GENE
xylene I-GENE
- I-GENE
free I-GENE
sections I-GENE
since I-GENE
1995 I-GENE
at O
the O
Vrinnevi I-GENE
Hospital I-GENE
is I-GENE
favorable I-GENE
. O

Acquired O
antithrombin O
deficiency I-GENE
in O
sepsis I-GENE
. O

SIP1 O
( O
Smad O
interacting O
protein O
1 O
) O
and O
deltaEF1 O
( O
delta I-GENE
- I-GENE
crystallin I-GENE
enhancer I-GENE
binding I-GENE
factor I-GENE
) I-GENE
are I-GENE
structurally I-GENE
similar I-GENE
transcriptional I-GENE
repressors I-GENE
. O

SERS I-GENE
spectra I-GENE
were I-GENE
obtained I-GENE
by I-GENE
vacuum I-GENE
evaporation I-GENE
and O
casting O
of O
p O
- I-GENE
NTP I-GENE
onto I-GENE
silver I-GENE
island I-GENE
films I-GENE
, O
and O
also I-GENE
from O
colloidal I-GENE
silver I-GENE
solutions I-GENE
. O

The O
moduli O
of O
elasticity O
of O
the O
gray I-GENE
and O
white I-GENE
matter I-GENE
were I-GENE
3 I-GENE
. O
4 I-GENE
+/- I-GENE
1 I-GENE
. O
4 I-GENE
kPa I-GENE
( I-GENE
mean I-GENE
+/- I-GENE
standard I-GENE
deviation I-GENE
) O
and O
3 O
. O
4 I-GENE
+/- I-GENE
0 O
. O
9 O
kPa O
in O
the O
axial I-GENE
section I-GENE
, O
3 I-GENE
+/- I-GENE
0 O
. O
3 O
kPa O
and O
3 O
. O
5 O
+/- I-GENE
0 O
. O
5 O
kPa O
in O
the O
frontal I-GENE
section I-GENE
, O
and O
3 O
. O
5 O
+/- I-GENE
0 O
. O
9 O
kPa O
and O
2 O
. O
8 O
+/- I-GENE
0 O
. O
4 O
kPa O
in O
the O
sagittal I-GENE
section I-GENE
, O
respectively I-GENE
. O

[ O
Clinical I-GENE
and O
epidemiological I-GENE
characteristics I-GENE
of O
squamous I-GENE
cell I-GENE
carcinoma I-GENE
of O
the O
oral I-GENE
cavity I-GENE
in O
women I-GENE
] I-GENE
BACKGROUND I-GENE
: O
Squamous I-GENE
cell I-GENE
carcinoma I-GENE
( O
SCC O
) O
of O
the O
oral I-GENE
cavity I-GENE
occurs I-GENE
mainly I-GENE
in O
the O
male I-GENE
population I-GENE
. O

The I-GENE
core I-GENE
promoter I-GENE
of O
human I-GENE
thioredoxin I-GENE
reductase O
1 I-GENE
: O
cloning I-GENE
, O
transcriptional I-GENE
activity I-GENE
, O
and O
Oct O
- I-GENE
1 I-GENE
, O
Sp1 I-GENE
, O
and O
Sp3 O
binding I-GENE
reveal I-GENE
a O
housekeeping I-GENE
- I-GENE
type I-GENE
promoter I-GENE
for O
the O
AU I-GENE
- I-GENE
rich I-GENE
element I-GENE
- I-GENE
regulated I-GENE
gene I-GENE
. O

Phase I-GENE
II I-GENE
trial I-GENE
of O
the O
anti I-GENE
- I-GENE
G I-GENE
( I-GENE
D2 I-GENE
) I-GENE
monoclonal I-GENE
antibody I-GENE
3F8 I-GENE
and O
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
for O
neuroblastoma I-GENE
. O

A I-GENE
log I-GENE
- I-GENE
linear I-GENE
dose I-GENE
- I-GENE
response I-GENE
was I-GENE
obtained I-GENE
for O
the O
average I-GENE
increase I-GENE
in O
FEV1 I-GENE
up O
to O
6 I-GENE
h I-GENE
( I-GENE
AUC0 I-GENE
- I-GENE
6 I-GENE
h I-GENE
) I-GENE
and O
peak I-GENE
FEV1 I-GENE
across I-GENE
the O
dose I-GENE
range I-GENE
administered I-GENE
by I-GENE
Respimat I-GENE
. O

Plasma I-GENE
DHE I-GENE
concentration I-GENE
rose I-GENE
promptly I-GENE
above I-GENE
5 I-GENE
ng I-GENE
/ I-GENE
ml I-GENE
after I-GENE
the O
application I-GENE
of O
the O
PSA O
tape I-GENE
onto I-GENE
the O
damaged I-GENE
skin O
in O
hairless O
rat O
. O

A O
complete O
drug I-GENE
history I-GENE
was I-GENE
compiled I-GENE
, O
specifying I-GENE
the O
amount I-GENE
and O
duration I-GENE
of O
VGB I-GENE
medication I-GENE
. O

Epithelial I-GENE
cytotoxicity I-GENE
of O
combined I-GENE
antibiotics I-GENE
was I-GENE
additive I-GENE
, O
with I-GENE
no O
evidence I-GENE
of O
competition I-GENE
or O
synergism I-GENE
. O

In I-GENE
Cd I-GENE
- I-GENE
spiked I-GENE
OECD I-GENE
soil I-GENE
, O
internal I-GENE
Cd I-GENE
levels I-GENE
were I-GENE
linearly I-GENE
related I-GENE
to O
external I-GENE
Cd I-GENE
concentrations I-GENE
, O
whereas I-GENE
the O
springtails I-GENE
maintained I-GENE
fixed I-GENE
internal I-GENE
levels I-GENE
of O
Cu I-GENE
and O
Zn I-GENE
regardless I-GENE
of O
spiked I-GENE
concentrations I-GENE
. O

Interestingly I-GENE
, O
the O
similarities I-GENE
with I-GENE
the O
endophilin I-GENE
proteins I-GENE
cover I-GENE
the O
entire O
sequence O
of O
the O
SH3GLB I-GENE
family I-GENE
, O
suggesting I-GENE
a O
common I-GENE
fold O
and O
presumably I-GENE
a O
common I-GENE
mode I-GENE
of O
action I-GENE
. O

Reovirus I-GENE
mRNAs I-GENE
are I-GENE
efficiently I-GENE
translated I-GENE
within I-GENE
host I-GENE
cells I-GENE
despite I-GENE
the O
absence I-GENE
of O
3 I-GENE
' I-GENE
polyadenylated I-GENE
tails I-GENE
. O

Grippers I-GENE
with I-GENE
integrated I-GENE
piezoresistive I-GENE
force I-GENE
sensors I-GENE
and O
with I-GENE
attached I-GENE
strain O
gauges I-GENE
have I-GENE
been I-GENE
reported I-GENE
. O

Both I-GENE
Z I-GENE
and O
R I-GENE
expression O
resulted I-GENE
in O
PML I-GENE
dispersion I-GENE
in O
EBV I-GENE
- I-GENE
positive I-GENE
cells I-GENE
. O

The I-GENE
small I-GENE
copepod I-GENE
Pseudonychocamptus I-GENE
proximus I-GENE
progressively I-GENE
replaced I-GENE
the O
large O
Tisbe O
furcata O
in O
sand O
filters O
during O
the O
fall I-GENE
of O
1995 I-GENE
and O
was I-GENE
responsible I-GENE
for O
the O
large O
increase I-GENE
in O
meiofaunal I-GENE
biomass I-GENE
observed I-GENE
after I-GENE
spring I-GENE
1996 I-GENE
. O

Evidence I-GENE
- I-GENE
based I-GENE
care I-GENE
: O
a O
new I-GENE
formula I-GENE
for O
an I-GENE
old I-GENE
problem I-GENE
? I-GENE

Nrf2 I-GENE
regulates I-GENE
expression O
of O
genes O
encoding O
enzymes O
with I-GENE
antioxidant I-GENE
( O
e O
. O
g I-GENE
. O
heme I-GENE
oxygenase O
- I-GENE
1 I-GENE
( I-GENE
HO I-GENE
- I-GENE
1 I-GENE
)) I-GENE
or O
xenobiotic O
detoxification O
( O
e O
. O
g I-GENE
. O

Workload O
, O
UAPs O
, O
and O
you O
. O

RESULTS I-GENE
: O
At I-GENE
latest I-GENE
examination I-GENE
, O
mean I-GENE
UPDRS I-GENE
II I-GENE
and O
III I-GENE
scores I-GENE
had I-GENE
improved I-GENE
by I-GENE
30 O
% I-GENE
( I-GENE
on I-GENE
stimulation O
, O
off I-GENE
therapy I-GENE
) I-GENE
with I-GENE
mean I-GENE
50 I-GENE
% I-GENE
reduction I-GENE
in O
daily I-GENE
off I-GENE
time I-GENE
. O

Perfusion I-GENE
technique I-GENE
for O
perfusion I-GENE
- I-GENE
assisted I-GENE
direct I-GENE
coronary I-GENE
artery I-GENE
bypass I-GENE
( I-GENE
PADCAB I-GENE
). O

Copyright I-GENE
2001 I-GENE
Academic I-GENE
Press I-GENE
. O

The I-GENE
amount I-GENE
of O
drained I-GENE
effusion I-GENE
was I-GENE
measured I-GENE
, O
and O
fluid O
was I-GENE
sent I-GENE
for O
diagnostic I-GENE
assessment I-GENE
. O

